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Abstract 
During my PhD course, I focused my attention on the 
conformational analysis of peptides that interact with GPCR and 
ligand-receptor interactions from NMR spectroscopy with possible 
application to cytotoxic agents binding to DNA. 
In particular, I investigated the conformational behaviour of 
peptide analogues of Urotensin, Melanocortin and Somatostatin in 
water solution and membrane mimetic environment (SDS and DPC 
micelles).  
Another research field was the NMR-based screening as potent 
technique for the identification of small molecules that interact with 
macromolecule targets. Several methods based on the ligand 
observation have been proposed in the literature, among these 
WaterLOGSY (water-ligand observed via gradient spectroscopy), and 
STD-NMR (saturation transfer difference) experiments. I applied 
these NMR techniques for the evaluation of the DNA interactions of a 
new series of thiophen-naphthoquinones with interesting cytotoxic 
activity. 
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Abbreviations 
Abbreviations used for amino acids and designation of peptides 
follow the rules of the IUPAC-IUB Commission of Biochemical 
Nomenclature in J. Biol. Chem. 1972, 247, 977-983. Amino acid 
symbols denote L-configuration unless indicated otherwise. The 
following additional abbreviations are used: 
1D, 2D and 3D, one-, two- and three-dimensional; 
ACTH, adreno-corticotropic hormone;  
AGRP, agouti-related protein;  
Boc, tert-butyloxycarbonyl;  
Bzl, benzyl;  
cAMP, Cyclic adenosine monophosphate;  
Cpa, p-chloro-phenylalanine;  
DBU, 1,8-Diazabicyclo(5.4.9)undec-7-ene;  
DCM, dichloromethane;  
DF, differential frequency;  
dh-DSA- N, dehydrodiaminosuberic acid, N-terminus;  
dh-DSA-C, dehydrodiaminosuberic acid, C-terminus;  
DIPEA, N,N-diisopropylethyl-amine;  
DMF, N,Ndimethylformamide;  
DMSO, dimethylsulfoxide;  
DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; EDT, 1,2-
ethanedithiol;  
DPC, dodecyl phosphocholine;  
DQF-COSY, double quantum filtered correlated spectroscopy;  
EL, extracellular loop;  
EM, energy minimization;  
ESI-MS, electrospray ionization-mass spectrometry;  
Fmoc, 9-fluorenylmethoxycarbonyl;  
GH, growth hormone; Hag, L-2-allyl-Gly;  
GPCR, G-protein-coupled receptor;  
HATU, exafluorophosphate salt of the O-(7-Azabenzotriazol-yl)-tetramethyl 
uranium cation (this acronym does not longer correspond to the true structure);  
HBTU, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate;  
h-MCR, human Melanocortin Receptor;  
HOBt, Nhydroxy-benzotriazole; 
hU-II, human Urotensin-II peptide;  
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h-UTR, human Urotensin II receptor;  
IL, intracellular loop;  
LC, liquid chromatography;  
MD, molecular dynamic;  
MSH, melanocyte stimulating hormones;  
MW, molecular weight;  
Nal, Naphtylalanine;  
NMM, N-methyl morpholine;  
NMR, nuclear magnetic resonance;  
NOE, nuclear Overhauser effect;  
NOESY, nuclear Overhauser enhancement spectroscopy;  
Orn, Ornitine;  
PE COSY, primitive exclusive correlated spectroscopy;  
Pen, penicillamine;  
POMC, proopiomelanocortin;  
RCM, ring closing metathesis;  
RMSD, root mean square deviation;  
ROESY, rotating-frame Overhauser effect spectroscopy;  
RP-HPLC, reverse phase-high performance liquid chromatography; SPE, Solid 
Phase Extraction;  
r-UTR, rat Urotensin II receptor;  
SAR, Structure activity relationship;  
SD, standard deviation;  
SDS, sodium dodecylsulphate;  
SPPS, solid phase peptide synthesis;  
SRIF, somatostatin; sst, somatostatin receptor;  
STD, saturation transfer difference;  
TES, triethylsilane;  
TFA, trifluoroacetic acid;  
THF, tetrahydrofuran;  
Tic, tetrahydroisoquinoline;  
TLC, thin-layer chromatography;  
TM, trans-membrane domain;  
TOCSY, total correlated spectroscopy;  
TSP, 3-(trimethylsilanyl)propionic acid;  
U-II, Urotensin-II peptide;  
WaterLOGSY, water-ligand observed via gradient spectroscopy. 
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Chapter 1 - CONFORMATIONAL 
ANALYSIS OF PEPTIDES THAT 
INTERACT WITH GPCR  
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1.1 New Insight into the Binding Mode of Peptide Ligands at 
Urotensin-II Receptor: Structure-Activity Relationships 
Study on P5U and Urantide 
 
Urotensin II (U-II) is a disulfide bridged peptide-hormone 
identified as the ligand of a G protein-coupled receptor. Human U-II 
(H-Glu-Thr-Pro-Asp-c[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH) has been 
described as the most potent vasoconstrictor compound identified to 
date. 
We have recently identified both a superagonist of hU-II termed P5U 
(H-Asp-c[Pen-Phe-Trp-Lys-Tyr-Cys]-Val-OH) and the compound 
termed Urantide (H-Asp-c[Pen-Phe-DTrp-Orn-Tyr-Cys]-Val-OH), 
which is the most potent UT receptor peptide antagonist described to 
date.  
In the present study, we have synthesized several analogues of P5U 
and Urantide in which the Asp4 residue in N-terminus position was 
replaced with coded and non-coded amino acids. The replacement of 
the Asp4 residue by Tic led to an analogue, compound 14, more potent 
as antagonist (pKB = 8.94) compared to Urantide. Furthermore, a 
different SAR was observed for the P5U compared to the Urantide 
analogues. NMR and docking studies revealed a different binding 
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mode for the agonist and antagonist ligands which could explain the 
observed SAR. 
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1.1.1. Introduction 
Urotensin-II (U-II) is a cyclic peptide originally isolated from 
goby fish urophysis.[1] Subsequently, it has been found that U-II is 
also present in tetrapods and that its gene is expressed in the CNS.[2] 
The U-II precursor has now been cloned in various vertebrate species 
including frog, rat and mouse, pig, monkey, and human.[3-6] U-II was 
identified as the natural ligand of an orphan G-protein-coupled 
receptor [7] now referred to as UT receptor. 
Recently, an analogue of  U-II, called urotensin-related peptide 
(URP), has been identified in mammals.[8] In all U-II and URP 
isoforms known so far, the sequence of the cyclic C-terminal 
hexapeptide has been fully conserved across species.[9] The U-II and 
URP genes are primarily expressed in motoneurons located in discrete 
brainstem nuclei and in the ventral horn of the spinal cord.[10-13] U-
II and URP mRNAs have also been detected, although at a much 
lower level, in various peripheral tissues including the pituitary, heart, 
spleen, thymus, pancreas, kidney, small intestine, adrenal, and 
prostate.[3, 8, 14]  
The U-II/UT receptor system seems to play an important role in 
cardiovascular functions; in fact, hU-II has been shown to be 1-2 
orders of magnitude more potent than endothelin-1 in producing 
vasoconstriction in mammals and thus is one of the most effective 
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vasoconstrictor compounds identified to date.[7, 15, 16] On the basis 
of its spectrum of activities, hU-II has been postulated to contribute as 
modulator to cardiovascular homeostasis and possibly to be involved 
in certain cardiovascular pathologies.[15, 17] It has been recently 
demonstrated that U-II is involved in inhibition of insulin release  [18] 
in the perfused rat pancreas and may play an important role in 
pulmonary hypertension.[19] Central nervous effects of U-II have also 
been described.[20] Hence, the hU-II ligands could be of therapeutic 
value in a number of pathological disorders. It has been demonstrated 
that the C-terminal octapeptide of U-II retains full biological activity 
and binding properties.[21-26] 
The (patho)physiological role(s) of the U-II/UT receptor system 
and, most importantly, the potential interest of UT receptor ligands as 
drug candidates prompted the development of low molecular weight 
compounds as non peptide UT receptor agonists and antagonists 
(Figure 1).[27] 
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Figure 1. Some representative structures of non-peptide UTR agonists (a), and 
antagonists (b). 
 
Our research group has been involved for a long time in the 
development of UTR peptide ligands. The optimization of a peptide as 
a lead structure is important to improve its pharmacokinetic 
properties, and in identifying the pharmacophore elements, that is, to 
determine the key amino acid residues that are involved in the 
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biological activity.[28] Interestingly, some common features are 
observable (two aryl moieties and a protonable nitrogen atom) in 
organic and peptide UTR ligands.[29] Hence, the structural 
information obtained by the peptide investigation might be useful for 
the design of both small-molecules and peptide ligands.  
In previous studies, we have identified both a superagonist 
named P5U (H-Asp-c[Pen-Phe-Trp-Lys-Tyr-Cys]-Val-OH) [30] and 
an antagonist, Urantide (H-Asp-c[Pen-Phe-DTrp-Orn-Tyr-Cys]-Val-
OH) [31] of hU-II. The latter is the most potent peptide antagonist at 
UT receptor described to date. Actually, Urantide behaves as a pure 
antagonist in the rat aorta bioassay,[31] and as a full agonist in a 
calcium mobilization assay performed in CHO cells expressing the h-
UTR.[32] This point has been widely discussed elsewhere.[33] For 
sake of simplicity, we will refer to Urantide as an antagonist 
throughout the manuscript. 
Recently, we performed extensive NMR and computational 
studies on both P5U and Urantide that allowed us to formulate a 
hypothesis about the structural changes that determine the switching 
from agonist to antagonist activity.[33, 34] 
To aim to identify new leads for the development of both agonists and 
antagonists at UT receptor, we have studied the structure-activity 
relationships of a series of novel P5U and Urantide analogues based 
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on the chemical substitution of the Asp4 residue, with several other 
amino acid residues with different physicochemical properties (Figure 
2 and Figure S1). The most interesting analogues were then analysed 
by NMR and their structures fitted within h-UTR models to gain 
insight into the agonist and antagonist binding modes. 
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1.1.2 Results 
Chemistry. Peptides were synthesized according to the solid 
phase approach using standard Fmoc methodology in a manual 
reaction vessel (Experimental Section). [35] 
The purification was achieved using a semi-preparative RP-HPLC C-
18 bonded silica column (Vydac 218TP1010). The purified peptide 
was 98% pure as determined by analytical RP-HPLC. The correct 
molecular weight of the peptide was confirmed by mass spectrometry 
and amino acid analysis (Supporting Information). 
 
 
Figure 2. New synthesized compounds 
  
Biological Data. Receptor affinity at h-UTR and biological 
activity (rat aorta bioassay) of the synthesized compounds are reported 
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in Table 1. Substitution of the native Asp4 residue in P5U by an Ala 
residue (compound 1), which generated an URP analogue, slightly 
reduced the contractile potency of the peptide (pEC50=8.04). Similar 
modification in Urantide sequence produced compound 2 with 
antagonist activity but slightly less potent than Urantide (pKB 7.84). 
Subsequently, to evaluate the role of an aromatic residue in position 4 
we replaced Asp4 with a Phe residue in both sequence of P5U and 
Urantide. Compound 3 showed to be a superagonist as  P5U 
(pEC50=9.18) while the same substitution in Urantide sequence 
generated compound 4 with a reduced binding affinity but with an 
increased antagonist activity (pKi 7.71 and pKB 8.68). Then, the Asp4 
residue was replaced with some uncoded aromatic amino acids 
(Figure 2). Compound 5, in which Asp4 was replaced with a Cpa 
residue resulted to be less potent as agonist compared to P5U (pEC50  
8.86). Similar trend was observed in compound 6 with a reduced 
antagonist potency (pKB 7.85). Analogue 7, containing in position 4 a 
Nal(1) residue, showed a sensible reduction both in binding (pKi  
7.58) and functional activity (pEC50 6.99), while the same substitution 
in Urantide sequence (compound 8) resulted in a conserved antagonist 
activity (pKB 8.50). Interestingly, Nal(2) derivative of P5U 
(compound 9) regained high agonist activity (pEC50 8.28). On the 
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other hand, compound 10 resulted to be slightly less potent compared 
to compound 8 and Urantide (pKB 7.89). 
 
Table 1. Receptor Affinity and Biological Activity of P5U and 
Urantide Analogues of General Formula: 
R-c[Pena-Phe-Xaa-Yaa-Tyr-Cys]-Val-OH 
Peptide Xaa Yaa R pKi b pEC50 c pKBd 
hU-II Trp Lys * 9.10 ±0.08 8.30 ±0.06 - 
hU-II(4-
11) Trp Lys Asp 9.60±0.07 8.60 ± 0.04 - 
P5U Trp Lys Asp 9.70±0.07 9.60 ± 0.07 - 
Urantide DTrp Orn Asp 8.30 ± 0.04 Inactive 8.30 
1 Trp Lys Ala 9.10±0.08 8.04±002 - 
2 DTrp Orn Ala 8.78±0.08 - 7.84 
3 Trp Lys Phe 9.55±0.05 9.18±0.17 - 
4 DTrp Orn Phe 7.71±0.10 - 8.68 
5 Trp Lys Cpa 9.05±0.04 8.86±0.05 - 
6 DTrp Orn Cpa 8.02±0.06 - 7.85 
7 Trp Lys Nal(1) 7.58±0.06 6.99±0.13 - 
8 DTrp Orn Nal(1) 8.41±0.01 - 8.50 
9 Trp Lys Nal(2) 8.19±0.10 8.28±0.10 - 
10 DTrp Orn Nal(2) 7.93±0.01 - 7.89 
11 Trp Lys (pNO2)Phe 7.87±0.08 7.14±0.09 - 
12 DTrp Orn (pNO2)Phe 7.80±0.10 - 7.90 
13 Trp Lys Tic 8.58±0.03 8.87±0.18 - 
14 DTrp Orn Tic 8.03±0.07 - 8.94 
15 Trp Lys Lys 8.03±0.11 8.22±0.24 - 
16 DTrp Orn Lys 6.66±0.01 - 7.49 
a Cys in hU-II and hU-II(4-11). b pKi: -log Ki   c pEC50: -log EC50. d pKB (-log KB) 
values are from experiments in the rat thoracic aorta.  Each value in the table is 
mean ± s.e.m. of at least 4 determinations.  * H-Glu-Thr-Pro-Asp- 
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Replacing the Asp4 residue with the amino acid pNO2Phe in both 
parent peptides, led to compounds  with reduction in activity. In fact, 
compound 11 resulted to have a reduced binding affinity at UT 
receptor (pKi 7.87) and a more considerable reduction in functional 
activity (pEC50 7.14). Compound 12, resulted to be slightly less potent 
respect to Urantide showing a pKB of 7.90. Analogue 13, in which 
Asp4 residue was replaced with a Tic residue, showed a slightly 
reduced activity (pEC50 8.87). Surprisingly, the same substitution in 
Urantide sequence produced analogue 14 with increased antagonist 
potency showing a pKB value of  8.94. This compound represents a 
new potent antagonist discovered by this study. Finally, the 
replacement of Asp4 with a Lys residue in P5U (analogue 15) resulted 
in a reduced activity (pEC50 8.22). Worthy of note, the same 
modification in Urantide sequence produced an analogue (compound 
16) showing a dramatic reduction in binding affinity and antagonist 
activity (pKi  6.66 and pKB  7.49), being by far the weakest ligand 
among the synthesized compounds. 
NMR Analysis. A whole set of 1D and 2D NMR spectra in 200 
mM aqueous solution of SDS were collected for compounds 14, and 
16. These peptides were chosen since 14 is the most potent antagonist 
of the series while 16 has very low binding affinity and antagonist 
potency (Table 1). Micelle solution was employed since we have 
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recently reported the NMR structure of UT agonists (among which 
P5U) [34] and antagonist (among which Urantide) [33] in this 
medium. Complete 1H NMR chemical shift assignments were 
effectively achieved for the two peptides according to the Wüthrich 
procedure[36] via the usual systematic application of DQF-COSY,[37, 
38] TOCSY,[39] and NOESY [40] experiments with the support of 
the XEASY software package (Supporting Information).[41] Peptides 
14 and 16 differs from Urantide only for the N-terminal residue 
substitution and show diagnostic NMR parameters (H proton 
chemical shifts, NOE contacts, 3JNH-H and 3JH coupling constants, 
NH exchange rates and temperature coefficients) all similar to those 
observed in the parent peptide (Supporting Information). In particular, 
NOE contacts between H-NHi+2 of D-Trp7 and Tyr9 and between NH-
NHi+1 of Orn8 and Tyr9 indicated the presence of a -turn. This result 
was supported by the observation of slowly exchanging NH resonance 
of residue 9, and low value of the temperature coefficient for this 
proton (-T < 3.0 ppb/K). A short stretch of antiparallel -sheet 
involving residues 5-6 and 10-11 is inferred from a number of long-
range NOEs including H-NH connectivities between residues 5, 11 
and 10, 6 and a NH-NH connectivity between residues 6 and 9. All the 
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data indicated the preservation, in 14 and 16, of the -hairpin 
structure. 
 
 
Figure 3. Superposition of the 10 lowest energy conformers of 14 (a), 16 (b). 
Structures were superimposed using the backbone heavy atoms of residues 5-10. 
Heavy atoms are shown with different colours (carbon, green; nitrogen, blue; 
oxygen, red; sulfur, yellow). Hydrogen atoms are not shown for clarity. 
 
NMR-derived constraints obtained for the analyzed peptides 
(Supporting Information) were used as the input data for a simulated 
annealing structure calculation. For each peptide, 20 calculated 
structures satisfying the NMR-derived constraints (violations smaller 
than 0.40 Å) were chosen (Figure 3 a-b). As shown, both the peptides 
14, and 16 show a well defined type II’ -hairpin structure 
encompassing residue 5-10 (backbone rmsd values are 0.41 and 0.37 
Å, respectively). In contrast, the N- and C-terminal residues were 
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highly flexible. Considering the side chains orientation, Phe6, Orn8, 
and Tyr9 side chains showed a large preference for trans, g-, and g- 
rotamers, respectively, while D-Trp7 side chain is found both in trans 
and g+ conformation.  
Docking Studies of Urantide and its Analogues. The theoretical 
structure of the h-UT receptor (Figure 4) was generated by homology 
modeling based on the crystal structure of bovine rhodopsin (PDB 
code 1F88),[42] as described previously.[43] The resulting structure 
represents an inactive form of the h-UT receptor (h-UTRi) with an 
overall conformation very similar to that of bovine rhodopsin (1.22 Å 
rmsd between the backbone atoms of the transmembrane domains).  
 
Figure 4. Serpentine model of the h-UTR sequence. The black lines represent the 
boundaries of the membrane. Filled circles indicate the residues highly conserved 
among the GPCRs superfamily. The TM helices are denoted by roman numerals. 
The arabic numbers indicate the position of the residues inside the TM domain. 
The glycosilation sites on the N-terminal region are also shown. 
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Since the currently available docking programs may not work 
very well for peptide compounds, manual docking was conducted for 
Urantide. The NMR-derived Urantide structure [33] was placed in 
between the trans-membrane domains of the h-UTRi, employing the 
following criteria to achieve meaningful docking modes: (i) The 
positively charged amino group of Orn8 had to be close to and 
pointing in the direction of the carboxylate group of Asp130, which is 
conserved in many GPCRs and positioned in the TM-III region; (ii) 
N-terminal residues should point towards extracellular loops as 
experimentally determined [44]; (iii) No steric clashes should occur 
between any atom. To assess the stability of the Urantide/h-UTRi 
complex and to analyze the potential ligand/receptor interactions, 
energy minimization and MD simulations of 2 ns at a constant 
temperature of 300 K were run. During the MD simulation, the ligand, 
the EL’s, and all the receptor side chains were allowed to relax, while 
the TM’s and IL’s backbone atoms were held frozen. The distances 
between the peptide and the key receptor residues were monitored 
along the complete 2 ns MD trajectory (Supporting Information). 
To inspect the variations in the ligand conformation, rmsd with 
respect to the starting structure was calculated. Interestingly, the rmsd 
of Urantide backbone atoms turned out to be remarkably stable 
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throughout all the MD simulations (0 < rmsd < 0.6), indicating that 
the peptide settles into the receptor-binding site in a stable -hairpin 
conformation. Also the side chain orientations are those described by 
NMR. Interestingly, D-Trp7 prefers a trans orientation about 1 angle 
(1 ≈ 180°, 2 ≈ -70°). As shown in Figure 5a, the hypothetical 
binding site of Urantide is located among TM-III÷TM-VII, and EL-II. 
The -hairpin is oriented along the receptor helical axis, with the N- 
and C-terminal residues pointing towards the extracellular side. The 
binding mode of the peptide is determined mainly by the interactions 
showed in Figure 5b and Table 2. 
 
Table 2. Urantide/h-UTRi Interactions 
Residue* Surrounding residue 
Asp4 Ala187 (EL-II), Met188 (EL-II), Cys199 (EL-II), Arg206 
(EL-II), Ala207 (EL-II) 
Pen5 Gln278 (TM-VI), Pro287 (EL-III) 
Phe6 Cys123 (EL-I), Val184 (TM-IV), Met188 (EL-II)  
D-Trp7 Phe131 (TM-III), Met134 (TM-III), His135 (TM-III), 
Leu212 (TM-V), Leu215 (TM-V), Phe216 (TM-V), Ile220 
(TM-V), Trp275 (TM-VI), Gln278 (TM-VI) 
Orn8 Asp130 (TM-III), Thr301 (TM-VII), Thr304 (TM-VII) 
Tyr9 Phe127 (TM-III), Phe274 (TM-VI), Asn297 (TM-VII), 
Thr301 (TM-VII) 
Cys10 Cys199 (EL-II), Pro287 ((EL-III) 
Val11 Cys123 (EL-I), Arg189 (EL-II), Cys199 (EL-II), Leu288 
(EL-III). 
* For sake of clarity, the residue numbers of the ligands are reported as apex while 
those of the receptor are not.  
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In particular, (i) a tight charge-reinforced hydrogen-bonding 
network involving the carboxylate group of Asp130 and the 
protonated -amino group of Orn8 of Urantide is established. Such an 
interaction, which we assume to be an anchoring point of the ligand to 
h-UTR, remained stable during the whole production run (Supporting 
Information, Figure S2). (ii) Three hydrophobic pockets, delimited by 
residues listed in Table 2, host the aromatic side chains of Phe6, D-
Trp7, and Tyr9 of Urantide. Particularly, the indole system of D-Trp7 
appears to be optimally oriented for a -stacking interaction with the 
aromatic indole system of Trp275. Furthermore, the phenolic OH of 
Tyr9 is at hydrogen-bonding distance with the side chain CO of 
Asn297, and OH of Thr301. (iii) Asp4 in Urantide is involved in a 
hydrogen-bonding network. Particularly, the oxygen atoms of the 
carboxylate form two charge-reinforced hydrogen bonds with Arg206 
guanidinium group. In addition, the protonated N-terminal group of 
Asp4 engages additional hydrogen bonds with the backbone CO of 
Ala187, Cys199 and Met188. (iv) Finally, the negatively charged C-
terminal group establishes two hydrogen bonds with backbone HN of 
Cys123 and Cys 199, and a salt bridge with the protonated 
guanidinium moiety of Arg189 (EL-II). All the aforementioned 
interactions resulted to be quite stable during the whole MD 
production run (see Figure S2-S11 for details). The mean structure of 
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the last 1 ns of MD was extensively minimized and used for 
subsequent analysis. 
Since the NMR results indicate that the 3D structure of the Urantide 
analogues 14 and 16 did not change after the replacement of the N-
terminal residue, we used the energy-minimized structure 
of the Urantide/h-UTRi complex as starting point for the docking 
procedure of these derivatives. After replacing Asp4 of Urantide with 
Tic4  to give compound 14 and with Lys4 to give 16, the complexes 
were minimized and then subjected to a 200 ps MD simulation. The 
mean structures of the last 100 ps of the MD trajectory were then 
minimized and used for subsequent analysis. 
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Figure 5. (a) Stereoview of h-UTRi model complexed with Urantide. Urantide 
heavy atoms are colour coded as in Figure 2. Receptor backbones are represented 
in azure and labeled. (b) Stereoview of Urantide within the binding pocket of h-
UTRi. Hydrogen bonds are represented with dashed lines. 
 
While the same interactions with h-UTRi were recorded for the 
unchanged residues, in the 14/UTRi complex, Tic4 interacts with 
Val184 (TM-IV), Ala187 (EL-II), Leu200 (EL-II), Pro201 (EL-II), 
and Tyr211 (TM-V); while in the 16/UTR complex Lys4 residue takes 
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contact with Leu200 (EL-II), and Tyr211 (TM-V). In Table 3 
ligand/receptor Gbind values are reported as calculated employing the 
AutoDock4 program native scoring function.[45-47] Interestingly, 
there is a clear, although qualitative, correlation between the predicted 
Gbind values and the experimental binding constants (Table 1).  
Docking of P5U and its Analogues. The three-dimensional 
model of the h-UTR, in the active state (h-UTRa), was constructed 
from the model structure of the bovine rhodopsin, proposed by 
Mosberg,[48] and was generated by homology modeling following the 
same steps described for the inactive model.[43]  
 
Table 3. Binding free energies (ΔGAD4) calculated for the energy 
minimized averaged complexes deriving from the MD simulations. 
Receptor Ligand Gbinda Electrb H-Bondb VdWb Desolvb Torsb 
h-UTRic Urantide -24.33 -4.99 -5.90 -26.50 7.09 5.97 
h-UTRi 14 -23.01 -3.21 -3.83 -26.98 5.94 5.07 
h-UTRi 16 -21.10 -3.31 -5.77 -25.16 6.28 6.86 
h-UTRa P5U -24.53 -4.99 -6.11 -25.89 6.69 5.76 
h-UTRa 13 -23.53 -3.35 -4.19 -27.40 6.03 5.37 
h-UTRa 15 -23.01 -4.11 -6.77 -25.40 6.31 6.96 
h-UTRa Urantide -20.65 -5.92 -6.42 -21.39 7.11 5.97 
h-UTRi P5U -18.68 -3.60 -3.47 -24.67 6.80 6.26 
aGbind: free energy of binding. bEnergy terms contributing to the AutoDock4 
scoring function. Electr: electrostatic; H-Bond: H-Bonding; VdW: Van der Waals; 
Desolv: desolvation; Tors: torsional entropy. All terms are given in kcal/mol. ch-
UTRi: receptor in the inactive state. h-UTRa: receptor in the active state.  
 
A comparison of models for the active and inactive states of h-
UTR reveals the structural changes that accompany activation. 
Chapter 1 
- 25 -	
 
Overall, the rmsd between these models is 2.3 Å calculated for the 
backbone atoms of all the TM’s, but decreases to 1.7 Å after 
excluding TM-VI, which experiences a rearrangements upon receptor 
activation. Indeed, TM-VI shifts outward and rotates 
counterclockwise (viewed from the extracellular side) during 
activation, moving its intracellular end away from TM-III and toward 
TM-V. As a result of this and other changes, the receptor structure 
tightens near its extracellular surface but opens up at the cytoplasmic 
side, providing a cavity for binding of the Gs subunit.  
The NMR-derived P5U structure [34] was placed in between the 
trans-membrane domains of the h-UTRa model, following the same 
criteria used for Urantide (see above) to achieve meaningful binding 
poses. Energy minimization and MD simulations (2 ns) were run to 
assess the stability of the P5U/h-UTRa complex and to analyze the 
potential ligand/receptor interactions.  
To inspect the variations in the ligand conformation, rmsd with 
respect to the starting structure was calculated. Interestingly, the rmsd 
of P5U backbone atoms turned out to be really stable throughout all 
the MD simulations (0 < rmsd < 0.5), indicating that the peptide 
settles into the receptor-binding site in a stable -hairpin 
conformation. Also the side chain orientations are those described by 
NMR.[34] 
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As shown in Figure 6a, the hypothetical binding site of P5U is 
located among TM-III÷TM-VII, EL-II and EL-III. The -hairpin is 
oriented along the receptor helical axis, with the N- and C-terminal 
residues pointing towards the extracellular side. The binding mode of 
P5U is determined mainly by the interactions showed in Figure 6b and 
Table 4. 
 
Table 4. P5U/h-UTRa Interactions 
Residue Surrounding residue 
Asp4 Pro201 (EL-II), Gln285 (EL-III) 
Pen5 His208 (EL-II), Trp277 (TM-VI), Ala281 (TM-VI), Ala286 
(EL-III) 
Phe6 Val184 (TM-IV), Met188 (EL-II), Leu212 (TM-V)  
Trp7 Phe131 (TM-III), Met134 (TM-III), Phe274 (TM-VI), 
Trp275 (TM-VI), Gln278 (TM-VI) 
Lys8 Asp130 (TM-III), Tyr305 (TM-VII) 
Tyr9 Trp116(TM-II), Cys123 (EL-I), Leu126 (TM-III), Phe127 
(TM-III), Cys199 (EL-II) 
Cys10 Trp277 (TM-VI) 
Val11 Arg189 (EL-II), Cys199 (EL-II) 
 
 
As for Urantide, a stable (Figure S12) charge-reinforced 
hydrogen-bonding network involved the carboxylate group of Asp130 
and the protonated -amino group of  Lys8 of P5U is observed. Three 
hydrophobic pockets, delimited by residues listed in Table 4, host the 
aromatic side chains of Phe6, Trp7, and Tyr9. These hydrophobic 
pockets only partially overlap with those of Urantide. For instance, 
Tyr9 OH group is not engaged in any hydrogen bond. Again, the 
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negatively charged C-terminal group of Val11 establishes a hydrogen 
bond with Cys199 backbone NH, and a salt bridge with the protonated 
guanidinium moiety of Arg189. 
Differently from Urantide, Asp4 in P5U is involved in a 
hydrogen-bond with the Gln285 (EL-III) NH2 group. This H-bond is 
not stable during the MD trajectory (Figure S13). The mean structure 
of the last 1 ns of MD was extensively minimized and used for 
subsequent analysis.  
Replacing the Asp4 residue of P5U with Tic or Lys residue 
(obtaining the derivatives 13 and 15, respectively) in the P5U/h-UTR 
model complex, and following the same optimization steps used for 
the complexes of Urantide analogues (see above), we obtained the two 
models: 13/h-UTRa and 15/h-UTRa, showing similar binding energy 
(Table 3) in accordance with the experimental binding data (Table 1). 
Switching the ligands. To assess the predictive value of the 
receptor models the ligands were switched, i.e. urantide was docked 
within h-UTRa and P5U within h-UTRi model (Figure S14). For the 
docking of urantide, we started from the optimized P5U/UTRa 
complex and superposed the NMR derived urantide structure with that 
of P5U (backbone atoms of residues 5-10). Then, we removed the 
P5U structure and optimized the urantide/UTRa complex. Analogous 
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steps were taken for the P5U/UTRi complex. In Table 3, the binding 
energies of the two complexes are reported. 
 
Figure 6. (a) Stereoview of h-UTRa model complexed with P5U. P5U heavy 
atoms are colour coded as in Figure 2. Receptor backbones are represented in 
azure and labeled. (b) Stereoview of P5U within the binding pocket of h-UTRa. 
Hydrogen bonds are represented with dashed lines. 
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1.1.3. Discussion 
Previous studies have demonstrated that the C-terminal 
octapeptide of hU-II [U-II(4-11), Table 1] mimicked the effects of U-
II on intracellular calcium concentration in UTR-transfected cells and 
contraction of rat aortic rings.[22, 24, 25] Recently, Coy et coll. have 
examined the role of the N-terminal Asp residue in UII(4–11) since 
this acidic amino acid embodies one of the main structural differences 
between the UII(4–11) and somatostatin octapeptides  which results in 
little somatostatin affinity for the UT receptor.[26] They found that 
the N-terminal amino acid does not require a negatively charged side 
chain, merely one which has a hydrogen bond acceptor CO group. The 
side chain can be constrained into a trans-olefinic configuration and 
can also contain an aromatic ring substituted with polar groups such as 
OH and NO2. Afterwards, Salvadori et coll. examined the same 
position of hU-II(4-11) using a number of aromatic residues.[49] They 
found that all of the new analogues behaved as full agonists, and that 
aromaticity is well tolerated; size, length and chirality of the side 
chain are not important, while substituents with a nitrogen atom are 
preferred. On bases of these considerations and to further investigate 
the contribution of the N-terminal Asp residue in the biological 
activity, we synthesized 16 analogues of P5U and Urantide substituted 
at this position with amino acids bearing different physicochemical 
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properties (Table 1). In particular, Urantide was used as lead 
compound to investigate the N-terminal position in analogues with 
potential antagonist activity. All synthesized compounds were tested 
for their binding affinity on h-UTR-transfected CHO cells and for 
their contractile activity on de-endothelialized rat aortic rings (Table 
1).[31] 
Overall, the biological data indicate that in the “agonist series” 
(i.e. derived from P5U) the N-terminal substitutions of Asp4 with 
uncharged, aromatic or positively charged residues are generally well 
tolerated. The consistent reduction in binding and activity is probably 
due to the lost of a hydrogen bond acceptor/donor group, in 
accordance with previous results.[26, 49] Concerning the “antagonist 
series” (i.e. derived from Urantide), while a positively charged amino 
acid (Lys) strongly reduces the binding and the activity (compound 
16), an aromatic residue is well tolerated and can increase the potency. 
In particular, compound 14, in which a Tic residue replaces the Asp4 
of Urantide, showed the highest antagonist potency in the functional 
rat aorta bioassay (pKB 8.94). Since the binding constant of 14 to h-
UTR is slightly reduced compared to Urantide, the enhanced 
functional potency should derive from improved tissue penetration of 
the more hydrophobic Tic amino acid in 14 replacing an Asp residue 
in Urantide. Species differences between h-UTR and r-UTR could 
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also be invoked. To check the last hypothesis, the sequences of h-UTR 
and r-UTR were compared (Figure S15). Since only minimal residue 
differences were observed near the bound ligand and, in particular, 
near to the Tic residue (EL2 is unchanged in the two receptors), the 
hypothesis was rejected.  
To determine whether the different biological activities of 
Urantide analogues were driven by different conformational properties 
of the peptides or by the different chemical functionalities at the N-
terminus, we performed an NMR study on the interesting analogues 
14 and 16 in SDS micelles solution. The use of SDS micelles to study 
the conformational properties of hU-II analogues is motivated on the 
basis of their interaction with a membrane receptor. For peptides 
acting as ligands of membrane receptors (such as GPCR), the use of 
membrane mimetic media, such as SDS or DPC, is suggested 
hypothesizing a membrane-assisted mechanism of interactions 
between the peptides and their receptors.[50] According to this model, 
the membrane surface plays a key role in facilitating the transition of 
the peptide from a random coil conformation adopted in the 
extracellular environment to a conformation that is recognized by the 
receptor. The increase of the local concentration of the peptide and the 
reduction of the rotational and translational freedom of the 
neuropeptide are membrane-mediated events acting as determinant 
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steps for the conformational transition of the peptide.[51, 52] NMR 
has proven useful to examine the structures of bioactive peptides that 
cross membrane barriers.[53-55] Actually, we succeeded in 
correlating the SDS-bound conformation of hU-II analogues with their 
biological activity.[33, 34] 
We showed that hU-II analogues, which retain high affinity for 
UT receptor, all possess a type II’ -hairpin backbone conformation 
regardless their agonist or antagonist activity, indicating that such 
backbone conformation is necessary for the UT recognition.[33, 34] 
The main conformational difference observed in the structures of the 
antagonists and the agonists was established in a different orientation 
of the (D/L)-Trp7 side chain. In particular, while in the agonists the 
(D/L)-Trp7 indole moiety is close to the Lys8 side chain, in the 
antagonists (D/L)-Trp7 side chain is more flexible and further from the 
ornitine side chain. The structural features of the “antagonist series” 
were found also for the analogues 14, and 16 (Figure 3) indicating that 
the different affinity-activity of the two compounds do not depend on 
a different spatial disposition of the “pharmacophoric” residues (i.e. 
(D/L)-Trp7, Lys/Orn8, Tyr9) [22, 23] but must depend on different 
interaction of the N-terminal residue with the receptor.  
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Figure 7. Stereoview of h-UTR models in the inactive (azure) and active (sienna) 
conformations complexed with Urantide (red) and P5U (gold), respectively. The 
h-UTR models are superimposed using the backbone heavy atoms of TM residues 
apart from TM-VI. Asp4 residue is evidenced by an arrow. 
 
To gain insight into this interaction mode we first undertook a 
docking study between the parent Urantide and h-UT receptor model. 
It is worth noting that, while docking studies regarding peptide agonist 
have been performed,[23, 43, 44, 56] the docking of peptide 
antagonist at UT receptor is unprecedented. Since the crystal structure 
of a GPCR in the active conformation is not yet disposable, we used 
the “active state” rhodopsin model developed by Mosberg et al. as 
template to build an h-UTRa model.[48] Hence, the rhodopsin receptor 
template was also chosen for the inactive state model (h-UTRi) to 
allow a direct comparison of the two models. The structures of other 
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mammalian GPCR’s in inactive state have been solved.[57-59] 
Interestingly, our h-UTRi model and the 2-adrenergic receptor 
(2AR, PDB code 2RH1) are quite similar around the urantide binding 
site showing an rmsd of the backbone heavy atoms of 1.5 Å (helices 
II÷VII, Figure S16).  
Urantide/h-UTRi complex (Figure 5) and the MD simulations 
indicated that: (i) the -hairpin structure adequately fits the binding 
site and is stable during the MD trajectory; (ii) the binding site, 
situated in the entrance of the TM bundle on the extracellular side, is 
formed by TM-III÷TM-VII, and EL-II; (iii) particularly important for 
the present study, the N-terminal Asp4 residue interacts with EL-II, 
mostly by stable electrostatic interactions with the Arg206. 
Replacement of Asp4 with a Lys residue (analogue 16), in the model 
complex, increase the binding energy (Table 3) since the favorable 
interactions are lost and, in contrast, electrostatic repulsions between 
N of Lys4 and the guanidinium group of five arginine and the N of 
one lysine residues located on the EL-II can occur. In contrast, the loss 
of favorable electrostatic interaction, upon the replacement of the Asp4 
of Urantide with a Tic residue (analogue 14), is partially compensated 
by van der Waals interactions of the phenyl ring of Tic and by a 
reduced desolvation energy.  
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Docking study between P5U and h-UTRa was also performed. 
The obtained complex (Figure 6) and the MD simulations indicated 
that: (i) the -hairpin structure adequately fits the binding site and is 
stable during the MD trajectory; (ii) the binding site, situated in the 
entrance of the TM bundle on the extracellular side, is formed by TM-
III÷TM-VII, EL-II; and EL-III; (iii) the N-terminal Asp4 residue lies 
between EL-II and EL-III. We found similarities, but also some 
differences, with previous reports describing the docking of peptide 
agonists (hU-II, and P5U) into an UTR model.[23, 43, 44, 56] In 
regards to our previous work,[43] the different docking results 
obtained for the P5U/h-UTR complex is ascribable to the different 
conformation of both the receptor and the ligand. In fact, in the 
present study the h-UTR structure is based on an active model of 
rhodopsin,[48] while in the previous work the receptor was 
constructed starting from the X-ray inactivated form of rhodopsin.[42] 
Moreover, herein the presented P5U 3D structure is obtained from a 
NMR study in SDS micelle solution,[34] while the one used in 2005 
was derived from a NMR study in DMSO solution.[30]  
To assess the predictive value of the models the ligands were 
switched, i.e. urantide was docked within h-UTRa model and P5U 
within h-UTRi (Figure S14). Both urantide/UTRa and P5U/UTRi 
complexes show negative binding energies (Table 3), but these are 
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significantly lower (absolute value) than the ones of urantide/UTRi 
and P5U/UTRa complexes, respectively. These results are not 
surprising. In fact, urantide still retains agonist activity being a full 
agonist in a calcium mobilization assay.[32] Interestingly, D-Trp7 
aromatic moiety of urantide within UTRa binding site is close to the 
Orn8 side chain in a conformation which characterizes the agonist 
peptide ligands (Figure S14).[33] As concern P5U/UTRi complex, the 
negative value of the binding energy can be explained admitting that, 
in a first step, even the agonists bind the receptor in its inactive 
(ground) state. Then, the system moves to a minimum of free energy 
which is reached with the receptor activation. 
Urantide/h-UTRi and P5U/h-UTRa interactions found in our 
models (Table 2, Table 4 and Figure 7) are different. In particular, 
Urantide plunges more deeply into the TM’s bundle compared to P5U, 
probably due to the ornitine side chain length reduction, and to the D-
Trp7 higher flexibility. As a consequence, the exocyclic carboxylate 
group of Asp4 of P5U, lying at the interface between EL-II and EL-III, 
is more external compared to the corresponding residue in Urantide, 
and establishes only non-stable hydrogen bond with the receptor. In 
accordance with SAR data obtained by us and others,[26, 49] the 
presence of both aromatic (13) or positively charged (15) residues at 
Chapter 1 
- 37 -	
 
position 4 of P5U leads to compounds with similar binding energy 
(Table 3).  
Recently published experimental results, reporting that the 
agonists and antagonists (partial agonists) interact differently with the 
UT receptor, are in accordance with our models.[44, 60] Boivin et al. 
measured the interactions of hU-II, URP and Urantide with separately 
synthesized h-UT receptor EL’s.[60, 61] They observed that agonist 
hU-II and URP bind EL-II and EL-III while the binding of Urantide 
was observed only with EL-II. None of these ligands were able to 
interact with EL-I. These results are fully consistent with our models. 
Leduc et al. found various interactions between photoreactive hU-II 
and Urantide analogues and r-UTR.[44, 62] Also, these interactions 
are compatible with our models. 
The proposed binding modes are also in qualitative agreement to 
the observed SAR at the core -Phe-Trp-Lys-Tyr- sequence. In fact, 
pharmacophoric residues Trp7, Lys(Orn)8, and Tyr9, whose 
substitution with Ala significantly reduces or abolishes the binding 
affinity of U-II analogues, show a high number of receptor 
interactions. In contrast, Phe6 shows only a few interactions in 
accordance with SAR indicating that its substitution with Ala results 
in a still full agonist peptide.  Furthermore, substitution of the 
hydroxyl group of Tyr9 of U-II with methoxy, nitro, amino, methyl, 
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fluoro, or a hydrogen atom does not affect the potency and the 
efficacy of the U-II analogues in the rat aorta bioassay.[63] These 
observations agree with our model since the phenolic OH is not 
involved in receptor binding in the P5U/UTRa model. Substitution of 
the Tyr residue by bulky aromatic amino acids such as (2-naphthyl)-L-
alanine, biphenylalanine,[23] or 3-iodo-tyrosine [25] may even 
increase the binding affinity and the biological activity. Consistently, 
the tyrosine-binding pocket of our model can accommodate a bulkier 
side chain with an enhancement of the hydrophobic interactions. SAR 
data suggest that the presence of an aliphatic amine at position 9 is 
mandatory for U-II activity.[63] The position of the NH2 from the 
peptide backbone has been investigated using ornithine, 2,4-
diaminobutyric acid (Dab), and 2,3-diaminopropionic acid (Dap), i.e. 
with distances of 3, 2 and 1 carbon atoms, respectively. Reduction of 
the distance between the primary aliphatic amine and the peptide 
backbone of 3 and 2 methylene groups gradually reduces the potency 
and efficacy of the analogs and switch the activity towards 
antagonism. Further shortening of the amino acid side-chain increases 
potency and restores efficacy. Interestingly, the Dab8-urantide 
analogue UFP-803 behaves as a pure antagonist (pA2 7.46).[64] Our 
model can explain these results. In fact, a distance of 3 methylene 
groups is suitable for both UTRi and UTRa ligands, such as urantide 
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(Gbind = -3.88 Kcal/mol, Table 3). A distance of 2 methylene 
groups is also suitable for the two receptor states but with a much 
preferred antagonist mode (for UFP-803, Gbind = -5.41 Kcal/mol; 
data not shown). Little attention has been paid to the Trp9 residue in 
the SAR studies of U-II apart from the Ala- and D-scan approaches. 
Replacement of the Trp residue with 2-Nal,[23] or 4-benzoyl-L-
phenylalanine (Bpa) [62] significantly decreased agonist binding 
affinity and potency. This would suggest that the indole NH function 
may establish a hydrogen bond with some UTR residue. We don’t 
observe this postulated H-bond and believe that the indole electron 
rich system is more suitable for a cation- interaction with the Lys8 
side chain observed in the peptide agonist ligands.[33] 
Based on the binding mode of UTR peptide agonists and 
antagonists, we derived new 3D pharmacophore models illustrated in 
Figure 8. The distances between the pharmacophoric residues (i.e. 
mean distances observed during the 2 ns MD simulations) are in good 
accordance with those previously reported both for peptide agonists 
and antagonists.[33] These pharmacophore models might be useful for 
the next design cycle and, in particular, for the design of small-
molecule ligands.  
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Figure 8. Stereoview of the pharmacophore model for peptide antagonists (a) and 
agonists (b). The distances between the aryl ring centroids of (D)Trp7 and Tyr9, 
and the N of Lys(Orn)8, are displayed. Distances and standard deviations are 
obtained from one hundred structures saved every 20 ps of the MD simulations. 
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1.1.4 Conclusions 
In conclusion, we observed a different SAR at the N-terminus for 
P5U compared to Urantide analogues. P5U shows a high degree of 
tolerance upon N-terminal substitutions. In Urantide analogues, an 
aromatic residue is well tolerated and can increase the potency. In 
fact, replacement of the Asp4 residue by Tic led to an analogue, 
compound 14, more potent as antagonist (pKB = 8.94) compared to 
Urantide. Conversely, a positively charged amino acid (Lys) 
drastically reduces the binding and the activity. The results could be 
explained on the basis of the different receptor binding mode of the 
agonist P5U vs the antagonist Urantide. Understanding of the impact 
of amino acid substitutions in position 4, combined with information 
regarding the interactions between UT receptor and its ligands, is 
crucial to increase the knowledge of structure-function relationships 
focused to the design of new potent UT receptor ligands. 
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1.1.5. Experimental Section 
Synthesis. N-Fmoc-protected amino acids, HBTU and HOBt 
were purchased from Inbios (Naples, Italy). Wang resin was 
purchased from Advanced ChemTech (Louisville, KY). Protected Pen 
was purchased from Bachem (Basel, Switzerland). Peptide synthesis 
solvents, reagents, as well as CH3CN for HPLC were reagent grade 
and were acquired from commercial sources and used without further 
purification unless otherwise noted. The synthesis of hU-II analogues 
was performed in a stepwise fashion via the solid-phase method. N-
Fmoc-Val-OH was coupled to Wang resin (0.5 g, 0.7 mmol NH2/g). 
The following protected amino acids were then added stepwise N-
Fmoc-Cys(Trt)-OH, N-Fmoc-Tyr(OtBu)-OH, N-Fmoc-Yaa(N -
Boc)-OH (Yaa: Lys, Orn), N-Fmoc-Xaa(Nin-Boc)-OH (Xaa: Trp, 
DTrp), N-Fmoc-Phe-OH, N-Fmoc-Pen(Trt)-OH and N -Fmoc-R-
OH (R = Phe, Cpa, Ala, (pNO2)Phe, Tic, Nal(1), Nal(2), Lys).  Each 
coupling reaction was accomplished using a 3-fold excess of amino 
acid with HBTU and HOBt in the presence of DIEA. 
The N -Fmoc protecting groups were removed by treating the 
protected peptide resin with a 25% solution of piperidine in DMF, 
(1x5 min and 1x20 min). The peptide resin was washed three times 
with DMF and the next coupling step was initiated in a stepwise 
manner. All reactions were performed under an Ar atmosphere. The 
Chapter 1 
- 43 -	
 
peptide resin was washed with DCM (3x), DMF (3x) and DCM (4x), 
and the deprotection protocol was repeated after each coupling step. 
The N-terminal Fmoc group was removed as described above and the 
peptide was released from the resin with TFA/ Et3SiH /H2O (90:5:5) 
for 3 h. The resin was removed by filtration and the crude peptide was 
recovered by precipitation with cold anhydrous ethyl ether to give a 
white powder which was purified by RP-HPLC on a semi-preparative 
C18-bonded silica column (Vydac 218TP1010, 1.0 x 25 cm) using a 
gradient of CH3CN in 0.1% aqueous TFA (from 10 to 90% in 45 min) 
at a flow rate of 1.0 mL/min. The product was obtained by 
lyophilization of the appropriate fractions after removal of the CH3CN 
by rotary evaporation. Analytical RP-HPLC indicated a purity > 98% 
and molecular weights were confirmed by FAB-MS (Fisons mod. 
Prospec) or HR-MS (Kratos Analytical mod. Kompact) (Supporting 
Information). 
General Method of Oxidation and Cyclization. The peptides 
were oxidized by the syringe pump method previously reported.[65] 
The linear peptide (300-500mg) was dissolved in 40ml of 
50%H2O/25% acetonitrile/25% methanol, and nitrogen gas was 
passed through the solution for 20 min. Five milliliters of saturated 
ammonium acetate solution were added, and the pH was taken to 8,5 
with NH4OH. The peptide solution was then added at room 
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temperature via syringe pump to a stirred oxidant solution. The 
oxidant solution was prepared as follows: 2 equiv of potassium 
ferricyanide were dissolved in 400ml of H2O/200ml of acetonitrile 
/200ml of methanol. To this solution was added 100 ml of saturated 
ammonium acetate, and the pH was then taken to 8,5 with NH4OH. 
The peptide solution was added at such a rate that approximately 
10mg of peptide were delivered per hour per liter of the oxidant. After 
the addition of peptide was complete, the reaction mixture was stirred 
for an additional 5-6h and then taken to pH 3.5 with glacial acetic 
acid. Amberlite IRA-68 (Cl - form) was added to remove the iron ions 
and the solution stirred for 20min and then filtered. The solution was 
concentrated using a rotary evaporator at 30°C and then lyophilized. 
The material thus obtained was dissolved in glacial acetic acid, 
filtered to remove inorganic salts, and relyophilized. The crude cyclic 
peptides were purified by preparative HPLC on the system described 
above, using a gradient of 100% buffer for 20min, then 0-20% 
acetonitrile in 5 min, followed by 20-60% acetonitrile in 40 min, all at 
40ml/min. Again the peptides eluted near 50% organic /50% buffer. 
The purity of the cyclic peptides was checked by analytical HPLC (C-
18 column, Vydac 218TP104, 4,6mm X 25cm), using a Shimadzu 
SPD 10A vp with detection at 230 and 254 nm and by TLC in four 
solvent systems in silica gel with detection by UV light, iodine 
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vapours, and ninhydrin. The analytical data of the compounds 
synthesized in this work are given in the Supporting Information. 
Organ Bath Experiments. The experimental procedures 
employed in this study were approved by Institutional Animal Care 
and Use Committee and carried out in accordance with the legislation 
of Italian authorities (D.L. 116 27/01/1992), which complies with 
European Community guidelines (CEE Directive 86/609) for the care 
and use of experimental animals. 
Male albino rats (Wistar strain, 275–350 g) were euthanized by 
cervical dislocation, under ether anaesthesia. The thoracic aorta was 
cleared of surrounding tissue and excised from the aortic arch to the 
diaphragm. From each vessel, a helically cut strip was prepared, and 
then it was cut into two parallel strips. The endothelium was removed 
by gently rubbing the vessel intimal  surface with a cotton-tip 
applicator; the effectiveness of this manoeuvre was assessed by the 
loss of relaxation response to acetylcholine (1 µM) in noradrenaline (1 
µM) precontracted preparations. All preparations were placed in 5ml 
organ baths filled with normal Krebs solution warmed at 37° C and 
oxygenated with 95% O2, 5% CO2. The tissues were connected to 
isotonic force transducers (Ugo Basile, VA, Italy) under a constant 
load of 5mN and motor activity was digitally recorded by an Octal 
Bridge Amplifier connected to PowerLab/8sp hardware system and 
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analyzed using the Chart 4.2 software (AD Instruments, Australia). 
After 60 min equilibration, tissue responsiveness was assessed by the 
addition of 1 µM noradrenaline followed by a further equilibration of 
60 min. 
To assess the agonist activity cumulative concentration-response 
curves to hU-II and to the agonist peptide under examination were 
constructed in paired aortic strips and responses obtained were 
normalized towards the control hU-II maximal contractile effect 
(Emax). 
To assess the antagonist activity concentration–response curves 
to hU-II were constructed cumulatively in paired aortic strips. One 
strip was pretreated with vehicle (DMSO; 1-3 µl/ml) and used as a 
control, while the other strip was pretreated with the antagonist 
peptide under examination and, after a 30-min incubation period, hU-
II was administered cumulatively to both preparations. 
In each preparation only one cumulative concentration-response 
curve to hU-II was carried out and only one concentration of 
antagonist was tested. Concentration-response curves were analyzed 
by sigmoidal nonlinear regression fit using the GraphPad Prism 4.0 
program (San Diego, CA, U.S.A.) to determine the molar 
concentration of the agonist producing the 50% (EC50) of its maximal 
effect. Agonist activity of all compounds was expressed as pEC50 
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(−log EC50). The antagonist potency was expressed as apparent pKB 
(−logKB) calculated from the equation: pKB = − (log CR - 1 - log 
antagonist concentration) where the concentration-ratio (CR) is the 
ratio of equieffective concentrations (EC50) of hU-II in the presence 
and absence of antagonist.[66, 67] The nature of the antagonism was 
checked by means of Schild analysis. 
Binding experiments. All experiments were performed on 
membranes obtained from stable CHO-K1 cells expressing the 
recombinant human UT receptor (Euroscreen ES-440-M, Bruxelles, 
Belgium). Assay conditions were: TRIS-buffer (20mM, pH 7.4 at 37° 
C) added with MgCl2 (5mM) and 0.5% BSA. Final assay volume was 
0.1 ml, containing 1 µg membrane proteins. The radioligand used for 
competition experiments was [125I]Urotensin II (specific activity 2000 
Ci/mmol; Amersham Biosciences, Buckinghamshire, U.K.) in the 
range 0.07–1.4 nM (corresponding to 1/10–1/5 of its KD). Non-
specific binding was determined in the presence of 1 µM of unlabelled 
hU-II, and ranged between 10–20% of total binding. Competing 
ligands were tested in a wide range of concentrations (1 pM – 10 µM). 
The incubation period (120 min at 37° C) was terminated by rapid 
filtration through UniFilter-96 plates (Packard Instrument Company), 
pre-soaked for at least 2 h in BSA 0.5%, and using a MicroMate 96 
Cell Harvester (Packard Instrument Company). The filters were then 
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washed 4 times with 0.2 ml aliquots of Tris-HCl buffer (20mM, pH 
7.4, 4°C). Filters were dried and soaked in Microscint 40 (50 µl in 
each well, Packard Instrument Company), and bound radioactivity 
was counted by a TopCount Microplate Scintillation Counter (Packard 
Instrument Company). Determinations were performed in duplicate. 
All binding data were fitted by using GraphPad Prism 4.0 in order to 
determine the equilibrium dissociation constant (Kd) from homologous 
competition experiments, the ligand concentration inhibiting the 
radioligand binding of the 50% (IC50) from heterologous competition 
experiments. Ki values were calculated from IC50 using the Cheng-
Prusoff equation (Ki = IC50/(1 + [radioligand]/Kd) according to the 
concentration and Kd of the radioligand.[56] 
NMR Sample Preparation. 99.9% 2H2O were obtained from 
Aldrich (Milwaukee, USA), 98% SDS-d25 was obtained from 
Cambridge Isotope Laboratories, Inc. (Andover, USA), [(2,2,3,3-
tetradeuterio-3-(trimethylsilanyl)]propionic acid (TSP) from MSD 
Isotopes (Montreal, Canada). 
NMR Spectroscopy. The samples for NMR spectroscopy were 
prepared by dissolving the appropriate amount of peptide in 0.45 ml of 
1H2O (pH 5.5), 0.05 ml of 2H2O to obtain a concentration 1-2 mM of 
peptides and 200 mM of SDS-d25. NH exchange studies were 
performed dissolving peptides in 0.50 ml of 2H2O and 200 mM of 
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SDS-d25. NMR spectra were recorded on a Varian INOVA 700 MHz 
spectrometer equipped with a z-gradient 5 mm triple-resonance probe 
head. All the spectra were recorded at a temperature of 25 °C. The 
spectra were calibrated relative to TSP (0.00 ppm) as internal 
standard. One-dimensional (1D) NMR spectra were recorded in the 
Fourier mode with quadrature detection. The water signal was 
suppressed by gradient echo.[68] 2D DQF-COSY,[37, 38] TOCSY 
[39], NOESY [40] and PE-COSY [69] spectra were recorded in the 
phase-sensitive mode using the method from States.[70] Data block 
sizes were 2048 addresses in t2 and 512 equidistant t1 values. Before 
Fourier transformation, the time domain data matrices were multiplied 
by shifted sin2 functions in both dimensions. A mixing time of 70 ms 
was used for the TOCSY experiments. NOESY experiments were run 
with mixing times in the range of 150-300 ms. The qualitative and 
quantitative analyses of DQF-COSY, TOCSY, and NOESY spectra, 
were obtained using the interactive program package XEASY.[41]  
3JHN-H coupling constants were obtained from 1D 1H NMR and 2D 
DQF-COSY spectra.  3JHH coupling constants were obtained from 
1D 1H NMR and 2D PE-COSY spectra, the last performed with a  
flip angle of 35°. The temperature coefficients of the amide proton 
chemical shifts were calculated from 1D 1H NMR and 2D TOCSY 
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experiments performed at different temperatures in the range 25°-40 
°C by means of linear regression.  
Structural Determinations. The NOE-based distance restraints 
were obtained from NOESY spectra collected with a mixing time of 
200 ms. The NOE cross peaks were integrated with the XEASY 
program and were converted into upper distance bounds using the 
CALIBA program incorporated into the program package 
DYANA.[71] Cross peaks which were overlapped more than 50% 
were treated as weak restraints in the DYANA calculation. In a first 
step only NOE derived constraints (Supporting Information) were 
considered in the annealing procedures. Overall, 76 meaningful NOE-
derived restraints (9 NOEs per residue; that is: 32 intraresidue, 32 
sequential, 11 medium-range, and 1 long-range) for peptide 14, and 73 
(9 NOEs per residue; that is: 34 intraresidue, 29 sequential, 9 medium-
range, and 1 long-range) for peptide 16, were used as input for the 
calculation. For each examined peptide, an ensemble of 200 structures 
was generated with the simulated annealing of the program DYANA. 
An error-tolerant target function (tf-type=3) was used to account for 
the peptide intrinsic flexibility. Non standard Pen, D-Trp, Orn, and Tic 
residues were added to DYANA residue library using MOLMOL.[72] 
From these structures we could univocally determine the hydrogen 
bond atom acceptors corresponding to the slowly exchanging NH’s 
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previously determined for each peptide. In a second DYANA run 
these hydrogen bonds were explicitly added as upper and lower limit 
constraints (NH of Phe6 with CO of Tyr9, and NH of Tyr9 with CO of 
Phe6), together with the NOE derived upper limit constraints 
(Supporting Information). The second annealing procedure produced 
200 conformations from which 50 structures were chosen, whose 
interprotonic distances best fitted NOE derived distances, and then 
refined through successive steps of restrained and unrestrained EM 
calculations using the Discover algorithm (Accelrys, San Diego, CA) 
and the consistent valence force field (CVFF) [73] as previously 
described.[34] Coupling constants were not used in the constrained 
simulated annealing calculation, however, backbone and side chain 
conformations are in accordance with the experimental 3JHH and 
3JHH coupling constants, respectively. The final structures were 
analyzed using the InsightII program (Accelrys, San Diego, CA). 
Graphical representation were carried out with the InsightII program 
(Accelrys, San Diego, CA). RMS deviation analysis between energy 
minimized structures were carried out with the program 
MOLMOL.[72] 
h-UTR Models and Docking. The theoretical structure of the h-
UT receptor, in the inactive state, was generated by homology 
modeling based on the crystal structure of bovine rhodopsin (PDB 
Chapter 1 
- 52 -	
 
code 1F88),[42] as previously described.[43] The three-dimensional 
model of the the h-UTR, in the active state, was constructed from the 
model structure of the bovine rhodopsin, proposed by Mosberg,[48] 
and was generated by homology modeling following the same steps 
described for the inactive model.[43] To validate the reliability of the 
calculated models, the program PROCHECK,[74, 75] which 
automatically checks the stereochemical accuracy, packing quality, 
and folding reliability, was employed. All amino acids in the -helices 
were located in the favored region of the right-handed -helix in the 
Ramachandran plot. From calculated  angles, there were no cis 
peptide bonds in the calculated h-UTR model. All C atoms except 
Cys displayed S-chirality. For the packing quality, there were no bump 
regions in the calculated h-UTR models. 
The peptides Urantide and P5U were manually docked in the 
suspected binding site of the h-UTRi and h-UTRa, respectively. 
Employing the criteria described in the Results section, we generated 
10 poses for both urantide/h-UTRi and P5U/h-UTRa complexes. 
Refinement of each pose was achieved by in vacuo energy 
minimization with the Discover algorithm (50 000 steps;  = 1). The 
backbone atoms of the TM and IL domains of the h-UTR were held in 
their position; the ligand and EL’s were free to relax. Minimization 
was followed by a brief MD simulation period (200 ps). After this 
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period, many poses (7 and 8 out of the 10 poses for urantide and P5U, 
respectively) were discarded since the ligand was driven away from its 
starting position and lost the salt-bridge with the conserved Asp 
residue. The other poses (3 for urantide and 2 for P5U) converged to a 
very similar conformation (rmsd of the backbone atoms < 1 Å) and the 
lowest energy complex for each ligand was chosen as starting point 
for subsequent 2 ns MD simulations (time step = 1 fs, T = 300 K). The 
backbone coordinates of the TM helices were fixed during the MD 
simulations because, without environmental constraints (i.e. lipid 
bilayer and water solution), they can move away from each other and 
can lose their helical structure. Fixing TM helices should still allows 
for sufficient spatial/conformational sampling of the docked 
complexes since the ligand, in the discarded poses (see above), 
significantly changed both the initial position and conformation, after 
the MD simulations. An average structure was calculated from the last 
1 ns trajectory and energy-minimized using the steepest descent and 
conjugate gradient methods until a rmsd of 0.05 Kcal/mol per Å was 
reached. Starting from these energy minimized structures, the model 
complexes of the Urantide and P5U analogues 13-16 were obtained. 
The Asp4 was replaced with a Lys or a Tic residue and the complex 
was minimized first relaxing only the replaced residue (10 000 steps); 
then relaxing all the ligand (40 000 steps). Whereupon, a 200 ps MD 
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simulations was performed. The average structure of the last 100 ps 
was re-minimized until a rmsd of 0.05 Kcal/mol per Å was reached. 
For the docking of urantide within UTRa (switching of the ligands), 
we started from the optimized P5U/UTRa complex and superposed the 
NMR derived urantide structure with that of P5U (backbone atoms of 
residues 5-10). Then, we removed the P5U structure. The complex 
was minimized relaxing the ligand (40 000 steps). Whereupon, a 200 
ps MD simulations was performed. The average structure of the last 
100 ps was re-minimized until a rmsd of 0.05 Kcal/mol per Å was 
reached. Analogous steps were taken for the P5U/UTRi complex. All 
the MD trajectories were analyzed by means of the Analysis module 
of InsightII package. Molecular graphics images of the complexes 
were produced using the UCSF Chimera package.[76] Rescoring of 
the ligand/receptor models according to the AutoDock4 (AD4) [45-
47] scoring function was attained using a script provided within the 
MGLTools software package (http://mgltools.scripps.edu/). 
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1.2 Conformational Study on Cyclic Melanocortin Ligands and 
New Insight into their Binding Mode at the MC4 Receptor 
 
The melanocortin receptors are involved in many physiological 
functions, including pigmentation, sexual function, feeding behavior, 
and energy homeostasis, making them potential targets to treat 
obesity, sexual dysfunction, etc. Understanding the basis of the ligand-
receptor interactions is crucial for the design of potent and selective 
ligands for these receptors. 
The conformational preferences of the cyclic melanocortin 
ligands MTII (Ac-Nle4-c[Asp5-His6-DPhe7-Arg8-Trp9-Lys10]-NH2) 
and SHU9119 (Ac-Nle4-c[Asp5-His6-DNal(2’)7-Arg8-Trp9-Lys10]-
NH2), which show agonist and antagonist activity at the h-MC4R, 
respectively, were comprehensively investigated by solution NMR 
spectroscopy in different environments. In particular, water and 
water/DMSO (8:2) solutions were used as isotropic solutions and an 
aqueous solution of DPC (dodecylphosphocholine) micelles was used 
as a membrane mimetic environment. NMR derived conformations of 
these two ligands were docked within h-MC4R models. NMR and 
docking studies revealed intriguing differences which can help explain 
the different activities of these two ligands. 
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1.2.1 Introduction 
The melanocortin family contains five human receptors (h-
MC1R-h-MC5R) cloned to date and stimulates the cAMP second 
messenger and other signal transduction pathways.[77-84] 
Melanocortin receptors belong to the class A superfamily of 
rhodopsin-like G-protein-coupled receptors (GPCRs), characterized 
by having seven transmembrane α-helices (TM1-TM7) linked by three 
extracellular and three intracellular loops.[78, 81, 82] The 
endogeneous agonists of the MCRs, the melanocortins, are a family of 
peptides comprised of α, β-, and γ-melanocyte stimulating hormones 
(MSH) and adreno-corticotropic hormone (ACTH). They are derived 
from post-translational modification of a common precursor, 
proopiomelanocortin (POMC).[85] The natural melanocortins are all 
agonist for h-MCRs with exception of the h-MC2R, for which only 
ACTH is a full agonist.[86] Also, synthetic melanocortins have 
different pharmacological profiles for the five h-MCRs. For example, 
NDP-α-MSH [87] and MTII [88] are agonist for all h-MCRs except 
the h-MC2R.[89] There are also the endogeneous protein antagonists 
known as agouti and agouti-related protein (AGRP).[90, 91] 
Interaction of these effectors with MCRs results in the modulation of 
numerous biological functions which include among others regulation 
of skin pigmentation (MC1R), steroid production (MC2R), the 
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immune response, thermoregulation, food intake, sexual function 
(MC3R and MC4R), and stress-induced anxiety and depression.[92-
97] The MC4R subtype is regarded as a potential drug target, because 
it is involved in feeding and sexual behaviour.[90, 97-100] Mammals 
with a defective MC4R gene, which is expressed in the brain, are 
characterized by obese phenotype and increased food intake.[101-103] 
Pharmacological studies indicate that activation of the MC4R in 
rodents [100] and humans [93] modulates erectile function. 
Consequently, research efforts have been focused on the development 
of potent and MC4R-selective agonists as potential antiobesity drugs 
or as treatments for sexual dysfunction. [104] On the other hand, a 
MC4R antagonist that blocks the satiety-inducing effect of α-MSH 
could be helpful for treatment of anorexia or cancer cachexia.[105] 
A molecular understanding of MTII and SHU9119 activity at the 
h-MC4R may have important implications in the design of drugs. In 
addition, the identification of the essential amino acid residues of the 
h-MC4R responsible for MTII agonism and SHU9119 antagonism 
should be important for understanding the signalling events that 
regulate the melanocortin system under physiologic conditions.[106, 
107] 
Hence, we first studied the conformational preferences of the 
cyclic melanocortin ligands MTII, and SHU9119 (Table 5), agonist 
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and antagonist at h-MC4R, respectively. Conformational analysis was 
carried out by NMR spectroscopy in water, water/DMSO solutions, 
and 200 mM aqueous solution of DPC as membrane mimetic 
environment. Then, NMR derived structures of MTII and SHU9119 
were docked within the h-MC4 receptor model, in the active and 
inactive state, respectively.  
 
Table 5. Ligand Sequences 
Peptide Sequence 
MTII Ac-Nle4-c[Asp5-His6-DPhe7-Arg8-Trp9-Lys10]-NH2 
SHU9119 Ac-Nle4-c[Asp5-His6-DNal(2’)7-Arg8-Trp9-Lys10]-NH2 
NDP-MSH Ser1-Tyr2-Ser3-Nle4-Glu5-His6-DPhe7-Arg8-Trp9-Gly10-Lys11-Pro12-Val13-Gly14
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1.2.2 Results 
Chemistry. Peptides were synthesized using the solid phase 
approach and standard Fmoc methodology in a manual reaction vessel  
(Experimental Section).[35] 
The purification was achieved using a semi-preparative RP-HPLC C-
18 bonded silica column (Vydac 218TP1010). The purified peptide 
was 98% pure as determined by analytical RP-HPLC. The correct 
molecular weight and composition of the peptide was confirmed by 
mass spectrometry and amino acid analysis (Table S5, Supporting 
Information). 
NMR Analysis.  Complete 1H NMR chemical shift assignments 
were achieved for MTII and SHU9119 according to the Wüthrich 
procedure [36] via the usual systematic application of DQF-COSY 
[37, 38], TOCSY [39], and NOESY [40] experiments (Tables S6-S13, 
Supporting Information) with the support of the XEASY software 
package.[41] The conformational preferences for the two peptides 
were investigated by solution NMR spectroscopy in different solvent 
environments. In particular, water and water/DMSO (8:2) solutions 
were used as isotropic solutions and 200 mM aqueous solution of 
DPC (dodecylphosphocholine micelles) was used as a membrane 
mimicking environment. 
Water solution. NMR analysis was performed in water at pH 5 
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and a peptide concentration of about 2 mM. First, we analyzed the 
peptides at 25 °C. Both peptides showed similar NMR parameters 
(Tables S6-S7) as previously reported.[108, 109] Almost all NMR 
parameters indicate structural flexibility: a) temperature effects 
|T| > 6 ppb/K; b) 3JHN-H coupling constants are all within the 
range 6-8 Hz; c) No standard -helix or -sheet structure from H 
CSI (chemical shift index) values [110] (Figure S17, Supporting 
Information); d) No unambiguous medium- or long-range backbone 
NOE connectivities were found in the ROESY or NOESY. Strong 
dN(i, i+1) NOEs, which are generally observed in extended 
structures, appeared along almost the entire length of the peptides.  
To reduce the conformational flexibility, we acquired the spectra 
also at 5°C. At this temperature, most of the NMR parameters did not 
change significantly (Tables S8-S9), though  improvements of the 
signal quality in the NOESY spectra were observed. Weak dN(i, i+2) 
NOEs between Nle4 and His6 and between His6 and Arg8 could be 
observed. Also the methyl protons of the N-terminal acetyl group 
show a weak NOE contact with the H of Asp5. Medium dNN(i, i+1) 
NOE between DPhe7 (DNal(2’)7) and Arg8 was observed. Among the 
possible observable contacts, the dN(i, i+2) NOE between Asp5 and 
DPhe7 could not be observed due to spectral overlap. 
Cryoscopic solution. To further reduce the peptide 
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conformational flexibility, NMR spectra were acquired at -10 °C in a 
cryomixture solution of water/DMSO 8:2. Such cryomixtures have 
been shown to produce physico-chemical conditions compatible with 
those of biological fluids.[111] Again, most of the NMR parameters 
did not change significantly (Tables S10-S11). Apart from the two 
dN(i, i+2) NOEs observed also in water (5 °C) the NOESY spectra 
showed dN(i, i+2) NOEs between Asp5 and DPhe7 (DNal(2’)7). 
Furthermore, dN(i, i+3) NOEs between Asp5 and Arg8 and dNN(i, i+2) 
NOEs between His6 and Arg8 also were observed.  
DPC micelles. Several NMR parameters indicate that MTII and 
SHU9119 are highly structured in DPC solution. In particular, 3JHN-H 
coupling constants (Tables S12-S13) and H CSI values (Figure S17) 
and many NOE signals (Tables S14-S15, Supporting Information) 
clearly point to a folded structure encompassing the N-terminal 
residues (4-7) and extended conformation of residues 8-9. Non-trivial 
medium range NOE interactions, among which dN(i, i+2) 4-6, 5-7, 6-
8, dNN(i, i+2) 6-8, and dN(i, i+3) 5-8, are observed indicating that the 
membrane mimetic environment stabilizes intrinsic conformational 
tendencies of the peptide. Additional medium and long range NOE 
contacts were observed. In particular, various NOEs connected the 
Nle4 side chain with both DPhe7 (DNal(2’)7) and Trp9 aromatic 
moieties indicating spatial proximity of these side chains. Other 
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interesting contacts were observed between the methyl protons of the 
N-terminal acetyl group and the HN of Asp5, and between amide 
protons of the C-terminal NH2 group and the H1 and H1 of Trp9. 
Structure Determination. NOE distance restraints obtained for 
MTII and SHU9119 in DPC micelles were used as the input data for a 
simulated annealing structure calculation using the program 
DYANA.[71] The annealing procedure produced 100 conformations 
from which 20 structures were chosen, whose interprotonic distances 
best fitted the NOE derived distances, and then refined through 
successive steps of restrained and unrestrained EM calculations using 
the Insight/Discover package (Accelrys Inc, San Diego, CA).  
Structure Description. Superposition of the 10 lowest energy 
conformers of MTII and SHU9119 are shown in Figure 9. Since a -
turn may be defined as four consecutive non-helical residues that have 
a C(i)-C(i+3) distance < 7 Å, two -turns that involve Nle4 to 
DPhe7 (DNal(2’)7) and Asp5 to Arg8, can be identified. Examination of 
the backbone dihedral angles at the central (i+1, and i+2) residues of 
the turns showed that these turn structures most closely resembled 
type I (residue 4 to 7) and type II (residue 5 to 8) -turns, although 
deviations from the standard dihedral angles of these two types of -
turn occurred (Table S16, Supporting Information). Residues 8 to 10 
are in extended conformations. The side chain 1-angles of Asp5, 
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Arg8, Trp9 and Lys10 are also well defined, preferring trans, gauche-, 
trans and gauche- orientations, respectively. Side chains of Nle4 and 
His6 are more flexible. The DPhe7 orientation in MTII is also well 
defined as trans. The DNal(2’)7 orientation in SHU9119 is less 
defined showing an equilibrium between trans and gauche+ rotamers. 
These results are consistent with the measured 3J coupling 
constants (Tables S12-S13).[112, 113]  
The peptide surface has amphipathic nature. In fact, considering 
the pseudo-plane defined by the backbone atoms (green ribbon, Figure 
9) the hydrophobic residues Nle4, DPhe7 (DNal(2’)7) and Trp9 lie on 
one side (right in Figure 9) while the positively charged residues His6 
and Arg8 lie on the other side. 
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Figure 9. Stereoviews of the 10 lowest energy conformers of MTII (a), and 
SHU9119 (b). Structures were superimposed using the backbone heavy atoms of 
residues 5-10. Heavy atoms are shown with different colours (carbon, green; 
nitrogen, blue; oxygen, red). Hydrogen atoms are not shown for clarity. 
 
Docking Studies. NMR derived structures of MTII and 
SHU9119 were docked within the h-MC4R models proposed by 
Mosberg.[114, 115] In particular, the agonist MTII was docked within 
an “active state” model (h-MC4Ra), while the antagonist SHU9119 
was docked within an “inactive state” model (h-MC4Ri). Figure 10 
shows a snake-like diagram of the h-MC4R sequence. 
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Figure 10. Snake-like diagram of the h-MC4R sequence. This plot was generated 
with the RbDe software.[116] Black residues indicate that mutation data are 
available. The ‘ . . .’ indicates hidden residues (see reference [114] for the 
complete sequence). 
 
Since the currently available docking programs may not work 
very well for peptide compounds (more than eight rotatable bonds) 
[117], manual docking was conducted. The NMR-derived MTII 
structure was placed in between the trans-membrane domains of the h-
MC4Ra. The following criteria were employed to achieve meaningful 
docking modes: (i) The positively charged side of the amphipathic 
surface of the peptides should be close to the carboxylate groups of 
Asp122, Asp126, and Glu100, as suggested by several mutagenesis 
studies [114, 115, 118-125]; (ii) DPhe7 residue should point towards 
Leu133 residue as suggested by a mutagenesis study [118]; (iii) No 
steric clashes should occur between any atom. To assess the stability 
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of the MTII/h-MC4Ra complex we analyzed the potential 
ligand/receptor interactions, energy minimization and MD simulations 
for 1 ns at a constant temperature of 300°K. During the MD 
simulation, the ligand, the EL’s, and all the receptor side chains were 
allowed to relax, while the TM’s and intracellular loops (ILS) 
backbone atoms were held frozen. The distances between the peptide 
and the key receptor residues were monitored along the complete 1 ns 
MD trajectory (Supporting Information). The mean structure of the 
last 0.5 ns of MD was energy minimized and used for subsequent 
analysis. 
 
Table 6. MTII/h-MC4Ra Interactions 
Residuea Surrounding residue 
Nle4 Val193(TM5), His264b (TM6), Leu265 (TM6), Tyr268 
(TM6) 
Asp5  
His6 Asp122 (TM3), Asn123(TM3), Asp126 (TM3) 
DPhe7 Asp126 (TM3), Ile129 (TM3), Leu133 (TM3), Phe184 
(TM4), Phe261 (TM6), Phe284 (TM7), Leu288 (TM7) 
Arg8 Glu100 (TM2), Asp122 (TM3), Ile125 (TM3), Asp126 
(TM3), Ile129(TM3)  
Trp9 His264 (TM6), Phe267 (TM6), Pro272 (EL3), Val278 
(EL3), Phe280 (EL3), Phe284 (TM7) 
Lys10 Tyr276 (EL3), Val278 (EL3), Met281 (EL3)  
a For sake of clarity, the residue numbers of the ligands are reported as superscript 
while those of the receptor are not. b Receptor residues involved in mutagenesis 
studies are shown in bold. 
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To inspect the variations in the ligand conformation, the rmsd 
with the respect to the starting structure was calculated. Interestingly, 
the rmsd of the MTII backbone atoms turned out to be stable 
throughout all of the MD simulations (0 < rmsd < 0.8 Å), indicating 
that the peptide settles into the receptor-binding site in a stable 
conformation. Also the side chain orientations are those described by 
NMR. In particular, the DPhe7 and Trp9 side chain prefer a trans 
orientation about 1 angle (1 ≈ 160° for DPhe7, 1 ≈ -163° for Trp9). 
As shown in Figure 11a, the hypothetical binding site of MTII is 
located among TM2-TM7, and EL3. C- and N-terminal residues point 
towards the extracellular side. The binding mode of the peptide is 
determined mainly by the interactions shown in Figure 11b and 
summarized in Table 6. 
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Figure 11. (a) Stereoview of h-MC4Ra model complexed with MTII. MTII heavy 
atoms are shown with different colours (carbon, green; nitrogen, blue; oxygen, 
red). Hydrogen atoms are not shown for clarity. Receptor backbones are 
represented in gray and labeled. (b) Stereoview of MTII within the binding pocket 
of h-MC4Ra. Hydrogen bonds are represented with dashed lines. 
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In particular, (i) a tight charge-reinforced hydrogen-bonding 
network involving the carboxylate groups of Glu100 and Asp126 with 
the protonated guanidinium group of Arg8 of MTII are established. 
The guanidinium group of Arg8 is also involved in an electrostatic 
interaction with the carboxylate group of Asp122. Such interactions, 
which we assume to be anchoring points of the ligand to the h-
MC4Ra, remained stable during the entire MD simulation (Figure S18, 
Supporting Information). The oxygen atoms of the carboxylate of 
Asp126 form a charge-reinforced hydrogen bond with the protonated 
imidazole group of His6, which was not stable during the MD 
simulation (Figure S18). (ii) Two hydrophobic pockets, delineated by 
residues listed in Table 6, host the side chains of DPhe7, and Trp9 of 
MTII. Particularly, the side chain of DPhe7 occupies the hydrophobic 
pocket involving residues Ile129, Leu133, Phe184, Phe261, Phe284, 
while the indole system of Trp9 is surrounded by Phe280, Pro272, 
Phe267, Phe284 and appears to be optimally oriented for a -stacking 
interaction with the imidazolic system of His264. iii) Terminal groups 
also contribute to the complex stabilization. The Nle4 side chain is 
close to Val193 and Tyr268. The acetyl group CO of Nle4 (N-
terminal) engages hydrogen bonds with imidazole NH of His264. 
Amide group NH2 of Lys10 (C-terminal) established a hydrogen bond 
with the phenolic OH of Tyr276. These H-bonds are not stable during 
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the MD production run (data not shown). 
The NMR-derived SHU9119 structure was placed within the 
trans-membrane domains of the h-MC4Ri model, following the same 
criteria used for MTII (see above) to achieve meaningful binding 
interactions. Energy minimization and MD simulations (1 ns) were 
run to assess the stability of the SHU9119/h-MC4Ri complex and to 
analyze the potential ligand/receptor interactions. The mean structure 
of the last 0.5 ns of MD was extensively minimized and used for 
subsequent analysis. SHU9119 backbone atoms turned out to be stable 
throughout all of the MD simulations (0 < rmsd < 0.9 Å), indicating 
that the peptide settles into the receptor-binding site in a stable 
conformation. Also the side chain orientations are those described by 
NMR. In particular, Trp9 prefers a trans orientation about the 1 angle 
(1 ≈ 175°). Finally, the DNal(2’)7 side chain adopts a gauche+ 
conformation (1 ≈ 80°). 
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Figure 12. (a) Stereoview of h-MC4Ri model complexed with SHU9119. 
SHU9119 heavy atoms are shown with different colours (carbon, orange; 
nitrogen, blue; oxygen, red). Hydrogen atoms are not shown for clarity. Receptor 
backbones are represented in cyan and labeled. (b) Stereoview of SHU9119 
within the binding pocket of h-MC4Ri. Hydrogen bonds are represented with 
dashed lines. 
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Table 7. SHU9119/h-MC4Ri Interactions 
Residuea Surrounding residue 
Nle4 His264b (TM6), Leu265 (TM6), Tyr268 (TM6), 
Tyr276(EL3) 
Asp5 Phe184 (TM4) 
His6 Thr118 (EL1), Asp122 (TM3), Asn123 (TM3), Asp126 
(TM3), Phe184 (TM4) 
DNal7 Leu133 (TM3), Phe184 (TM4), Cys196 (TM5), Leu197 
(TM5), Met200 (TM5), Phe261 (TM6), Phe262 (TM6), 
Leu265 (TM6) 
Arg8 Glu100 (TM2), Asp122 (TM3), Ile125 (TM3), Asp126 
(TM3),  
Trp9 His264 (TM6), Leu265 (TM6), Tyr268 (TM6), Phe267 
(TM6), Phe280 (EL3), Met281 (EL3), Phe284 (TM7) 
Lys10 Thr112 (EL1), Asp113 (EL1), Ser116 (EL1), Thr118 
(EL1), Tyr268 (TM6), Tyr276 (EL3), Val278 (EL3), 
Met281 (EL3) 
a For sake of clarity, the residue numbers of the ligands are reported as superscript 
while those of the receptor are not. b Receptor residues involved in mutagenesis 
studies are evidenced in bold. 
 
As shown in Figure 12a, the hypothetical binding site of 
SHU9119 is located among TM2-TM7, and EL3. C- and N-terminal 
residues point towards the extracellular side. The binding mode of the 
peptide is determined mainly by the interactions showed in Figure 12b 
and Table 7. In particular, (i) considering Arg8 and His6, the same 
interactions observed in the MTII/h-MC4Ra complex are observed 
also for SHU9119. Again, Hbonds involving the Arg8 guanidinium 
group remained stable during the whole MD production run (Figure 
S19, Supporting Information), while those of His6 were not. (ii) Two 
hydrophobic pockets, involving the residues listed in Table 7, host the 
aromatic side chains of DNal(2’)7, and Trp9 of SHU9119. These 
Chapter 1 
- 73 -	
 
pockets only partially overlap with those hosting the aromatic side 
chains of MTII. Particularly, the side chain of DNal(2’)7 occupy the 
hydrophobic pockets involving residues Leu133, Phe184, Cys196, 
Leu197, Met200, Phe261, Phe262, Leu265, while the indole group of 
Trp9 is surrounded by His264, Phe267, Met281, Phe284 and appears 
to be optimally oriented for a -stacking interaction with the aromatic 
group of Tyr268. This is different from MTII, because Trp9 in MTII 
makes -stacking with His264. The Nle4 side chain is close to Leu265, 
Tyr268, and Tyr276. The acetyl group CO of Nle4 (N-terminal) in 
SHU9119 isn’t involved in hydrogen-bonding. Finally, the amide 
group NH2 and the oxygen atom of the terminal carboxamide group of 
Lys10 (C-terminal) established two hydrogen bonds: with the OH of 
Ser116 and with the phenolic OH of Tyr268. These Hbonds are not 
stable during the MD production run (data not shown). 
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1.2.3 Discussion 
We investigated the conformational preferences of the cyclic 
melanocortin ligands MTII and SHU9119 by solution NMR 
spectroscopy in different environmental situations: water, 
water/DMSO (8:2) and an aqueous solution of DPC 
(dodecylphosphocholine). In water and water/DMSO cryoscopic 
mixture, NMR parameters were very similar for both peptides and 
indicate structural flexibility. A few NOEs, however, point to a 
tendency of the peptides to form a turn-helical conformation at the N-
terminus (residue 4-8). The data could be indicative of a nascent helix 
in solution.[126] The nascent helix consists of a population of 
different conformations, in which a significant proportion contains 
backbone conformations in the -region of (, ) space in the 
Ramachandran plot, rather than of any single defined solution 
conformation. 
In DPC micelle solution, the peptides exhibited a higher 
conformational stability. The use of micelles to study the 
conformational properties of peptides has been described in section 
1.1.3.[50-55]  
Two consecutive -turns that involved Nle4 to DPhe7/DNal(2’)7 
(distorted type I) and Asp5 to Arg8 (distorted type II) and a short 
extended segment along residues Trp9 and Lys10 were observed in the 
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calculated structures of MTII and SHU9119 (Figure 9 and Table S16). 
It is noteworthy that an amphiphilic molecular surface was obtained 
for the message sequence residues in both peptides. The main 
conformational difference observed in the structures of the two 
ligands was established in a different orientation of the DPhe7 and 
DNal(2’)7 side chains. DPhe7 of MTII preferred the trans rotamer, 
while the DNal(2’)7 side chain of SHU9119 was more flexible.  
A type II -turn structure encompassing residues 5-8 was already 
found by NMR analysis of MTII and SHU9119 in water solution.[108, 
109] This -turn led to stacking between the aromatic rings of His6 
and DPhe7 in MTII while no aromatic stacking between His6 and 
DNal(2’)7 was found in SHU9119. This stacking was not observed in 
the structures obtained in DPC micelles. Considering the -turn 
encompassing residues 4-7, it has never been observed in the structure 
of MTII or SHU9119. Interestingly, the presence of this turn is in 
accordance with the results of N-methylation of MTII backbone amide 
bonds. In fact, N-methylation of DPhe7, which should destabilize this 
-turn, caused a total loss of binding as well as adenylate cyclase 
activity at the h-MC4R (h-MC1R, h-MC3R and h-MC5R).[127] N-
Methylation of Arg8 caused a dramatic reduction of the binding (about 
500-fold at the h-MC4R) but yielded a compound that retained full 
agonist activity toward all subtypes of melanocortin receptors. 
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To gain insight into the interaction mode of these ligands with 
the h-MC4R, we first undertook a docking study between MTII and h-
MC4R model. Since the crystal structure of a GPCR in the active 
conformation has not yet been obtained, we used a h-MC4R model in 
the “active state” proposed by Mosberg et al. (h-MC4Ra).[114] 
According to these authors, upon activation, the receptor experiences 
a rearrangement which involves mainly the TM6 helix. The TM6 
helix shifts outward and rotates counterclockwise (viewed from the 
extracellular side) during activation, moving its intracellular end away 
from TM3 and toward TM5. As a result of this and other changes, the 
receptor structure tightens near its extracellular surface but opens up at 
the cytoplasmic side, providing a cavity for binding of the Gs subunit. 
In the active state model, several side chains change their orientation 
among which Trp258, in accordance with earlier spectroscopic 
results.[128] Similar conformational changes upon activation of the 
MC4R were subsequently proposed also by Hogan et al.[121] During 
the manuscript preparation another model of the h-MC4Ra has been 
published.[129] This model was based on recent crystal structures of 
the GPCR opsin in the ligand-free and in the G-protein-interacting 
conformations.[130, 131] Interestingly, our h-MC4Ra model and that 
built by Chapman et al. are quite similar showing an rmsd of the TM’s 
backbone heavy atoms of 2.0 Å (Figure S20, Supporting Information).  
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For the MTII/h-MC4Ra complex, docking and the MD 
simulations (Figure 11) indicated that: (i) the structure adequately fits 
the binding site and is stable during the MD trajectory; (ii) the binding 
site, situated in the entrance of the TM bundle on the extracellular 
side, is formed by TM2-TM7, and EL3 (Figure 11a); (iii) the 
pharmacophore residues DPhe7, the Arg8 and Trp9 side chains 
establish the highest number of interactions with the receptor. In 
particular, Arg8 residue is involved in a charge-reinforced hydrogen 
bonding network with carboxylate groups of Glu100, Asp122, and 
Asp126 which was stable during the MD simulations (Figure S18). In 
contrast, the His6 imidazole group participates only in an unstable 
hydrogen bond with Asp126 (Figure S18). Two wide hydrophobic 
pockets host the side chains of DPhe7, and Trp9 of MTII (Figure 11b). 
The N- and C-terminal groups point towards the extracellular side and 
are involved only in limited interactions with the receptor consistent 
with the observation that these termini can be substituted with 
retention of potent binding affinity.  
The proposed binding mode is in qualitative accordance with the 
known structure-activity relationships of MTII. In fact, substitution of 
DPhe7 or Trp9, which show a large number of receptor interactions, 
with alanine resulted in compounds with very low affinities for h-
MC4R (h-MC3R and h-MC5R).[132] The Arg8 involved in stable 
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interactions with the receptor, its replacement with the neutral residue, 
alanine, led to an active analogue but with more than a 1000-fold 
reduced affinity at h-MC4R compared to the parent compound, in 
accordance with the stable interactions exhibited by this residue. In 
contrast, the substitution of His6 with alanine yielded a peptide with 
activation and binding affinity similar to MTII towards the h-MC4R 
(h-MC3R and h-MC5R). Therefore, the imidazole group was shown 
not to be essential to binding of MTII with the h-MC4R (h-MC3R and 
h-MC5R). A similar result was reported for the ‘core’ peptide Ac-
His6-DPhe7-Arg8-Trp9-amide in which the omission of histidine 
resulted in the tripeptide that was only 2-fold less potent at h-MC4R 
than the tetrapeptide.[124] Considering N-terminal acetyl group, an 
analogue of MTII without the acetyl group was as potent as MTII at 
the h-MC4R (h-MC3R and h-MC5R).[133] Replacement of Ac-Nle4 
with Ala or Ac-Ala yielded compounds with agonist potencies at h-
MC4R similar to that of MTII. The analogue without both acetyl 
group and norleucine was 200-fold less active at h-MC4R. Also 
replacement of MTII residues with proline (Pro-scan) gave similar 
results. Proline replacement was acceptable only at Nle4 and His6 
positions yielding compounds with agonist potencies at the h-MC4R 
similar to that of MTII.[133] 
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Interestingly, many residues of the receptor involved in the 
interaction with MTII were identified as molecular determinants of 
ligand binding by mutagenesis studies (Table 6).[107, 115, 118-124] 
In particular, His264 has been demonstrated to be essential for 
melanocortin peptide activation of the MC4R.[134] -stacking 
interaction of imidazolic nucleus of His264 and indole system of Trp9 
can trigger the MC4R activation. Interestingly, this -stacking 
interaction is not observed in the SHU9119/h-MC4Ri complex 
described below.  
A docking study between SHU9119 and h-MC4Ri also was 
performed. The h-MC4Ri model, built by Mosberg et al. and based on 
the rhodopsine crystal structure, was used.[115] The main differences 
between inactive and active models of h-MC4R were discussed above. 
The obtained complex (Figure 12) and the MD simulations indicated 
that SHU9119 positioning within the h-MC4Ri is similar to that 
observed for MTII/h-MC4Ra (Figure 12 and Figure 13). In particular, 
backbone atoms of MTII and SHU9119 are almost superimposable 
lying inside the TM2-TM7 bundle. Also the side chains of the 
positively charged residues His6 and the Arg8 show the same 
orientation and the Arg8 residue is involved in a charge-reinforced 
hydrogen bonding network with carboxylate groups of Glu100, 
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Asp122, and Asp126 which was stable during the MD simulations 
period (Figure S19). 
 
Figure 13. Stereoview of h-MC4R models in the active (gray) and inactive (cyan) 
conformations complexed with MTII (carbon, green; nitrogen, blue; oxygen, red) 
and SHU9119 (carbon, orange; nitrogen, blue; oxygen, red), respectively. The h-
MC4R models are superimposed using the backbone heavy atoms of TM residues 
apart from TM6. Hydrogen atoms are not shown for clarity. 
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In contrast, the DNal(2’)7 and Trp9 binding pockets are quite 
different compared to those of the corresponding residues of MTII. 
These differences depend on the different orientations of the 
DNal(2’)7 and Trp9 side chains and on the movement of TM6 during 
activation.[115] In the SHU9119/h-MC4Ri complex the DNal(2’)7 
prefers a gauche+ orientation due to steric interaction with Leu133, 
while in the MTII/h-MC4Ra complex the DPhe7 side chain could 
adopt a trans orientation. Furthermore, the χ2 torsion angle of Trp9 
rotates from 9,7° in the MTII/h-MC4Ra to -56,0° in SHU9119/h-
MC4Ri. Interestingly, the 2’-naphthalene and indole moieties of 
SHU9119 show many van der Waals interactions with hydrophobic 
residues of the TM6 helix which could stabilize the inactive state of 
the h-MC4R (Table 7). As a matter of fact, different groups have 
proposed that large aromatic side chain substitutions at the Phe7 
position of -MSH analogues can interfere with MC4R activation by 
interacting with receptor residues within TM6, physically hindering 
the conformational changes necessary to elicit full efficacy.[120, 125] 
Our model is also supported by the observation that the DNal(2’)7 
naphthalene external ring fills the same cleft as the Phe113 benzene 
ring of AGRP (Agouti related protein, an endogenous antagonist) in a 
model of AGRP/h-MC4Ri complex (Figure 14).[115] It can be 
observed in the same Figure 14 that also the Arg8 guanidinium group 
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of SHU9119 is perfectly overlapped with the same groups of Arg111 of 
AGRP.  
 
Figure 14. Stereoview of SHU9119/h-MC4Ri (orange-cyan) and AGRP/h-MC4Ri 
(gold-purple) models in the inactive conformations. On the left side, AGRP’s 
labels are shown; on the right side, SHU9119’s labels are shown. The h-MC4R 
models are superimposed using the backbone heavy atoms of TM residues. 
Hydrogen atoms are not shown for clarity. 
 
 
Similar conformation and positioning of MTII and SHU9119 
within the MC4R are not surprising since it was shown that the single 
substitution of Leu133 with a methionine residue in the receptor 
converted SHU9119 from an antagonist into an agonist at the h-
MC4R.[118] Probably, according to our model, when Leu133 was 
replaced with methionine, which is more flexible than leucine, the 
hindering amino acid was removed and the DNal(2’)7 bulky aromatic 
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side chain could be accommodated in the same cleft occupied by 
DPhe7 of the agonist MTII. An analogous point mutation in the h-
MC3R had the same effect on SHU9119 activity.[135] Interestingly, 
SHU9119 behaves as an agonist at the h-MC1R and h-MC5R where a 
methionine or a (smaller) valine residue, respectively, occupies the 
position corresponding to Leu133 according to the sequence 
alignment reported in the reference.[115]  
Other groups have suggested modeled docked conformations of 
melanotropin peptides with the MC4R for both agonist and antagonist 
ligands. In particular concerning the agonists, a few models of the 
NDP-MSH,[114, 129, 136] a model of -MSH-ND (the open 
analogue of MTII),[137] and a model of the tetrapeptide His-DPhe-
Arg-Trp [121] complexed with h-MC4R have been proposed. It is 
noteworthy that different ligand conformations were employed for the 
peptide agonist/MC4R models proposed (Table 8). As a consequence 
of the lack of an accepted melanocortin peptide active conformation, 
all the models proposed in literature, included the MTII/h-MC4R 
presented here, were only partially superposable. 
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Table 8. 
Peptide Conformation Central Residues Reference 
NDP-MSH type II (hairpin) 6-7 [112]  
NDP-MSH type I’ 6-7 [135]  
NDP-MSH type II’ 7-8 [127]  
α-MSH-ND type I 6-7 [136]  
Corea type II’ 7-8 [118]  
a His-DPhe-Arg-Trp tetrapeptide core sequence. 
 
For example, considering the NDP-MSH/h-MC4R complex 
proposed by Mosberg et al.,[114] it is quite different from our 
MTII/h-MC4R model described above (Figure 15). NDP-MSH [87] 
and MTII [88] differ by cyclization at Asp5-Lys10 residues (in MTII), 
but share the same pharmacophoric sequence His6-DPhe7-Arg8-Trp9.  
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Figure 15. (a) Stereoview of MTII/h-MC4Ra (green-gray) and NDP-MSH/h-
MC4Ra (gold-purple) models in the active conformations. (b) Bottom stereoview 
of MTII and NDP-MSH within the binding pocket of h-MC4Ra. Only 
pharmacophoric side chains of ligands (His6-Arg9) are showed for clarity. 
Important residues of receptors are represented. The h-MC4R models are 
superimposed using the backbone heavy atoms of TM residues. Hydrogen atoms 
are not shown for clarity. 
 
The receptor coordinates of the two complexes are very similar; 
indeed, we started from the Mosberg’s h-MC4Ra coordinates, and 
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only marginal changes of the extracellular loops could be observed 
after the MTII/h-MC4Ra complex optimization (Figure 15). In 
contrast, ligand conformations are different considering the common 
tetrapeptide fragment. A -hairpin-like structure with a distorted type 
II -turn spanning His6-DPhe7 was proposed for Mosberg’s NDP-
MSH, while our NMR-derived MTII structure shows two consecutive 
-turns spanning residues Asp5-His6 and His6-DPhe7 (see above). Also 
side chain orientation of Trp9 was different in the two peptides being 
trans in MTII and gauche- in NDP-MSH. Hence, even if both 
peptides are located within the TM2-TM7 bundle at the extracellular 
side, their interactions with h-MC4Ra appear to be different. In 
particular, in the MTII/h-MC4Ra model His6 and Arg8 are swapped 
compared to NDP-MSH/h-MC4Ra in Mosberg’s model. In Mosberg’s 
model, His6 forms the most stable interactions with the Glu100, 
Asp122, and Asp126 negatively charged side chains, while Arg8 is 
more solvent exposed. Furthermore, in the NDP-MSH/h-MC4Ra 
model, the indole group of Trp9 roughly occupies the same position as 
DNal(2’)7 or Phe113 of the antagonists SHU9119 and AGRP, 
respectively. Finally, the DPhe7 residues are located in similar 
positions within the receptor.  
Some differences in the SAR data of NPD-MSH and MTII were 
observed both in terms of binding affinity: alanine substitutions were 
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generally better tolerated in linear NDP-MSH than in cyclic MTII 
[119, 125, 132]; and in terms of efficacy: the D-(4-Cl)Phe7 
substitution in NDP-MSH substantially reduces Emax but does not 
appreciably affect MC4R activation by the cyclic MTII.[106, 125] 
Different SARs could indicate different orientations of MTII and 
NDP-MSH (or other linear peptides) within the binding pocket thus 
justifying the different interactions found in the complex models. 
Finally, Mosberg et al. also proposed a MTII/h-MC4Ra complex 
model.[138] In this complex, the receptor model was the same as 
previously developed by the authors while the MTII structure was 
modeled from that of NDP-MSH. The lack of details about the 
interactions within this complex model does not allow any comparison 
with our model. 
Considering the peptide antagonists, a SHU9119/h-MC4R 
complex model has been very recently proposed.[139] Apart from 
Arg8 which was close to Glu100, Asp122, and Asp126 also in this 
model, other side chain interactions were different from those 
observed in our model. Again, a different backbone conformation of 
the bound peptide, a type-I -turn in that case, can explain these 
differences. A few AGRP derived peptides were also docked within 
MC4R models. The triplet peptide Arg-Phe-Phe, the smallest 
conserved motif of AGRP which mediates the key interactions with 
Chapter 1 
- 88 -	
 
MC4R, was docked into the h-MC4R.[140] A bicyclic hAGRP 
derivative was docked into the mouse MC4R (m-MC4R).[141] The 
refined averaged NMR structure of hAGRP(87-132) was docked both 
into a h-MC4R [115] and a m-MC4R [142] model. When considered 
the Arg111-Phe112-Phe113 triad, the docked structures of AGRP 
derivatives all maintain similar putative ligand-receptor locations, 
which are illustrated in Figure 14. 
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1.2.4 Conclusions 
In conclusion, NMR-derived MTII and SHU9119 structures 
show two consecutive -turns spanning residues Asp5-His6 and His6-
DPhe7 (or DNal(2’)7) with some differences in the Phe/Nal7 side chain 
orientation. Computational docking experiments of these structures, 
using three-dimensional homology molecular model of the h-MC4R, 
identified the main interactions between MC4 receptor and its peptide 
ligands. These findings may be crucial to increase our knowledge of 
structure-function relationships focused on the design of new potent 
MC4 receptor ligands. 
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1.2.5 Experimental Section 
Synthesis. N-Fmoc-protected amino acids, HBTU and HOBt 
were purchased from Inbios (Naples, Italy). Wang resin was 
purchased from Advanced ChemTech (Louisville, KY). Synthesis of 
MT-II and SHU-9119 were performed by standard FMOC 
Strategy.[35] 
NMR Sample Preparation. 99.9% 2H2O were obtained from 
Aldrich (Milwaukee, USA), 98% SDS-d25 was obtained from 
Cambridge Isotope Laboratories, Inc. (Andover, USA), [(2,2,3,3-
tetradeuterio-3-(trimethylsilanyl)]propionic acid (TSP) from MSD 
Isotopes (Montreal, Canada). 
NMR Spectroscopy. The samples for NMR spectroscopy were 
prepared by dissolving the appropriate amount of peptide to obtain a 
concentration 1-2 mM in 0.55 ml of 1H2O (pH 5.5), 0.05 ml of 2H2O 
for water samples, 0.48 mL of 1H2O (pH 5.5), 0.12 mL of DMSOd6 for 
cryoscopic solution,  200 mM of SDS-d25 or DPC-d38 for micelle 
samples. NMR spectra were recorded on a Varian INOVA 700 MHz 
spectrometer equipped with a z-gradient 5 mm triple-resonance probe 
head. All the spectra were recorded at a temperature of 25 °C. The 
spectra were calibrated relative to TSP (0.00 ppm) as internal 
standard. One-dimensional (1D) NMR spectra were recorded in the 
Fourier mode with quadrature detection. Water suppression was 
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achieved by using the double-pulsed field gradient spin-echo 
(DPFGSE) scheme [68]. 2D DQF-COSY [37, 38], TOCSY [39], 
NOESY [40], and PE-COSY [69] spectra were recorded in the phase-
sensitive mode using the method of States.[70] Data block sizes were 
2048 addresses in t2 and 512 equidistant t1 values. Before Fourier 
transformation, the time domain data matrices were multiplied by 
shifted sin2 functions in both dimensions. A mixing time of 70 ms was 
used for the TOCSY experiments. NOESY experiments were run with 
mixing times in the range of 150-300 ms. The qualitative and 
quantitative analyses of DQF-COSY, TOCSY, and NOESY spectra, 
were obtained using the interactive program package XEASY.[41].  
3JHN-H coupling constants were obtained from 1D 1H NMR and 2D 
DQF-COSY spectra. The temperature coefficients of the amide proton 
chemical shifts were calculated from 1D 1H NMR and 2D TOCSY 
experiments performed at different temperatures by means of linear 
regression.  
Structural Determinations. The NOE-based distance restraints 
were obtained from NOESY spectra collected with a mixing time of 
200 ms. The NOE cross peaks were integrated with the XEASY 
program and were converted into upper distance bounds using the 
CALIBA program incorporated into the program package 
DYANA.[71] Cross peaks which overlapped more than 50% were 
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treated as weak restraints in the DYANA calculation. For each 
examined peptide, an ensemble of 200 structures was generated with 
the simulated annealing of the program DYANA. An error-tolerant 
target function (tf-type=3) was used to account for the peptide 
intrinsic flexibility of the peptide. The annealing procedure produced 
200 conformations from which 50 structures were chosen, whose 
interprotonic distances best fitted NOE derived distances, and then 
refined through successive steps of restrained and unrestrained EM 
calculations using the Discover algorithm (Accelrys, San Diego, CA) 
and the consistent valence force field (CVFF) [73] as previously 
described. Coupling constants were not used in the constrained 
simulated annealing calculation, however, backbone and side chain 
conformations are in accordance with the experimental 3JHH and 
3JHH coupling constants, respectively. The PROMOTIF program, 
was used to extract details on the location and types of structural 
secondary motifs.[143] Graphical representation were carried out with 
the InsightII program (Accelrys, San Diego, CA). RMS deviation 
analysis between energy minimized structures were carried out with 
the program MOLMOL.[72] 
Docking Procedures. The peptides MTII and SHU91119 were 
manually docked in the proposed binding site of the h-MC4Ra and h-
MC4Ri, respectively. Employing the criteria described in the Results 
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section, we generated 10 structures for both MTII/h-MC4Ra and 
SHU9119/h-MC4Ri complexes. Refinement of each structure was 
achieved by in vacuo energy minimization with the Discover 
algorithm (50 000 steps;  = 1). The backbone atoms of the TM and IL 
domains of the h-MC4R were held in their position; the ligand and 
EL’s were free to relax. Minimization was followed by a brief MD 
simulation period (200 ps). After this period, many poses (7 and 8 out 
of the 10 poses for MTII and SHU9119, respectively) were discarded 
since the ligand was driven away from its starting position and lost the 
salt-bridge with the conserved Asp residues. The other structures (3 
for MTII and 2 for SHU9119) converged to a very similar 
conformation (rmsd of the backbone atoms < 1 Å) and the lowest 
energy complex for each ligand was chosen as the starting point for 
subsequent 1 ns MD simulations (time step = 1 fs, T = 300 K). The 
backbone coordinates of the TM helices were fixed during the MD 
simulations because, without environmental constraints (i.e. lipid 
bilayer and water solution), they can move away from each other and 
can lose their helical structure. Fixing TM helices should still allows 
for sufficient spatial/conformational sampling of the docked 
complexes since the ligand, in the discarded poses (see above), 
significantly changed both the initial position and conformation, after 
the MD simulations. An average structure was calculated from the last 
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0.5 ns trajectory and energy-minimized using the steepest descent and 
conjugate gradient methods until a rmsd of 0.05 Kcal/mol per Å was 
reached. All the MD trajectories were analyzed by means of the 
Analysis module of the InsightII package. Molecular graphics images 
of the complexes were produced using the UCSF Chimera 
package.[76] Rescoring of the ligand/receptor models according to the 
AutoDock4 (AD4) [45-47] scoring function was attained using a 
script provided within the MGLTools software package 
(http://mgltools.scripps.edu/). 
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1.3 Novel Octreotide Dicarba-Analogues with High Affinity and 
Different Selectivity for Somatostatin Receptors. 
 
A limited set of novel octreotide dicarba-analogues with non-
native aromatic side-chains in positions 7 and/or 10 were synthesized. 
Their affinity towards the ssts1-5 was determined. Derivative 4 
exhibited a pan-somatostatin activity, except sst4, and derivative 8 
exhibited high affinity and selectivity towards sst5. Actually, 
compound 8 has similar sst5 affinity (IC50 4.9 nM) to SRIF-28 and 
octreotide. Structure-activity relationships suggest that the Z geometry 
of the double bond bridge is that preferred by the receptors. The NMR 
study on the conformations of these compounds in SDS-d25 micelles 
solution shows that all these analogues have the pharmacophore -
turn spanning Xaa7-d-Trp8-Lys9-Yaa10 residues. Notably, the 
correlation between conformation families and affinity data strongly 
indicates that the sst5 selectivity is favored by a helical conformation 
involving the C-terminus triad, while a pan-SRIF mimic activity is 
based mainly on a conformational equilibrium between extended and 
folded conformational states. 
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1.3.1 Introduction 
The cyclic tetradecapeptide somatostatin (H–Ala1–Gly2-c[Cys3–
Lys4–Asn5–Phe6–Phe7–Trp8–Lys9–Thr10–Phe11–Thr12–Ser13–Cys14]–
OH, SRIF-14) was first isolated from mammalian hypothalamus. 
[144] This hormone is widely distributed in the human body and is 
found in the gut, pancreas, nervous system and in some exocrine and 
endocrine glands. By interactions with a family of five SRIF receptors 
(ssts), the native peptide exerts a great number of regulatory effects, 
especially those related to GH release. Different receptor subtypes 
mediate various functions but only sst2 and sst5 activities have been 
precisely related to specific physiological activities.[145] SRIF 
receptors are strongly expressed in various types of malignant cells, 
particularly in some neuroendocrine or neuroendocrine-like tumors. 
Over the last three decades, this has prompted researchers to prepare a 
huge number of new cyclic and acyclic analogues, which are more 
stable than SRIF in physiological conditions. Amongst these, a large 
number of reduced-size cyclic analogues, with or without the disulfide 
bridge, were synthesized and tested for their affinity towards the ssts. 
Furthermore, their pharmacological behaviour was studied and several 
NMR investigations on their affinity/conformations relationships were 
carried out. J. E. Rivier’s group, at the Salk Institute of La Jolla, 
carried out a careful structure/affinity study on SRIF analogues, 
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introducing non natural aminoacids in the sequence and preparing 
variably sized S-S bridged cyclopeptides. These authors related the 
structure/conformation of the cyclopeptides to the sst1-4 specific 
affinity by means of NMR studies.[146-149] 
Octreotide [150] (compound 1, Figure 16), a cyclic octapeptide 
analogue of somatostatin, containing a disulfide tether, and showing 
high affinity and selectivity for sst2, was the first analogue to be used 
in clinical protocols. Following the enormous growth in preparation 
and application of radiolabelled peptides for tumor imaging and 
therapy, the somatostatin analogues thus far obtained were designed 
mainly for the targeting of malignant cells with - or -emitting 
radionuclides.[147, 151, 152] As a matter of fact, octreotide 
derivatives [111In-DTPA]octreotide (OctreoScan) and [90Y-DOTA-
Tyr3]octreotide (OctreoTher) are both quite successfully used in the 
clinical diagnosis and therapy of neuroendocrine tumors, 
respectively.[153] Nevertheless, the vulnerability of the S-S bridge to 
endogenous and exogenous oxidating and reducing agents, such as 
those employed in the experimental conditions of labelling with the 
radioisotopes 99mTc or 188Re,[154] prompted us to synthesize dicarba-
analogues of similar ring size, by the RCM reaction on two 
allylglycines, substituting the relevant Cys3,14 residues in the linear 
peptide. Compound 2, reported in Figure 16 as an example, is the first 
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octreotide dicarba-tethered analogue synthesised by us and has the 
same aminoacid sequence of the corresponding, S-S bridged, 
molecule.[155, 156]  
 
Figure 16. Structure of Octreotide (SMS201-995) (1) and of the first dicarba 
SRIF mimetic (2).[155] (Note: numbering of the residues follows that of the 
native SRIF). 
 
The resulting unsaturated dicarba bridge proved to be insensitive 
to the conditions used for 99mTc or 188Re labelling (unpublished 
results) and the molecules obtained were very stable in human 
serum.[155, 156] Recently, the stability of these compounds was 
exploited in the successful conjugation of cytotoxic dichloroplatinum 
complexes to analogue 2 as well as to the double bond hydrogenated 
derivative.[157] The same reaction, attempted with the octreotide 
molecule, failed. When the affinities of these analogues towards the 
five ssts were determined, we ascertained that some of them showed 
unexpected specific affinity for the sst5 subtype, which led us to define 
a novel pharmacophore model for this receptor.[156]  
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This study reports the synthesis of new cyclooctapeptide dicarba-
analogues, that have structures similar to those depicted in Figure 16, 
but are designed to carry different aromatic residues in positions 7 
and/or 10 (Table 9). In the following, ssts subtypes affinities found for 
the new compounds 4-8 are correlated with the C=C bridge geometry 
and with the conformational behaviour in SDS-d25 micelles solution, 
investigated by NMR experiments. Characteristic structure/affinity 
relationships of this class of somatostatin analogues are widely 
discussed. 
 
Table 9. Peptide Sequences; General Formula: d-Phe2-c[dhDSA-N3-
Xaa7-d-Trp8-Lys9-Yaa10-dhDSA-C14]-Thr(ol)15-OH. 
a These compounds were previously reported.[156]  
  
Peptide Xaa7 Yaa10 Double bond geometry 
2a Phe Thr Z 
3a Phe Tyr(Bzl) E 
4 Phe Tyr(Bzl) Z 
5 1-Nal Thr Z 
6 Phe Tyr E 
7 Phe Tyr Z 
8 1-Nal Tyr(Bzl) Z 
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1.3.2 Results 
Peptide Synthesis and Purification. The synthesis of dicarba-
analogues followed the procedure described in our previous articles. 
[155, 156] Starting from H–L-Thr(tBu)–ol–2-chlorotrityl resin (0.5 
mmol/g) already containing [Thr(ol)15], the elongation of the peptide 
sequence was stopped after the coupling of Hag3 residue, with the aim 
of removing any possible interference of the aromatic ring of D-Phe in 
the correct orientation of the allylglycine side chains. After the Fmoc-
Hag3 coupling, the resin loading (0.5 mmol/g) already met the 
requirements of the pseudo-dilution effect, minimizing the risk of the 
formation of intermolecular bonds. The linear heptapeptides were then 
converted by RCM by the 2nd generation Grubbs catalyst (9) (Figure 
17) to the corresponding cyclic analogues.  
 
 
Figure 17.  2nd Generation Grubbs Catalyst. 
 
The D-Phe2 terminal residue was added only after ring-closing, 
thus facilitating the cyclization step. Cleavage of the crude peptides 
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from the resin was obtained using the standard cleavage mixture 
TFA/H2O/EDT/Phenol (94:2:2:2, 3 h) for compounds 5, 6 and 7 and 
with the new percentage mixture (70:26:2:2, 2,30 h) for compounds 4 
and 8, in order to overcome the loss of the benzyl group of the 
Tyr(Bzl) residue by hydrolysis, as described in our previous 
article.[156] All compounds obtained by RCM with 9 were pre-
purified by SPE. The concentrated compound adsorbed on the SPE 
was eluted with an increased percentage of CH3CN in H2O (from 0% 
to 100%). The fractions enriched with each desired compound were 
then purified by semi-preparative RP-HPLC and characterized by ESI-
MS. For each peptide, with the exception of 5 and 8, the HPLC 
chromatogram showed two peaks with the same MW, corresponding 
to the geometric isomers (Z/E ratio  90:10). In particular, the E 
structure of the C-C=C-C tether of the sample eluted at lower Rt and 
the Z structure one of the second, more intense, peak, was ascertained 
by 1H NMR inspection. The HPLC purity of each compound studied 
was > 97% and the isolated compounds showed unique E or Z 
configuration, confirmed by NMR analysis. No oligomer by-products 
were observed. 
Binding Affinity to sst1-5 Receptors. All compounds were tested 
for their ability to bind to the five human sst1-5 receptors subtypes in 
complete displacement experiments using the universal somatostatin 
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radioligand [125I]-[Leu8,D-Trp22,Tyr25]-somatostatin-28. SRIF-28 was 
run in parallel as control. IC50 values were calculated after 
quantification of the data using a computer-assisted image processing 
system. Binding data indicate that all compounds show sub-M 
binding affinities towards the sst5 (Table 10). Compounds 2 and 3 
have already been described [156] and are reported for comparison. 
While peptide 3 was a potent and selective sst5 ligand, its Z-isomer, 
peptide 4, exhibited a pan-somatostatin affinity, apart from sst4. In 
fact, the analogue 4 doubled the affinity toward sst5 but completely 
lost the selectivity of 3.  
Peptide 5 is the 1-Nal7 analogue of 2 (Table 9). This peptide 
exhibited a low nanomolar sst2,5 affinity. Actually, it is the most potent 
sst2 ligand among the dicarba analogues prepared to date. The double-
bond isomer analogues 6 (E) and 7 (Z), in which the phenolic group of 
Tyr10 replaces the Tyr(Bzl) residue of 3 and 4, respectively, did not 
show any significant affinity toward sst1-5 subtypes apart from a slight 
affinity of 7 to sst2.  
Finally, analogue 8 shared Tyr(Bzl)10 residue with peptide 4 and 
1-Nal7 residue with peptide 5. Like compound 4, it showed affinity for 
all the receptor subtypes except sst4. However, the significant 
enhancement of the sst5 affinity (nearly 3-fold compared to compound 
4) and the simultaneous reduction of affinity towards sst1-4 make 
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compound 8 a strong and selective sst5 ligand. Indeed, compound 8 is 
the most potent sst5 dicarba-analogue synthesized so far, showing an 
affinity close to the value found for the reference compound SRIF-28 
(Table 10). 
 
Table 10. Receptor affinities of the somatostatin analogues. 
IC50 (nM)a 
No. sst1 sst2 sst3 sst4 sst5 
SRIF-28 2.3 ± 0.4 (7) 3.0 ± 0.2 (7) 3.6 ± 0.5 (7) 1.6 ± 0.3 (7) 2.4 ± 0.2 (6) 
2b > 1000 (2) 44 ± 1 (2) > 1000 (2) 412 ± 68 (2) 28 ± 2 (2) 
3b > 1000 (2) > 1000 (2) 892 ± 245 (2) > 1000 (2) 29 ± 1 (2) 
4 25 ± 1 (3) 46 ± 3 (3) 25 ± 4 (3) 346 ± 23 (3) 12.3 ± 0.3 (3) 
5 > 1000 (3) 9.6 ± 0.9 (3) > 1000 (3) 249 ± 51 (3) 16.5 ± 4.5 (3) 
6 1000 (3) 355.5 ± 45.5 (3) 1000 (3) 1000 (3) 418 ± 56 (3) 
7 > 1000 (3) 87 ± 18 (3) > 1000 (3) > 1000 (3) 161 ± 27 (3) 
8 57.5 ± 12.5 (3) 101 ± 9 (3) 92.5 ± 0.5 (3) > 1000 (3) 4.9 ± 1.0 (4) 
a The number of independent repetitions to obtain the mean values  SEM are 
indicated between brackets. SRIF-28 is used as internal control. b Corresponds to 
data published previously.[155]  
 
NMR Analysis. NMR analysis of the analogues 3-8 was 
performed by means of 1D and 2D proton homonuclear experiments. 
NMR experiments were recorded on a Varian Inova-Unity 700 MHz 
spectrometer. Spectra were collected in SDS-d25 (200 mM) micelles 
solution. All samples (about 2 mM) were kept at 308 K and at pH  5. 
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Complete 1H NMR chemical shift assignments were effectively 
achieved for all the analyzed molecules according to the Wüthrich 
procedure,[36] via the usual systematic application of TOCSY [39] 
and NOESY [40] experiments with the support of the XEASY 
software package (Tables S19-S24, Supporting Information).[41] 
NMR-derived constraints obtained for all compounds were used as the 
input data for a simulated annealing structure calculation, as 
implemented within the standard protocol of the DYANA 
program.[71]  
Compound 3. The analogue 3 bears Tyr(Bzl) in position 10. We 
have already analyzed this peptide in our previous work in 
water/DMSO-d6 solution.[156] The geometry of the double bond was 
confirmed as trans (E) from the coupling constant (3JCH=CH = 15.1 Hz) 
between the two olefinic protons of the bridge and NOE contacts 
between the same olefinic and the Hβs of residue 14 (3). A qualitative 
analysis of short- and medium-range NOEs, 3JNH-H coupling 
constants, and temperature coefficients for exchanging NH was used 
to characterize the secondary structure of 3. Spectra analysis pointed 
to the presence of a -turn about residues 7–10. Interestingly, the 
upfield shift observed for Hγs of Lys9 (δ = 0.52, 0.43 ppm) has been 
used for decades as diagnostic for biological activity.[158] NOE-
derived constraints obtained for 3 were used as the input data for a 
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simulated annealing structure calculation (Table S25, Supporting 
Information). The backbone arrangement of 3 was well-defined, 
possessing an average root mean square deviation (rmsd) of the heavy 
atoms equal to 0.15 Å. No violation higher than 0.1 Å was observed 
again indicating conformational stability (Table S25). Main backbone 
features were a type II’ β-turn spanning residues D-Trp8-Lys9, 
followed by a short 310-helix along residues Tyr(Bzl)10-dhDsa-C14-
Thr(ol)15 (Figure 18) The turn structure is stabilized by hydrogen 
bonds between Phe7-CO and Tyr(Bzl)10-NH. The helical structure is 
stabilized by H-bonds between D-Trp8-CO and dhDsa-C14-NH and 
between Lys9-CO and Thr(ol)15-NH. These bonds are typical of 310-
helix structure (i, i+3). The side chains of dhDsa-N3, D-Trp8, Lys9, 
Tyr(Bzl)10, and dhDsa-C14 showed well-defined 1 values (i.e., trans, 
trans, gauche-, gauche-, and gauche+ orientations, respectively). These 
orientations allowed a close spatial proximity between D-Trp8/Lys9 
side chains; moreover, the tyrosyl group of the residue 10 points 
toward the Lys9 side chain. In contrast, D-Phe2 and Phe7 side chain 
showed almost free rotation about the 1 torsion angle. Also, the Bzl 
group of residue 10 was highly flexible.  
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Figure 18. Stereoview of the lowest energy conformer of compound 3. Backbone 
is evidenced as a ribbon. Side chains of the ten lowest energy conformers are also 
shown as mesh surface. Surfaces are distinguished with different colors. N-Term, 
N-terminus; C-Term, C-terminus. 
 
Compound 4. The analogue 4 is the geometric (Z) isomer of 3 as 
established by the coupling constant (3JCH=CH = 8.1 Hz) between the 
two olefinic protons of the bridge and the relative strong NOE 
between the same olefinic Hγs. This analogue shows spectral features 
similar to those found in 3 but with a greater tendency to 
conformational heterogeneity. In fact, NOESY spectra of 4 showed, 
simultaneously, both diagnostic connectivities consistent with folded 
structures: dN(i, i+2) between H-8/NH-10, H-9/NH-14, H-10/NH-
15 and dN(i, i+3) between H-9/NH-15; and NOE contacts 
characteristic of extended regions: strong dN(i, i+1) between H-
9/NH-10, H-10/NH-14, and H-14/NH-15 (Table S26, Supporting 
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Information). The apparently contradictory NOEs are indicative of the 
presence of at least two conformations in solution. The impossibility 
of resuming all the data in a single structure prompted us to consider 
incompatible NOEs separately in different calculation cycles 
(Experimental Section). Hence, we obtained two families of 
conformations. The first calculation cycle gave an ensemble of 
structures (family I) showing a similar conformation to compound 3, 
with a type II’ β-turn spanning residues D-Trp8-Lys9, followed by a 
short 310-helix along residues Tyr(Bzl)10-dhDsa-C14-Thr(ol)15 (Figure 
19a). Moreover, side chain orientations were the same as those 
described for 3. The main difference was a better definition of the 
Phe7 side chain which preferred the trans rotamer. For this set of 
structures, a number of consistent violations were observed (Table 
S26). In a second MD cycle, the violated upper limit constraints were 
upweighted for the contribution to the target function. Thus, a second 
conformational family (family II) was obtained which differed from 
the first mainly in that C-terminal residues were in extended 
conformations (Figure 19b). Furthermore, the side chain orientation of 
Tyr(Bzl)10 was trans. Hence, the tyrosyl nucleus was further from the 
Lys9 side chain. This is in accordance with the down-field shifts of the 
H resonances of Lys9 compared to the corresponding shifts of 
compound 3. Interestingly, the complete ensemble of structures (helix 
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and extended) fulfilled the NOE restraints, with no violations 
exceeding 0.5 Å (Table S26). 
 
Figure 19. Stereoview of the lowest energy conformer of compound 4: family I 
(a), family II (b). Backbone is evidenced as a ribbon. Side chains of the ten lowest 
energy conformers are also shown as mesh surface. Surfaces are distinguished 
with different colors. N-Term, N-terminus; C-Term, C-terminus. 
 
Compound 5. Compound 5 maintains the same octreotide 
scaffold, but position 7, which bears 1-Nal. Apart from the dicarba 
bridge, it has the same peptide sequence of the analogue NOC, 
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formerly prepared and studied as DOTA-conjugate by Maecke, Reubi 
and co-workers.[159] The coupling constant (3JCH=CH = 8.1 Hz) 
between the two olefinic protons of the bridge and the relative strong 
NOE between the same olefinic Hγs established (Z) configuration for 
compound 5. Only one isomer is obtained from RCM.  
NMR-based structure calculations gave two conformational 
families, like compound 4. Family I, obtained by a first run of MD 
calculation, showed a type II’ β-turn spanning residues D-Trp8-Lys9, 
followed by a short 310-helix along residues Thr10-dhDsa-C14-Thr(ol)15 
(Figure 20a). As found with compound 4, a number of consistent 
violations were observed (Table S27, Supporting Information). In a 
second MD run, we obtained a second conformational family (II), 
which differed from the first mainly because the C-terminal residues 
were in extended conformations (Figure 20b). In both the families, 
residue 7 showed a defined trans orientation which forces 1-Nal7 
naphthyl moiety close to D-Trp8 residue. This orientation is in 
accordance with the intense up-field shift observed for many D-Trp8 
proton resonances. 
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Figure 20. Stereoview of the lowest energy conformer of compound 5: family I 
(a), family II (b). Backbone is evidenced as a ribbon. Side chains of the ten lowest 
energy conformers are also shown as mesh surface. Surfaces are distinguished 
with different colors. N-Term, N-terminus; C-Term, C-terminus. 
  
Chapter 1 
- 111 -	
 
Compounds 6 and 7. The analogues 6 and 7 differ from 
compounds 3 and 4 in that the Tyr(Bzl)10 residue was replaced by a 
Tyr (i.e. without the Bzl group). Following the same arguments given 
for 3 and 4, an E configuration was assigned to compound 6 and a Z 
configuration to the compound 7 at the double bond.  
Many potential diagnostic NOEs could not be observed in the 
NOESY spectra of these analogues due to signal overlapping and this 
precluded structure calculations. For instance, H protons of Lys9 and 
Thr-ol15 resonated at the same chemical shift for both peptides. 
Actually, the NMR parameters of 6 (H shifts, coupling constants, and 
temperature coefficients) are very similar to those of compound 3, and 
this was also true for 4 and 7. Therefore, it could be hypothesized that 
3D structures should be similar too.  
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Figure 21. Stereoview of the lowest energy conformer of compound 8: family I 
(a), family II (b). Backbone is evidenced as a ribbon. Side chains of the ten lowest 
energy conformers are also shown as mesh surface. Surfaces are distinguished 
with different colors. N-Term, N-terminus; C-Term, C-terminus. 
 
Compound 8. The analogue 8 structure was rationalized starting 
from the peptide sequence of the previous compounds 4 and 5. In fact, 
it bears both 1-Nal7 and Tyr(Bzl)10. For compound 8, a Z configuration 
was established from the NOEs and coupling constant (3JCH=CH = 8.1 
Hz) between the two olefinic protons. NMR-based structure 
calculation (Table S28, Supporting Information), gave two 
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conformational families, as it did for compounds 4 and 5, the first 
(family I) showing a short 310-helix along the Thr10-dhDsa-C14-
Thr(ol)15 residues (Figure 21a), and the second (family II) an extended 
conformation along the same residues (Figure 21b). In both families, 
the D-Trp8, Lys9 and Tyr(Bzl)10 side chains were spatially closed in 
accordance with the increased up-field shift of the H and H 
resonances of Lys9. Differently from compound 5, 1-Nal7 residue 
could not adopt a trans conformation, probably due to steric hindrance 
with Tyr(Bzl)10. In fact, 1-Nal7 side chain was preferentially in a 
gauche- conformation.  
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1.3.3 Discussion 
In our ongoing efforts to develop new somatostatin ligands with 
improved stability and affinity towards sst receptors, we have 
rationally designed and analyzed a limited set of peptides (Table 9). In 
these peptides the labile disulfide bridge was replaced by a dicarba-
bridge, through the RCM reaction. As can be seen from Table 10, 
variation of the residues 7 and 10  results in analogues having a low 
sub-molar potency and a range of sst receptor subtype selectivities.  
Recently, we have investigated some octreotide analogues, 
including compound 3, in a water/DMSO-d6 8:2 solution.[156] Here, 
an NMR study was performed on the developed analogues of 
octreotide in SDS micelles solution (see section 1.1.3).  
Some apparently contradictory NOEs were indicative of the 
presence of at least two conformations in solution for analogues 4, 5, 
and 8. To deal with this incongruence we used a practical approach. 
Incompatible NOEs were considered separately in different 
calculation cycles. Hence, two families of conformations were 
obtained which differed mainly in that C-terminal residues were in 
310-helix (family I) or extended (family II) conformation. Eventually, 
the experimental restraints were fulfilled over the entire ensemble. It 
is noteworthy that the NMR data of the cognate molecule octreotide, 
using a single average conformation reveal several important 
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inconsistencies, including severe violations of mutually exclusive 
backbone-to-backbone NOEs.[160]  
On the basis of the NMR results, some general conformation-
affinity relationships concerning the binding to the sst receptors can be 
outlined. Similar to most of the bioactive analogues of SRIF reported 
so far,[161] the structures of the peptidomimetics presented here have 
a -turn of type II′ spanning residues D-Trp8 and Lys9. The side chain 
of D-Trp8 is in the trans conformer, and the side chain of Lys9 is in the 
gauche- conformer, bringing the two side chains adjacent to each other 
in close proximity. Analogues with the Z configuration at the double 
bond can adopt both helical and extended structures at the C-terminus, 
showing a conformational equilibrium (Figures 19-21). As a 
consequence of this conformational behavior, Z analogues show 
greater potency compared to the corresponding E isomers (4 vs 3 and 
7 vs 6) although it can go to the detriment of the selectivity, as in the 
case of compound 4 compared to 3. It could be argued, from the data 
of Table 10, that Z-geometry of the double bond is a better mimic of 
the S-S bridge which, in turn, was hypothesized to be directly 
involved in the interaction with the sst receptors.[162, 163]  
Analogues 3 and 4 bear a Tyr(Bzl) residue in position 10. The 
side chain of Tyr(Bzl)10 was designed to replace Phe6, Phe7, and Phe11 
of SRIF14.[164] Compound 3 (E-isomer) selectively binds sst5 while 
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its Z-isomer, 4, showed a pan-SRIF-activity, apart from sst4. In 
compound 3, the -turn motif is followed by a short 310-helix along 
residues Tyr(Bzl)10- dhDsa-C14-Thr(ol)15. The side chain of Tyr(Bzl)10 
is in the gauche- conformer and is located in close proximity to the D-
Trp8-Lys9 pair (Figure 18). This is in accordance with our recent 
results which correlates sst5 selectivity to conformationally restricted 
helical structure at the C-terminus.[156] The conformational 
properties of 3 in SDS micelles are similar to those observed in 
water/DMSO solution (data not shown). Only N-terminal residue D-
Phe2 is more flexible in the SDS solution compared to DMSO. 
In addition to high-affinity binding to sst2,3,5 like octreotide (1), 
compound 4 also exhibited a low nanomolar binding to sst1, hence its 
affinity pattern resembles that of the hexa-cyclic peptide SOM230 
(pasireotide) which also bears a Tyr(bzl)10 residue.[164] Since 
compound 4 fits 4/5 receptor binding sites, it was expected to display 
a high degree of flexibility. In fact, a dynamical equilibrium between 
extended and helical conformations was observed. Moreover, 
Tyr(Bzl)10 side chain orientation was different in the two 
conformations (Figure 19). Notably, NMR [160] and X-ray 
crystallography analyses have already suggested an equilibrium 
between extended and folded conformational states for the parent 
peptide 1.[165] Furthermore, SOM230 exhibited similar backbone 
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conformational equilibrium in a theoretical MD study; the side chain 
of Tyr(Bzl) of SOM230 underwent great flexibility which was 
associated with low selectivity.[166] Although sst2 is probably the 
most abundantly expressed SRIF receptor in human cancer,[167] 
recent literature data indicates that also sst1 and sst3-5 may also be 
present in some human tumors.[168] Hence, peptides with an 
improved receptor binding profile are desirable in order to extend the 
spectrum of tumors accessible to diagnosis and internal radiotherapy. 
As a matter of fact, SOM230 is being investigated in clinical trials as a 
potential treatment for acromegaly, neuroendocrine tumors and 
Cushing’s disease.[169, 170] 
Among the tested compounds, peptide 5 showed the highest 
affinity towards sst2 and also a good affinity towards sst5. The 
sequence of this cyclopeptide is the same as the S-S bridged 
NOC,[159] whose DOTA derivative, DOTA-NOC, exhibited high 
affinity towards sst2,3,5. The loss of sst3 affinity in 5 is probably due to 
the absence of the D-Phe2-bonded DOTA chelating group. Insertion of 
different arms at the N-terminus may, in fact have, a dramatic effect 
particularly on sst3 affinity.[171] Compound 5 is also closely related 
to the previously described compound 2, sharing its configuration at 
the double bond and the amino acid sequence but with Nal7 in 
replacing Phe7.[155] The activity profile of analogues 2 and 5 is 
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similar, showing an increase in the sst2 (~4-fold) and sst5 affinity (~2-
fold) of 5 compared to 2 (Table 10). Since 2 showed similar 
conformational properties as 5 (data not shown), the improved affinity 
towards sst2 and sst5 is probably attributable to the 1-Nal7 aromatic 
side chain which, oriented in a trans conformation, adequately fits the 
binding pocket of both receptors. 
Compounds 6 and 7 are analogues to 3 and 4, respectively, with 
the Tyr(Bzl)10 residue replaced by a tyrosine. This change renders 
compounds 6 and 7 strictly related to U-II. Analogue 6 showed a 
marked reduction of affinity towards sst5 compared to the correlated 
compound 3. Analogously, compound 7 showed a marked reduction 
of affinity towards sst1,3,5 and a 2-fold reduction towards sst2 
compared to 4. NMR data of the analogue couples pointed to similar 
conformational behavior, hence it can be argued that the Tyr10 phenol 
group is detrimental for binding to the sst receptors. This is in 
accordance with the low affinity of U-II to the sst2A receptor.[172] On 
the other hand, residual affinity of compound 7 towards sst2 and sst5 
(Table 10) parallels the capability of U-II to activate these two 
receptors at high doses.[173] 
By combining 1-Nal7 and Tyr(Bzl)10 residue replacements, we 
obtained compound 8 as a pure Z-isomer. Compound 8 showed the 
highest affinity towards sst5 (Table 10) with at least a 10-fold 
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selectivity compared to the other ssts. Compound 8 is closely related 
to compound 4, sharing its configuration at the double bond and the 
amino acid sequence but with 1-Nal7 replacing Phe7. Actually, the 
activity profile of the two analogues is similar (pan-SRIF-activity, 
apart from sst4) with a decrease of the sst1-3 affinity (2- to 4-fold) and 
increase of the sst5 activity (~3-fold) of 8 compared to 4. The 
conformational behavior of 8 also resembles that of 4, in accordance 
to the activity similarity (Figure 19 and Figure 21). Since the helical-
extended conformational equilibrium is also observable in the case of 
analogue 8, the affinity changes could be tentatively attributed to the 
orientation of the 1-Nal7 side chain which was differently oriented in 
the two peptides. In particular, it passed from a trans conformation 
observed in 4, to a gauche- conformation in 8. Such gauche orientation 
of the naphthyl group is likely still suitable (or preferred) for sst5 but 
not for sst1-3 binding.  
Based on the results reported above, we updated the previously 
proposed pharmacophore model for sst5-selective analogues.[156] The 
model involves the classical four side chains of the sst2/3/5 
pharmacophore,[162] namely, those of residues D-Phe2, Phe7 (Nal7), 
D-Trp8 and Lys9, plus the Tyr(Bzl)10 side chain. The distances 
between the Cγ atoms of these side chains, observed in the potent sst5 
ligands 3-5, 8 are reported in Table 11. The Cγ-Cγ distances found by 
Chapter 1 
- 120 -	
 
Melacini et al. for the sst2/3/5-selective SRIF analogues are also 
reported in the same table.[162] It can be observed that the distances 
found in our derivatives agree with the sst2/3/5 pharmacophore. 
 
Table 11. C-C distances (Å) between putative pharmacophoric 
residues.a 
Compd 3 4 5 8 sst2/3/5b 
Ar2-Ar7 8.5±0.8c 9.0±1.2 9.5±0.5 8.4±1.0 5-11 
Ar2-Ar8 14.3±0.6 14.0±0.5 14.3±0.6 13.4±0.5 11-15 
Ar2-Lys9 14.8±0.9 14.4±1.0 13.9±1.0 14.5±1.0 12-15 
Ar2-Ar10 8.1±1.1 7.8±1.2 - 13.4±1.0 - 
Ar7-Ar8 7.8±0.8 7.6±0.3 6.8±0.2 8.2±0.5 7-9 
Ar7-Lys9 10.9±0.6 9.8±0.7 9.7±0.3 11.0±0.6 9-11 
Ar8-Lys9 5.5±0.2 5.6±0.2 4.7±0.3 5.2±0.4 5 
Ar8-Ar10 8.8±0.2 8.9±0.2 - 8.1±0.1 - 
Lys9-Ar10 7.2±0.2 7.2±0.1 - 5.9±0.2 - 
a Only the family I of peptides 4, 5, 8 were considered. bPharmacophore for the 
sst2, sst3, sst5 selective SRIF analogues [162] cAverage distance and standard 
deviation calculated from the ensemble of ten structures. 
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1.3.4 Conclusions 
A limited set of compounds of biostable SRIF analogues with 
dicarba bridge replacing the disulfide bridge of the parent octreotide 
(1) were prepared. Compounds were obtained by on-resin RCM by 
second generation Grubbs catalyst. All the analogues were tested for 
their affinity toward the sst1-5 receptor subtypes. Among the 
synthesized compounds, derivative 4 exhibited a pan-somatostatin 
activity (except sst4) and derivative 8 exhibited high affinity and 
selectivity towards sst5. Actually, compound 8 had a similar sst5 
affinity (IC50 4.9 nM) to SRIF-28 and octreotide. Conformation-
affinity relationships confirmed that helical propensity correlates with 
the peptide sst5-affinity while a pan-SRIF activity is obtained by 
conformational equilibria. Both pan- and selective-SRIF analogues are 
potentially useful for the diagnosis and internal radiotherapy of 
tumors. 
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1.3.5 Experimental Section 
General Procedures. Fmoc protected  amino acids were 
purchased from Calbiochem-Novabiochem (Laufelfingen. 
Switzerland). 2nd generation Grubbs catalyst was obtained from 
Aldrich. Fmoc-Hag, FmocObenzyl-L-tyrosine and H–l-Thr(tBu)–
ol–2–chlorotrityl resin were purchased from Iris Biotech 
(Marktredwitz, Germany). HATU was obtained from Chempep 
(Miami, USA). Peptide grade DMF was from Scharlau (Barcelona, 
Spain). All the other solvents and reagents used for SPPS were of 
analytical quality and used without further purification. Analytical 
RP-HPLCs were performed on a Waters instrument equipped with a 
UV detector on a Phenomenex Juppiter C18 column (5 m, 250 x 4.6 
mm) using a flow rate of 1 ml/min, with the following solvent system: 
0.1% TFA in H2O (A), 0.1% TFA in MeCN (B)). Semi-preparative 
RP-HPLC analyses were performed on the same instrument using a 
flow rate of 4 ml/min with the same solvent system, on a Phenomenex 
Juppiter C18 column (10 μm, 250 x 10 mm). Mass spectra were 
registered on an ESI LCQ Advantage mass spectrometer (Thermo-
Finnigan). LC-ESI-MS analyses were performed on a Phenomenex 
Juppiter C18 column (5 μm, 150 x 2.0 mm) using a flow rate of 500 
μL/min on a ThermoFinnigan Surveyor HPLC system coupled to ESI-
MS, using the solvent system: H2O (A), MeCN (B), 1% TFA in H2O 
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(C). Routine NMR spectra were acquired on a Varian Inova 700 
apparatus. TSP was purchased from MSD Isotopes (Montreal, 
Canada). 2H2O was obtained from Aldrich. SDS-d25 was obtained 
from Cambridge Isotope Laboratories, Inc. (Andover, MA). SPPS was 
performed in Teflon reactor on a manual synthesizer PLS 4x4 
(AdvancedChemTech). Receptor autoradiography was performed on 
20-m thick cryostat (Microm HM 500, Walldorf, Germany). 
Synthesis and Purification of Compounds 3-8. Peptides were 
synthesized following the method reported in the preceding 
work.[156] Briefly, the peptides were prepared using the general 
Fmoc-SPPS strategy on pre-swelled H–L-Thr(tBu)–ol–2–chlorotrityl 
resin. Couplings were performed by adding two equivalents of 
protected amino acid activated by HATU and four equivalents of 
NMM in DMF. Each coupling was monitored by the qualitative 
ninhydrin (Kaiser) test.[35] At the end of the linear peptides synthesis, 
a microscale cleavage was performed. RP-HPLC analysis of the crude 
products revealed the presence of the linear peptides in approximately 
95% purity, without traces of isomers due to amino acid racemization. 
The cyclization was performed on-resin by 2nd generation Grubbs 
catalyst (0.5 mole equiv. calculated on the basis of 0.5 mmol/g of 
peptide). After swelling, NH2 terminal Fmoc–Hag was deprotected  
and coupled with Fmoc–D-Phe affording the on-resin peptides 4-8 
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which were deprotected and cleaved [5, 6 and 7 with 
TFA/H2O/EDT/phenol (94:2:2:2, 3 h) while  4 and 8 with 
TFA/H2O/EDT/phenol (70:26:2:2, 2.30 h)]. The aqueous solutions of 
the peptides 4-8 were pre-purified by SPE, and after subjected to the 
purification by semi-preparative RP-HPLC and subsequently 
characterized by ESI-MS. Analytical RP-HPLC and ESI-MS analysis 
of the crude compounds revealed two chromatographic peaks with the 
same MW for compounds  4, - 7, corresponding to the geometric 
isomers (Z/E ratio  90:10). Compounds were then purified by semi-
preparative RP-HPLC and the most abundant chromatographic peaks 
were collected. For all the products HPLC purity was  97%.. Further 
experimental data are reported in the Supporting Information. 
NMR Spectroscopy. The samples for NMR spectroscopy were 
prepared by dissolving the appropriate amount of peptide in 0.55 ml of 
1H2O (pH 5), 0.05 ml of 2H2O to obtain a concentration 1-2 mM of 
peptides and 200 mM of SDS-d25. TSP was used as internal chemical 
shift standard. The water signal was suppressed by gradient echo.[68] 
NMR experiments were recorded on a Varian Inova-Unity 700 MHz 
at 308.1 K. Complete 1H NMR chemical shift assignments were 
effectively achieved for all the analyzed peptides (Supporting 
Information, Tables S19-S24) according to the Wüthrich procedure 
[36] via the usual systematic application of TOCSY [39] and NOESY 
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[40] experiments recorded in the phase-sensitive mode using the 
method from States.[70]  
Typical data block sizes were 2048 addresses in t2 and 512 
equidistant t1 values. Before Fourier transformation, the time domain 
data matrices were multiplied by shifted sin2 functions in both 
dimensions. A mixing time of 70 ms were used for the TOCSY 
experiments. NOESY experiments were run with mixing times of 100 
and 200 ms. The qualitative and quantitative analyses of TOCSY and 
NOESY spectra were obtained with the support of the XEASY 
software package.[41]  
Structural Determinations and Computational Modeling. The 
NOE-based distance restraints were obtained from NOESY spectra 
collected with the mixing time of 100 ms. The NOE cross peaks were 
integrated with the XEASY program and were converted into upper 
distance bounds using the CALIBA program incorporated into the 
program package DYANA.[71] Only NOE derived constraints 
(Supporting Information, Tables S25-S28) were considered in the 
annealing procedures. In a first calculation run, all the upper distance 
bounds were used, generating an ensemble of 100 structures with the 
simulated annealing standard protocol of the program DYANA. For 
peptides 4, 5, and 8, a number of consistent (i.e. in all calculated 
structures) violated upper limit constraints (> 0.1 Å) were observed 
Chapter 1 
- 126 -	
 
(Supporting Information, Tables S25-S28). These violations were 
discarded in a subsequent MD run. This step was repeated till no 
violation was observed (two runs were enough for all peptides). Thus, 
we obtained a first family of structures (family I). In a second MD 
cycle, the violated upper limit constraints of the first cycle were 
upweighted (10-fold) for the contribution to the target energy function 
of DYANA. Hence, we obtained a new set of violated constraints 
which were discarded in the subsequent MD runs. After two MD runs, 
no violations were observed. In the final calculation run, we applied 
the same weight to the undiscarded constraints and obtained a second 
family of structures (family II). Since, the two sets of violations had 
no common member we did not repeat further the described 
procedure.  
Finally, 20 structures for peptide 3, and 20 structures for each 
family of peptides 4, 5 and 8 were chosen, whose interprotonic 
distances best fitted NOE derived distances, and then refined through 
successive steps of restrained and unrestrained energy minimization 
calculations using the Discover algorithm (Accelrys, San Diego, CA) 
and the consistent valence force field (CVFF).[73] 
The minimization lowered the total energy of the structures. The 
final structures were analyzed using the InsightII program (Accelrys, 
San Diego, CA). Graphical representation were carried out with the 
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UCSF Chimera package.[76] The root-mean-squared-deviation 
analysis between energy-minimized structures were carried out with 
the program MOLMOL.[72]  
Determination of Somatostatin Receptor Affinity Profiles. Cell 
membrane pellets were prepared from human sst1-expressing CHO 
cells, sst2-, sst3-, sst4-expressing CCL39 cells and sst5-expressing 
HEK293 cells and stored at -80C. Receptor autoradiography was 
performed on 20-m thick cryostat (Microm HM 500, Walldorf, 
Germany) sections of the membrane pellets, mounted on microscope 
slides, and then stored at -20C as previously described.[174, 175] For 
each of the tested compounds, complete displacement experiments 
with the universal SRIF radioligand [Leu8, D-Trp22, 125I-Tyr25]-SRIF-
28 (125I-[LTT]-SRIF-28) (2,000 Ci/mmol; Anawa, Wangen, 
Switzerland) using 15,000 cpm/100 L and increasing concentrations 
of the unlabelled peptide ranging from 0.1 – 1000 nM were 
performed. As control, unlabelled SRIF-28 was run in parallel using 
the same increasing concentrations. The sections were incubated with 
125I-[LTT]-SRIF-28 for 2 hours at room temperature in 170 mmol/L 
Tris-HCl buffer (pH 8.2), containing 1% BSA, 40 mg/L bacitracin, 
and 10 mmol/L MgCl2 to inhibit endogenous proteases. The incubated 
sections were washed twice for 5 min in cold 170 mmol/L Tris-HCl 
(pH 8.2) containing 0.25% BSA. After a brief dip in 170 mmol/L Tris-
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HCl (pH 8.2), the sections were dried quickly and exposed for 1 week 
to Kodak BioMax MR film. IC50 values were calculated after 
quantification of the data using a computer-assisted image processing 
system as described previously.[175] Tissue standards 
(Autoradiographic [125I] and/or [14C] microscales, GE Healthcare; 
Little Chalfont, UK) that contain known amounts of isotope, cross-
calibrated to tissue-equivalent ligand concentrations were used for 
quantification.[146]  
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2.1 Design, Synthesis, and Cytotoxic Evaluation of Acyl 
Derivatives of 3-Aminonaphtho[2,3-b]thiophene-4,9-dione, a 
Quinone-Based System 
 
A series of 3-acyl derivatives of dihydronaphtho[2,3-b]thiophen-
4,9-dione system were studied with respect to cytotoxicity and 
topoisomerase II inhibitory activity. These analogues were designed 
as electron-deficient anthraquinone analogues with potential 
intercalation ability. Derivatives 3-(diethylamino)-N-(4,9-dioxo-4,9-
dihydronaphtho[2,3-b]thiophen-3-yl)propanamide (11m) and 3-(2-
(dimethylamino)ethylamino)-N-(4,9-dioxo-4,9-dihydronaphtho[2,3-
b]thiophen-3-yl) propanamide (11p) showed a high efficacy in cell 
lines that were highly resistant to treatment with doxorubicin, such as 
MDA-MB435 (melanoma), IGROV (ovarian), SF-295 (glioblastoma) 
human cell lines. Both compounds inhibit topoisomerase II mediated 
relaxation of DNA, while only 11p incites arrest at S phase in Caco-2 
cells, inducing a delay of cell cycle progression and an increase of cell 
differentiation. The ability of these derivatives of  modulate small heat 
shock proteins and the cardiotoxicy effects were also explored. In 
addition, DNA-binding properties of these compounds were 
investigated and discussed.  
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2.1.1 Introduction 
Anthracyclines are among the most effective and useful anti-
cancer agents developed, and they are used to treat more types of 
cancer than any other chemotherapy agent.[176, 177] Their clinical 
importance has stimulated wide research [178-181] directed to the 
development of new structurally related compounds with the goal of 
bypassing significant problems that limit their utility, such as their 
failure in resistant tumors expressing the ABCB1 (MDR1) gene [182-
184] and the emergence of severe short- and long-term side effects 
associated with bone marrow and myocardial cell toxicity.[185, 186] 
With this aim, our research group has developed different series of 
quinone-based compounds containing the 3-amino-3-
(ethoxycarbonyl)-2,3-dihydrothieno[2,3-b]naphtho-4,9-dione system 
(4, DTNQ) as chromophore (Figure 22).[187] The effected 
modifications on this template and the analysis of the structure-
activity relationship (SAR) on the different synthesized series showed 
that the incorporation of a distal protonated alkyl amine linked to 
chromophore DTNQ system through a five- or six-membered 
heterocycle or the presence of a cycloalkyl as the fifth ring were 
effective approaches to identify new compounds endowed with potent 
cytotoxic activity, and able to overcome multidrug resistance of tumor 
cells. Thus, the 3-glycyl-amino-3-(ethoxycarbonyl)-2,3-
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dihydrothieno[2,3-b]naphtho-4,9-dione (5),[188] the spirohydantoin 
derivatives 3-[2-(N,N-dimethylamino)ethyl or propyl]-
spiro[(dihydroimidazo-2,4-dione)-5,3′-(2′,3′-dihydrothieno[2,3-
b]naphtho-4′,9′-dione)] (6a,b) [189] as well as the 
spirodiketopiperazine derivatives 4-[(2-N,N-
dimethyl)amino]ethylspiro[(dihydropirazin-2,5-dione)-6,3′-(2′,3′-
dihydrothieno[2,3-b]naphtho-4′,9′-dione) (7) [190] and spiro 
[(hexahydropyrrolo[1,2-a]pyrazine-1,4-dione)-6,3′-(2′,3′-
dihydrothieno[2,3-b]naphtho-4′,9′-dione)] (8) [191] showed 
remarkable cytotoxic activity against several solid tumors and 
doxorubicin- and cis-platinum-resistant human cell lines. 
 
Figure 22. Structure of some DTNQ derivatives and the new TNQ system. 
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In addition, STD-NMR spectroscopy investigation performed on 
compounds 7 and 8 demonstrated that these derivatives interact with 
DNA with a dual binding mode: intercalative for the 
dihydrothieno[2,3-b]naphtho-4,9-dionetricyclic core and external 
considering the side-chain moiety.[190, 191] However, even though 
these derivatives had many of the structural characteristics of classical 
quinone-based DNA intercalating agents, they were not able to inhibit 
topoisomerase II (topo II) at equicytotoxic concentrations, indicating 
that other factors such as differences in cellular uptake, distribution 
within the cell, and additional targets within the cell might also affect 
the cytotoxicity of these derivatives.[192] 
Now we have considered the possibility of using a new DTNQ 
derivative, the 3-aminonaphtho[2,3-b]thiophene-4,9-dione (9, TNQ) 
recently synthesized in our laboratories,[193] as a more planar 
chromophore. This quinone-based amine system showed interesting 
cytotoxic activity toward the MCF-7 human breast carcinoma (IC50 = 
3.2 M) and SW 620 human colon carcinoma cell lines (IC50 = 4.0 
M) indicating its potential as a template in the development of 
efficient cytotoxic agents. The new system presents a more “planar 
core” compared to initial DTNQ structure and an amine group able to 
be functionalized with appropriate side chain in a defined orientation 
with respect to the chromophore, thus guaranteeing two of the main 
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structural requisites for the antineoplastic activity of intercalating 
agents. According to literature data, among heterocyclic quinones 
endowed with cytotoxic activity, those containing a thiophene nucleus 
fused to a quinone system have received little attention, despite the 
antitumoral activity of thiophene analogues of daunomycin and 
mitoxantrone described by the work groups of Kita [194] and 
Krapcho,[195] respectively. 
Thus, we developed a series of 3-substituted-aminonaphtho[2,3-
b]thiophene-4,9-dione derivatives in which the amine group of the 
planar chromophore (TNQ) was linked to several amino acids (Gly, 
Ala, Phe, Lys, Pro, -Ala), substituted-alkylcarbonyl chains 
(hydroxyacetyl, hydroxypropionyl, (N,N-diethyl)aminoacetyl, (N,N-
diethyl)aminopropionyl, 2-morpholinacetyl, 3-morpholinpropionyl, 
(N’,N’-methyl)(N-aminoethyl)-aminopropionyl, thioacetyl, 
thiopropionyl) and carbamoyl chains (propyl, aminoethyl), which 
represent the side chain functionalities of the more active compounds 
of the precedent series. The objectives of this investigation are: a) 
validation of TNQ system as template in the development of new 
quinone-based antitumoral agents exploring so new chemical spaces; 
b) identification of the structural parameters which are important for 
the cytotoxic activity, through a comparative study of the structure 
activity relationships (SARs) of TNQ derivatives; and c) exploration 
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of the basic biochemical events correlated to cytotoxic activity of new 
derivatives. The present work deals with the preliminary studies 
concerning the synthesis of novel TNQ derivatives, the cytotoxic 
activity, the interaction with topo II and DNA, and their influence on 
cell cycle progression. 
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2.1.2 Results and Discussion  
Chemistry. The synthetic approach to new 3-substituted-
aminonaphtho[2,3-b]thiophene-4,9-dione derivatives was based on the 
capacity of DTNQ system and its 3-N-acyl derivatives to undergo 
oxidative decarboxylation in hydrolytic basic way, as we recently 
described.[193] Condensation of 3-amino-3-ethoxycarbonyl-2,3-
dihydrothieno[2,3-b]naphtho-4,9-dione (4, DTNQ) with different Boc-
amino acids (a = Gly, b= Ala, c = Phe, d = Lys, e = Pro, f = -Ala,) 
using HBTU, HOBt, and DIPEA in DMF afforded, with high yields 
(50-65%), the appropriate pseudodipeptide intermediates 10’a-f, as 
shown in Figure 23. Treatment with DBU in MeOH/H2O medium 
gave directly the corresponding decarboxylated intermediates 11’ a-f 
in 76-82% yields. Finally, after removal of the Boc protecting group 
using 20% TFA in dichloromethane and triethylsilane as scavanger, 
the final compounds 11a-f were obtained as trifluoroacetate salts in 
40-48 % overall yields. 
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Figure 23. Reagents and conditions: i) Boc-Aaa-OH HBTU, HOBt, DIPEA in 
DMF, room temperature ii) DBU in MeOH/H20, room temperature, iii) 
TFA/DCM, TES. 
 
Two homologue series of compounds containing a linear 
substituted-alkyl chain were synthesized from 3-(2′-chloro)acetamide-
3-ethoxycarbonyl-2,3-dihydrothieno[2,3-b]naphtho-4,9-dione (12) and 
3-(acrylamido)-3-ethoxycarbonyl-2,3-dihydrothieno[2,3-b]naphtho-
4,9-dione (13) respectively, followed a similar methodology (Figure 
24). 
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Figure 24. Reagents and conditions: i) chloroacetyl chloride, TEA in THF; ii) 
bromopropionyl chloride, TEA in THF, iii) DBU in MeOH/H2O, room 
temperature; iv) Nucleophilic reagents in THF, TEA, reflux temperature; v) then, 
for 11i and 11n 20% TFA in dichloromethane; vi) then, for 11j and 11k, 11m, 
11o, and 11p HCl (g)/diethyl ether solution. 
 
Condensation of 4 with chloroacethyl chloride in THF, using 
triethylamine as base, afforded the (2′-chloro)acetamide derivative 12 
with 92% yield. Under these conditions, the reaction of 4 with 
bromopropionyl chloride gave the 3-bromopropionamide intermediate 
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(90% yield), which partially evolved to -elimination product 3-
(acrylamido)-3-ethoxycarbonyl-2,3-dihydrothieno[2,3-b] naphtho-4,9-
dione (13), during work-up of reaction. Decarboxylation performed on 
12 and 13 intermediates gave directly the 2-hydroxyacetamide (11g) 
and 3-hydroxypropyonamide (11l) as final compound, respectively. 
Nucleophilic displacement of the chlorine atom (12) or Michael-type 
addiction to acrylamido moiety (13) using diethylamine, 
triphenylmethanethiol, morpholine or N,N-diethylethylendiamine, in 
THF and triethylamine at reflux, readily provided the corresponding 
acetamide (12’h-k) or propionamide (13’m-p) analogues. Basic 
hydrolysis of these derivatives afforded the corresponding 
decarboxylated compounds (11h-j and 11m-p), except in the case of 
12’k (R = HNCH2CH2N(CH3)2). In fact, under the cited conditions, 
this intermediate gave the cyclic derivative 4-[(2-N,N-
dimethyl)amino]ethylspiro[(dihydropirazin-2,5-dione)-6,3′-(2′,3′-
dihydrothieno[2,3-b]naphtho-4′,9′-dione)] (7) previously 
described.[190] Then, final compounds presenting an amine 
functionality 11j, 11k, 11m, 11o, and 11p, were treated with a 
solution of gaseous hydrochloric acid in diethyl ether to provide 
corresponding hydrochloride salts. This was found to both aid 
purification, and provide an improved solubility profile for the 
biological assays. The final thioacetamide 11i and thiopropyonamide 
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11n derivatives were obtained after S-Trt deprotection using 20% 
TFA in dichloromethane in quantitative yields. 
For the synthesis of compound 11k and the urea-based 
derivatives 11q and 11r we chose an alternative route which implied 
the use of 3-amino-naptho[2,3-b]thiophene-4.9-dione (TNQ, 9) as 
starting material (Figure 25). The condensation of 9, obtained after 
deprotection of corresponding N-Boc TNQ (14) using 50% TFA in 
dichloromethane,[193] with chloroacethyl chloride afforded the (2′-
chloro)acetamide intermediate 15 (88% yield). Reaction of 15 with 
diethylamine in THF and triethylamine at reflux, afforded the final 
derivative 11k. Compounds 11q and 11r were obtained by treatment 
of 9 with triphosgene and TEA in THF followed by addiction of 
propylamine or N,N-dimethylethylendiamine. Also in this case, the 
use of 9 as starting material was necessary since the corresponding N-
carbamoyl derivatives of DTNQ (compounds 6’) evolved rapidly to 
spirohydantoin derivatives 6 under hydrolitic conditions.[189] 
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Figure 25. Reagents and conditions: i) (Boc)2O, ii) DBU in MeOH/H2O, room 
temperature; iii) 50% TFA/dichloromethane; iv) chloroacetyl chloride, TEA in 
THF; v) (N,N-dimethyl) ethylenediamine in THF, TEA, reflux temperature; vi) 
triphosgen, TEA, THF, room temperature, 10 min, then R-NH2. 
 
In Vitro Cytotoxicity. TNQ derivatives were first examined for 
antiproliferative activity against the MDA231 human breast 
carcinoma, SW 620 human colon carcinoma, and U937 human 
leukemic monocyte lymphoma cell lines, and the obtained IC50 values 
are summarized in Table 12. For comparative purposes, the template 9 
and doxorubicin were also included in the assay.  
Results in Table 12 confirmed the compound 9 as potential 
scaffold of new antitumoral agents with a cytotoxic activity into the 
micromolar range on three cell lines used in the assay. The improved 
antitumor activity and spectra of some of the newly synthesized 
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compounds, compared to 9, demonstrated that chemical modification 
at C-3 was an effective approach to optimize the activity profiles of 
TNQ moiety. The wide activity range observed for compounds 11a-
11r (IC50 from 0.6 to >40 M) indicated that the nature of substituents 
on amine group at C-3 position markedly affects the activity profile of 
these compounds. Incorporation through the 3-amino group of 
different amino acids was well tolerated in the case of linear amino 
acids such as glycine (11a). The presence of amino acids containing 
alkyl (Ala, 11b) or benzyl (Phe, 11c) side chain, relatively more rigid 
and more electron rich when compared to non substituted side chain, 
led to significant loss of activity, especially in the MDA231 cell line. 
This negative effect was more noteworthy with the introduction of an 
alkyl amino side chain (Lys, 11d). The incorporation of Pro gave the 
derivative 11e, which turned out to be the most active in the leukemic 
cell line (IC50 = 0.9 M).  
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Table 12. Cytotoxic activities of 3-(amino)naphtho[2,3-b]thiophene-
4,9-dione (9) and 3-[(acyl)amino]naphtho[2,3-b]thiophene-4,9-dione 
derivatives (11 a-f). 
 
compd R IC50 (M) ±SD
a TopoII-activitye
5M      10M MDA231b SW620c U937d 
9  11.3±0.4 4.0±0.3 10.1±0.4   
11a CH2NH2f 6.2±4.6 2.3±0.4 7.0±0.07  
11b CH(CH3)NH2 f >40 12.4 ±1.5 9.1±0.2  
11c CH[CH2(C6H5)]NH2 f >40 30.50±6.4 >40 + +  
11d CH[(CH2)4NH2]NH2 f >40 >40 20±0.01   
11e 2-pyrrolidinyl f 6.7±2.5 5.4 ±0.1 0.9±0.06  
11f CH2CH2NH2 f 3.7±0.9 0.8±0.27 1.7±0.01  
11g CH2OH 10.1±0.2 18.5 ±0.7 15.1±0.06  
11h CH2N(CH2CH3)2g 8.5±0.12 4.0 ±0.14 5.1±0.07  
11i CH2SH 13.6±0.15 20.9 ±0.16 30.1±0.04  
11j CH2-morpholine g 7.1±0.2 10.8 ±0.12 4.3±0.02  
11k CH2NH(CH2)2N(CH3)2 g 4.9±0.4 2.1±0.3 4.0±0.03  
11l (CH2)2OH 9.2±0.6 20.3± 0.8 15±0.06   
11m (CH2)2N(CH2CH3)2 g 2.5±0.1 1.5 ±0.2 1.1±0.01 + +++  
11n (CH2)2SH 15.2±0.1 20.7 ±0.8 23.9±0.34   
11o (CH2)2-morpholine g 10.1±1.3 20.1 ±0.3 7.2±0.07  
11p (CH2)2NH(CH2)2N(CH3)2g 2.0±0.1 0.6 ± 0.08 1.3±0.03 ++ +++  
11q NH(CH2)2CH3 g 9.5±0.52 6.5 ±1.20 10.1±0.50   
11r NH(CH2)2N(CH3)2 g 8.7± 0.30 5.9 ±0.20 9.8±0.20  
 Doxorubicin 1.13±0.01 0.12±0.01 0.93±0.01 0 0  
a Data represent mean values (SD) for three independent determinations. b Human 
melanoma cell line. c Human colon carcinoma cell line. d Human leukemic 
monocyte lymphoma cell line. e The semiquantitative evaluation of TopoII-
mediated DNA relaxation activity was as follows: +++, high; ++, intermediate; +, 
low; 0, absent. All the rest compounds were not tested. f Evaluated as TFA salts. g 
Evaluated as HCl salts.  
 
Other interesting results were obtained with the incorporation of 
a primary or tertiary amine to the end of the ethyl side chains. 
Compounds 11f, 11m, and 11p retained cytotoxic levels similar to 
those of doxorubicin on the SW 620 cell line, with IC50 values of 0.8, 
1.5, and 0.6 M respectively, and maintained the activity on the 
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MDA231 and U937 cell lines within the micromolar range (2.0-3.7 
M and 1.1-1.7 M, respectively). These derivatives were 2-5 fold 
more potent than their methylene homologues (11a, 11h, and 11k, 
respectively) on all the cell lines. Congeners with a hydroxyl 
(compounds 11g and 11l), thiol (compounds 11i and 11n) or 
morpholin (compounds 11j and 11o) groups were remarkably less 
potent compared to their primary and tertiary amine analogues. 
Finally, the incorporation of an alkyl or alkylamino side chain 
through an ureide group led to a decrease of the activity in the 
resultant analogues 11q and 11r, respectively. These results imply a 
minor tolerance to structural modifications in this series compared to 
precedent series. 
To further determine the antitumor spectra, the most potent 
compounds 11f, 11m, and 11p were selected and screened against a 
panel of human tumor cell lines, including MDA-MB435 and SK-
MEL 28 (melanoma), IGROV (ovarian), SF-295 and SNB-19 
(glioblastoma), and Colo205, HT-29, and undifferentiated Caco-2 
(colon). Differentiated Caco-2, a well accepted model of normal cell 
line due to its ability to acquire the phenotype of mature small-
intestinal cell,[196, 197] was utilized to characterize a safety profile of 
the compounds at least in terms of “cell-selectivity”.[198, 199] 
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As observed in Table 13, selected compounds were more potent 
than doxorubicin on the melanoma, colon and CNS human tumor cell 
lines, with IC50 values in the range 0.1–1.0 μM. Compounds 11m and 
11p turned out to be the most active derivatives against SK-MEL 28 
human melanoma cell line (IC50 = 0.6 and 0.3 M, respectively) and 
were equipotent to doxorubicin (IC50 = 0.4 M). Analogously to that 
observed in the previously described series,[189-191] these 
compounds showed a remarkable activity against tumoral cell lines 
generally highly resistant to treatment with doxorubicin. Compounds 
11m and 11p presented a cytotoxic activity in the micromolar range 
against undifferentiated Caco-2 tumoral colon cell lines (IC50 = 0.8-
1.0 M), while showed to be 4-fold less active (IC50 = 3.8-4.1 M) on 
differentiated Caco-2 cell line. These data indicated a good profile of 
cell-selectivity for our derivatives (Selectivity Index (SI) ~ 0.22) 
especially if they are compared with the high toxicity data obtained 
with doxorubicin (SI = 11.1). 
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Table 13. Inhibition of multiple human tumor cell lines by selected 
compound. 
Origin of tumor Cell line IC50 (M) ±SD
a 
11f 11m 11p Doxorubicin 
Melanoma MDA-MB435 0.4±0.10 0.5±0.08 0.5±0.09 1.3±0.21 
 SK-MEL 28 1.5±0.08 0.6±0.08 0.3±0.07 0.6±0.09 
Ovarian IGROV 1.2±0.30 2.5±0.10 2.0±0.20 1.3±0.30 
Glioblastoma SF-295 2.8±0.20 0.6±0.06 0.6±0.09 4.4±0.50 
 SNB-19 1.6±0.60 0.7±0.04 0.9±0.10 0.8±0.05 
Colon Colo205 0.4±0.04 0.9±0.05 1.1±0.05 1.5±0.30 
 HT-29 0.6±0.08 0.8±0.05 0.5±0.10 1.1±0.20 
 Caco-2b 2.6±0.2 1.0±0.6 0.8±0.03 6.7±0.80 
 Caco-2c 6.1 ±0.32 4.1±0.10 3.8 ±0.09 0.6±0.05 
 SId 0.43 0.25 0.21 11.1 
a Data represent mean values (SD) for three independent determinations. b Pre 
confluent Caco-2 cell line. c Post confluent Caco-2 cell line. d SI = selectivity 
index (IC50 on undifferentiated Caco-2 cell line/IC50 on differentiated Caco-2 cell 
line ratio) 
 
Subcellular distribution of TNQ derivatives in MCF-7 cell line. 
Distribution of the labelled forms of our derivatives within the cell 
was investigated by confocal microscopy in MCF-7 cell line, using 50 
nM of 11m (IC50= 0.5 M) and 11p (IC50 = 0.6 M). As showed in 
Figure 26, these TNQ derivatives are clearly localized in the nuclei 
indicating a site of cytotoxic action similar to classic quinone-based 
intercalators.[200]  
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Figure 26. Distribution of labeled 11m and 11p in MCF-7 cells by confocal 
microscopy. 
 
Topoisomerase inhibition. A number of quinone antitumor drugs 
are thought to be cytotoxic by virtue of their ability to stabilize a 
covalent topo II-DNA intermediate, the cleavable complex.[201] Topo 
II is an essential enzyme that plays an important role in DNA 
replication, repair, transcription, and chromosome segregation.[202] 
Topo II alters the topological state of nucleic acids by passing an 
intact DNA helix through a transient break which generates a separate 
DNA helix.[203, 204] We analyzed the possibility that compounds 
11m and 11p could inhibit the activity of topo II. The effect of 
cytotoxic compounds 11m and 11p and of the inactive compound 11c 
on the strand passage activity of topo II was determined by the 
enzyme-mediated negatively supercoiled pBR322 relaxation.[205]  
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Figure 27. Effects of compounds 11p, 11m and 11c on the topo II-mediated DNA 
cleavage. Supercoiled plasmid pBR 322 (0.5 pmol) was incubated with 1 unit of 
purified human topo II in the presence or absence of the tested agents: (lane 1), 
supercoiled DNA;  (lane 2) relaxated DNA enzyme control; (lanes 3 and 4) 5 and 
10 μM of compound 11p; (lanes 5 and 6) 5 and 10 μM of compound 11m; (lanes 
7 and 8) 5 and 10 μM of compound 11c. 
 
As indicated in Figure 27, compounds 11m and 11p displayed 
significant inhibition of topo II mediated relaxation in a concentration-
dependent mode, while 11c does not inhibit this activity at the 
concentrations tested. These results, showed also in Table 12 as semi-
quantitative form,  parallel the cytotoxicity data enumerated in the 
same table, thus suggesting a behavior similar to classical 
intercalators. Moreover, at the assay concentrations, the doxorubicin 
showed a lack of activity (see Supporting Information) which agrees 
with the results described in different studies.[206, 207] These works 
show as the doxorubicin inhibits topo II only at the concentration 
range of 0.04 to 0.92 M while at higher concentration the inhibition 
is either diminished or totally abolished.  
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DNA Binding Properties by NMR. Representative compounds, 
11c, 11m and 11p, were tested to see if they interact with DNA, using 
both saturation transfer difference (STD) [208] and water-ligand 
observed via gradient spectroscopy (WaterLOGSY) NMR 
techniques.[209] STD NMR and WaterLOGSY are techniques that 
can be used to characterize and identify binding. These techniques 
have become increasingly important as a tool in the investigation of 
biomolecular recognition phenomena.[210] In the STD NMR, 
resonances of the macromolecule are selectively saturated, and in a 
binding ligand, enhancements are observed in the difference (STD 
NMR) spectrum resulting from subtraction of this spectrum from a 
reference spectrum in which the macromolecule is not saturated. All 
the proton resonances of 11m and 11p were observed in the STD 
spectra acquired in the presence of poly(dG-dC)·poly(dG-dC) 
copolymer as DNA target (Figure 28), demonstrating that 11m/ and 
11p/DNA interactions did occur. In contrast, the absence of the proton 
resonances of 11c in its STD spectra (Figure 28) demonstrates that 
11c does not interact with DNA. The same results were obtained using 
the WaterLOGSY experiment. In this experiment, the large bulk water 
magnetization is partially transferred via the macromolecule-ligand 
complex to the free ligand. Due to the very different tumbling times of 
the free ligand and of the macromolecule-ligand complex, LOGSY 
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signals are typically negative for free ligands in solution, and 
relatively less negative or positive for binders in the presence of the 
macromolecule. Figure 29 shows the WaterLOGSY spectra of 11c, 
11m and 11p with and without the poly(dG-dC)·poly(dG-dC) 
copolymer. As observed, 11m and 11p signals became positive in the 
presence of DNA while 11c signals remain negative demonstrating 
that 11m and 11p but not 11c interact with the DNA polymer.  
Furthermore, we applied the so-called DF-STD (differential 
frequency STD) spectroscopy,[211] to study the binding modes of 
11m and 11p with the DNA. The method allows the discrimination of 
base-pair intercalators, minor-groove, and external binders. The 
approach is based on the comparison of two parallel sets of STD 
experiments performed under the same experimental conditions, in 
which saturation is centered either in the aromatic or in the low-field 
aliphatic spectral regions.  
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Figure 28. 1D proton spectra (a, d, g) and the corresponding STD NMR spectra 
recorded upon saturation at 10 ppm (b, e, h) and -1 ppm (c, f, i) of 11c/, 11m/, and 
11p/DNA complexes, respectively. The STD NMR spectra were plotted with the 
same noise level. 
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Figure 29. Water LOGSY spectra of 11c, 11m, and 11p in the absence (b, d, e) or 
in the presence (a, c, e) of poly(dG-dC)•poly(dG-dC) copolymer.* DMSO 
residual signal. 
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A ligand making proximate contacts with aromatic base protons, 
such as an intercalator sandwiched by consecutive base pairs, would 
receive more saturation upon irradiation of DNA aromatic protons 
rather than irradiation of deoxyribose protons. The converse would be 
true for an external ligand. The “binding mode index” (BMI), a 
numerical parameter that expresses the relative sensitivity of ligand 
protons to the perturbation arising from base versus sugar/backbone 
saturation was used.[211] Three BMI ranges were defined in the 
original contribution:[211] 0 < BMI < 0.50 for external (nonspecific) 
electrostatic backbone binding; 0.90 < BMI < 1.10 for minor groove 
binding; and 1.20 (0.90) < BMI < 1.50 for base-pair intercalation. DF-
STD analysis of compound 11m gave different BMI values: BMI = 
0.86, for the aliphatic signals; and BMI = 1.35 for the aromatic 
signals. This result can be explained assuming two different DNA 
binding modes for 11m. An intercalative mode of binding is sustained 
by its tricyclic planar core, and an external backbone binding can be 
attributed to its side chain. This is similar to that observed for 
doxorubicin [211] and for compounds 7 and 8 in our previous 
works.[190, 191] Considering 11p, BMI = 1.01 was measured for the 
aromatic protons and BMI = 0.90 for the aliphatics. These BMI values 
are compatible with both intercalative and minor groove binders. 
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Cell Cycle Effects. To investigate the cytotoxic effects of these 
derivatives in more detail, we examined the effects on cell cycle 
progression in CaCo-2 cell line. The percentage of these cells in G1, 
S, and G2/M phases was analyzed after 48 h of treatment with 1 M 
of 11m, 11p, and 11c (Figure 30). Under these conditions, the control 
cells were in the G1 phase 42%, G2/M phase 21%, and S phase 36%. 
The treatment with 11p resulted in a significant accumulation of cells 
in the S phase while concomitantly the G1 populations decreased. 
About 53% of the CaCo-2 cells treated with this compound were 
arrested at the S phase. Under the same conditions, treatment with 
11m induces an weak increased of cell in both G2 and S phases and 
with compound 11c tempts a less significant response.  
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Figure 30. Effects of 11m, 11p, and 11c on the distribution of Caco-2 cell 
populations data represent the percentage of cells in each cell cellular cycle 
phases. For 11m: G1, 29%; G2/M, 28%; S, 41%; 11p: G1, 20%; G2/M, 26%, S, 
53%; 11c: G1, 37%; G2/M , 18%, S, 44%. 
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Accordingly, treatment of Caco-2 cells with 1 M of our 
derivatives for 48h induced an increase of cyclin A expression [212] 
only in the case of 11p (43%, see Supporting Information) indicating 
that the cell cycle progression of cells in the S phase was prompted. 
The expression of cyclin A was not upset in treated Caco-2 cells with 
11m and 11c. 
Since cell division arrest is one of the prerequisites for cell 
differentiation,[213] we determined the effect of our molecules on 
Caco-2 differentiation. In Figure 31 we report alkaline phosphatase 
(ALP) activity, a marker of enterocytic differentiation correlated to 
post-confluent phase.[214]  
 
 
Figure 31. Differentiation of Caco-2 cells assessed by measurement of alkaline 
phosphatase activity after 48h of culture in the presence of 0, 1, 5, and 10 M of 
11p, 11m and 11c. 
 
Treatment of pre-confluent Caco-2 with 1M 11p increased ALP 
activity of 35% (p value< 0.005). A more significant increase of the 
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differentiation, with ALP augment of >180%, was only obtained by 
treatment of Caco-2 cells with 5 M 11p or 10 M 11m for 48 h. All 
these preliminary results suggested that, for this series, the cell growth 
inhibition was not related to cell cycle perturbation.  
Modulation of heat shock protein (hsp) expression. Small heat 
shock proteins are involved in a variety of cellular processes including 
cell growth and differentiation.[215, 216] We previously reported the 
ability of a DTNQ analogue, compound 8, to modulate the heat shock 
protein expression on Caco-2 cells.[192] In order to evaluate the 
behavior of the  new synthesized derivatives, we carried out a study 
preliminary of the effect of  11m and 11p at 1 and 5M on Hsp27 
expression in Caco-2 cells for 48h. Hsp27 is weakly expressed in 
Caco-2 (Figure 32), and treatment of this cell line with 11p led to 
significant dose-dependent increase of  its expression. 11m  produced 
a weak enhanced of hsp27 expression at 1M, which was not 
observed at 5M.  
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Figure 32. Effects of Caco-2 cells treatment with 1 and 5 M  of compounds 11p 
and 11m on hsp27 expression. 
 
Cardiomyocyte cell viability. It is well known that the clinical 
use of anthracyclines, specially doxorubicin, in the treatment of many 
neoplastic diseases is limited by cumulative cardiotoxicty.[186] One 
of the cause of this effect has been attributed to the redox process 
involving the quinone system which results in the formation of 
reactive oxygen species and ultimately in myocyte death. In order to 
evaluate the potential toxicity of our quinone ring we examined the 
cell viability in cardiac derived H9C2 myocytes exposed to 1M 11m 
11p and doxorubicin for 24, 48, 72, 96 and 120 h. Previous studies 
reported in the literature used this cell line as a model system to 
evaluate the  cardiotoxicity caused by doxorubicin.[217, 218] As show 
in Figure 33, treatment with doxorubicin induced cardiotoxicity in a 
time-dependent manner [186] while compounds 11m and 11p 
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maintained an good cell viability after 120 h (74 and 76%, 
respectively)  
 
Figure 33. Results of cell viability assay of compounds 11m, 11p , and 
doxorubicin on H9C2 cells at concentration of 1M. 
 
The possible correlation [219] between these data and the 
preliminary results obtained with our products on the modulation of 
hsp27, will  be  object of more in-depth studies. 
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2.1.3  Conclusions 
We report the synthesis and biological evaluation of a series of 
quinone-based derivatives, designed as conjugated structures linking 
a planar naphtho[2,3-b]thiophenedione core with different acyl-
substituted groups. Among the designed molecules, compounds 
containing an 3-(diethylamino)propanamide (11m) or 3-(2-
(dimethylamino)ethylamino)propanamide (11p) protonable side chain, 
showed a greater cytotoxic potency than doxorubicin against cell lines 
which were highly resistant to treatment with this drug, such as the 
melanoma (MDA-MB435), glioblastoma (SF-295) and colon (SW 
620, Col205, and HT-29) human tumor cell lines,  
Preliminary results about the mechanism of action indicate that 
these derivatives had a significant effect on topoisomerase II activity 
targeting the nuclear DNA, which is generally considered as an 
attractive target for anticancer therapy. The NMR results suggested 
that DNA interactions do occur for highly active compounds 11m and 
11p but not for inactive compound 11c. Experimental data indicate 
that 11m and 11p intercalate the DNA through their aromatic portion. 
Furthermore, a non intercalative mode of binding to DNA can also 
hold for 11p. These data revealed significant similarities in the 
cytotoxic behavior and the site of action of these compounds 
compared to classical intercalators. However, tested compounds 
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showed a minor influence on the regulation of the cellular cycle and 
only derivative 11p prolonged the S phase of the Caco-2 cell cycle 
inducing both delay of cell cycle progression in responsive cells and 
moderate cellular differentiation. This last compound showed also a 
high ability of increase hsp27 expression. Finally, the compounds 
under study affect the viability of H9C2 cells after chronic treatment 
at less extend compared to doxorubicin. Further development and 
more in-depth studies on mechanism of action of this series are in 
progress. 
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2.1.4  Experimental Section 
General: Reagents, starting materials, and solvents were 
purchased from commercial suppliers and used as received. Analytical 
TLC was performed on plates coated with a 0.25 mm layer of silica 
gel 60 F254 Merck and preparative TLC on 20×20 cm glass plates 
coated with a 0.5 mm layer of silica gel PF254 Merck. Flash and 
gravity chromatographic purification were performed using 230-400 
mesh silica gel unless otherwise noted. Melting points were taken on a 
Kofler apparatus and are uncorrected. 1H NMR and 13C NMR spectra 
were recorded with a Varian-400 spectrometer, operating at 400 and 
100 MHz, respectively. Chemical shifts are reported in δ values (ppm) 
relative to internal Me4Si, and J values are reported in Hertz (Hz). 
ESI-MS experiments were performed on an Applied Biosystem API 
2000 triple-quadrupole spectrometer. Combustion microanalyses were 
performed on a Carlo Erba CNH 1106 analyzer and all reported values 
are within 0.4% of calculated values. These elemental analyses 
confirmed ≥ 95% purity. 
General procedure for the synthesis of 3-
[(Acyl)amino]naphtho[2,3-b]thiophene-4,9-dione trifluoroacetate 
salts (11 a-f). The 3-amino-3-ethoxycarbonyl-2,3-dihydrothieno[2,3-
b]naphtho-4,9-dione system (DTNQ) (1), the 3-(N-tert-
butyloxyaminoacyl)amino-3-ethoxycarbonyl-2,3-dihydrothieno[2,3-
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b]naphtho-4,9-dione (10’ a-f), and the 3-(N-tert-
butyloxyaminoacyl)aminonaphtho [2,3-b]thiophene-4,9-dione (11’ a-
f) derivatives were synthesized according to the references 12, 13, and 
17 respectively. Then, TFA was added to a solution of decarboxylated 
Boc-protected derivatives (11’ a-f) (0.1 mmol) in DCM (10 mL), 
using triethylsilane as scavenger. Stirring was continued for 3–4 h at 
room temperature, the reaction mixture was concentrated to half 
volume and ether was added. The title compounds as the 
trifluoroacetate salt, were collected by filtration as yellow solids. 
3-[(Glycyl)amino]naphtho[2,3-b]thiophene-4,9-dione 
trifluoroacetate (11a). 45%, mp 207-208 C. 1H NMR (400 MHz, 
CD3OD) 4.10 (s, 2H, CH2,); 7.85–7.87 (m, 2H, H-6and H-7); 8.20-
8.23 (m, 2H, H-5 and H-8); 8.50 (s, 1H, H-2). 13C NMR (100 MHz, 
CD3OD) 45.7(CH2), 119.2 (C-2); 127.5 (C-6 and C-7); 129.4 (C-3); 
132.9 (C-8a); 134.2 (C-4a); 134.7 (C-5 and C-8); 135.9 (C-3a); 147.1 
(C-9a); 171.8, 180.7 and 182.7 (C=O). ESI-MS m/z calcd for 
C16H11F3N2O5S, 400.03; found, 400.11. 
3-[(L-phenylyl)amino]naphtho[2,3-b]thiophene-4,9-dione 
trifluoroacetate (11c). 41%, mp 195-196 C. 1H NMR (400 MHz, 
CD3OD) 2.96-3.07 (2 H, m, CH2), 4.44-4.47 (1 H, m, CH), 7.12-
7.22 (5 H, m, aryl), 7.87–7.89 (2 H, m, H-6 and H 7), 8.22–8.25 (2 H, 
m, H-5 and H 8), 8.47 (1H, s, H-2). 13C NMR (100 MHz, 
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CD3OD)37.9 (CH2), 50.6 (CH), 118.8 (C-2); 127.9 (C-6 and C-
7); 125.9, 127.6, 128.3, 128.9 and 137.9 (aryl),131.4 (C-3); 133.6 (C-
8a); 134.2 (C-4a); 134.9 (C-5 and C-8); 139.0 (C-3a); 142.5 (C-9a); 
172.7 179.8 and 181.9 (C=O). ESI-MS m/z calcd for C23H17F3N2O5S, 
490.08; found, 490.01. 
General procedure for the synthesis of N-(4,9-dioxo-4,9-
dihydronaphtho[2,3-b]thiophen-3-yl)-3-(substituted)propanamide 
(11 m-p). To a solution of 13 (0.1-0.3 mmol) in THF (20 mL) were 
added N,N-diethylamine, or triphenylmethanethiol, or morpholine, or 
N,N-dimethylethylendiamine (1.1 equiv) and DIPEA (2 equiv). After 
stirring at reflux temperature for 12–24 h, the solvent was evaporated. 
Then, the residues (13’ m-p) were dissolved into methanol–water (9:1, 
20 mL) and DBU (5 equiv) was added dropwise to these solutions. 
The reaction mixtures were stirred for 0.5-1 h, then the solvents were 
evaporated and the reaction residues were dissolved in chloroform and 
washed with water and dried with Na2SO4. The corresponding free 
bases of compounds 11m, 11n, and 11p were first purified by FC 
using DCM/Methanol 9/1 as eluent system. Then, the treatment with a 
HCl (g)/diethyl ether solution give the final compounds as 
hydrochloride saltsand yellow solids. Compound protected 11o was 
purified by FC using n-hexane/ethylacetate 3/2 as eluent. Then, the 
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final compound was obtained after Trt removal with a 50% 
TFA/DCM solution. 
3-(diethylamino)-N-(4,9-dioxo-4,9-dihydronaphtho[2,3-
b]thiophen-3-yl)propanamide hydrochloride (11m). 43%, mp 201-
202C. 1H NMR (400 MHz, CD3OD) 1.36–1.40 (t, 6H, CH3); 3.10-
3.13 (m, 2H, CH2); 3.30-3.34 (q, 4H, CH2); 3.56-3.59 (m, 2H, CH2); 
7.85–7.87 (m, 2H, H-6and H-7); 8.20-8.24 (m, 2H, H-5 and H-8); 
8.48 (s, 1H, H-2). 13C NMR (100 MHz, CD3OD)15.8 (CH3), 35.8 
(CH2), 47.9 (CH2CH3), 51.5 (CH2), 118.6 (C-2); 126.9 (C-6 and C-
7); 129.2 (C-3); 132.7 (C-8a); 133.1 (C-4a); 134.8 (C-5 and C-8); 
138.9 (C-3a); 145.0 (C-9a); 172.5, 178.9 and 182.6 (C=O). ESI-MS 
m/z calcd for C19H21ClN2O3S, 392.10; found, 390.17. 
3-(2-(dimethylamino)ethylamino)-N-(4,9-dioxo-4,9-
dihydronaphtho[2,3-b]thiophen-3-yl) propanamide dihydrochloride 
(11p). 45%, mp 227-228 C. 1H NMR (400 MHz, CD3OD) 2.98 (s, 
6H, CH3), 3.09-3.12 (t, 2H, CH2); 3.29-3.31 (m, 2H, CH2N(Me)2); 
3.47-3.50(m, 2H, CH2) 3.50-3.53 (m, 2H, NHCH2), 7.85-7.87 (m, 
2H, H-6  and H-7); 8.20-8.25 (m, 2H, H-5 and H-8); 8.49 (s, 1H, H-2). 
13C NMR (100 MHz, CD3OD)32.1 (CH2), 42.4 (NHCH2), 42.8 
(CH3),43.9 (CH2) 53.1 (CH2N(Me)2), 119.5 (C-2); 126.8 and 127.0 
(C-6 and C-7); 129.0 (C-3); 132.9 (C-8a); 133.5 (C-4a); 134.2 and 
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134.3 (C-5 and C-8); 137.5 (C-3a); 144.0 (C-9a); 171.9, 178.9 and 
182.5 (C=O). ESI-MS m/z calcd for C19H23Cl2N3O3S, 443.08; found, 
443.18. 
Biology. Dulbecco’s modified Eagle’s medium (DMEM), fetal 
bovine serum (FBS), trypsin-EDTA solution (1 x) penicillin and 
streptomycin, phosphate-buffered saline (PBS) were from Cambrex 
Biosciences. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), propidium iodide (PI), Triton X-100, sodium citrate, 
formamide, mouse monoclonal anti-tubulin were purchased from 
Sigma (Milan, Italy). Rabbit polyclonal anti-cyclin A primary 
antibody were from Cell Signaling Technology (Celbio; Milan, Italy). 
ECL reagent was obtained from Amersham Pharmacia Biotech, UK. 
Cell culture. Human breast MDA231, human colon carcinoma 
SW620, Colo205, HT-29, and Caco-2, human monocytic leukemia 
U937, human melanoma MDA-MB435 and SK-MEL28 human 
ovarian cancer IGROV, and human glioblastoma SF-295 and SNB-19 
cell lines, were grown at 37 °C in Dulbecco’s modified Eagle’s 
medium containing 10 mM glucose (DMEM-HG) supplemented with 
10% fetal calf serum and 100 units/ml each of penicillin and 
streptomycin and 2 mmol/L glutamine. In each experiment, cells were 
placed in fresh medium, cultured in the presence of synthesized 
compounds (from 0.1 to 25 mM) and followed for further analyses. 
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Cell Viability Assay. Cell viability for all cell lines was 
determined using the 3-[4,5-demethylthiazol-2,5-diphenyl-2H-
tetrazolium bromide (MTT) colorimetric assay. The test is based on 
the ability of mitochondrial dehydrogenase to convert, in viable cells, 
the yellow MTT reagent (Sigma Chemical Co., St Louis, MO.) into a 
soluble blue formazan dye. Cells were seeded into 96-well plates to a 
density of 105 cells/100 μL well. After 24 h of growth to allow 
attachment to the wells, compounds were added at various 
concentrations (from 0.1 to 25 mM). After 24 or 48 h of growth and 
after removal of the culture medium, 100 μL/well of medium 
containing 1 mg/mL of MTT was added. Cell cultures were further 
incubated at 37 °C for 2 hrs in the dark. The solution was then gently 
aspirated from each well, and the formazan crystals within the cells 
were dissolved with 100 µL of DMSO. Optical densities were read at 
550 nm using a Multiskan Spectrum Thermo Electron Corporation 
reader. Results were expressed as percentage relative to vehicle-
treated control (0.5% DMSO was added to untreated cells ) IC50 
(concentration eliciting 50% inhibition) value were determined by 
linear and polynomial regression. Experiments were performed in 
triplicate. 
Topo II-mediated supercoiled pBR322 relaxation. DNA 
relaxation assays were based on the procedure of Osheroff et al.[204] 
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Reaction buffer contained 10 mM Tris.HCl (pH 7.9), 50 mM KCl, 50 
mM NaCl, 5 mM MgCl2, 0.1 mM EDTA, and 15 μg/mL of bovine 
serum albumin (BSA), 0.15 μg supercoiled pBR322, 4 units of topo II 
in a total of 20 μL. Relaxation was employed at 37 °C for 6 min and 
stopped by the addition of 3 μL of stop solution (100 mM EDTA, 
0.5% SDS, 50% glycerol, 0.05% bromophenol blue). Electrophoresis 
was carried out in a 1% agarose gel in 0.5 × TBE (89 mM Tris base, 
89 mM boric acid and 2 mM EDTA) at 4 V/cm for 1 h. DNA bands 
were stained with 0.5 μg/mL of ethidium bromide (E.B.) solution and 
photographed through a Gel Document System GDS8000 (UVP). The 
amount of DNA bands was quantified by Gel 1D Intermediate 
software. 
Confocal microscopy. For immunocytochemistry, cells were 
fixed in 0.04 g/liter paraformaldehyde for 30 min at 4 °C and 
permeabilized with 0.01 g/liter Triton X-100 for 30 min at 4 C. Cells 
were then washed and stained with Hoechst 33342 (Vector, 
Burlingame, CA). Images were acquired with a LSM510 inverted 
confocal microscope (Zeiss, Oberkochen, Germany) using 63X oil 
objective and processed using LSM software (Zeiss). 
Flow Cytometry. Analysis of Cell Cycle. CaCo-2 cells were 
seeded in six multiwell plates at the density of 25 × 105 cells/plate. 
After 48 h of incubation with 11m, and 11p derivatives and 
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doxorubicin in DMEM without serum at 37 °C, cells were washed in 
PBS, pelleted in centrifuged, and directly stained in a propidium 
iodide (PI) solution (50 mg PI in 0.1% sodium citrate, 0.1% NP40, pH 
7.4) for 30 min at 4 °C in the dark. Flow cytometric analysis was 
performed using a FACScan flow cytometer (Becton Dickinson, San 
Jose, CA). To evaluate cell cycle PI fluorescence was collected as FL2 
(linear scale) by the ModFIT software (Becton Dickinson). For the 
evaluation of intracellular DNA content, at least 20000 events for each 
point were analyzed in at least three different experiments giving a 
s.d. less than 5%. 
Western Blot Assay. The effects of 11m, 11p and 11c on 
expression of Ciclyn A and of 11m and 11p on HSP27, were 
determined by Western blots. Compounds stimulated and 
unstimulated (control) cell lysates were prepared using an ice cold 
lysis buffer (50 mMTris, 150 mM NaCl, 10 mM EDTA, 1% Triton) 
supplemented with a mixture of protease inhibitors containing 
antipain, bestatin, chymostatin, leupeptin, pepstatin, phosphoramidon, 
Pefabloc, EDTA, and aprotinin (Boehringer, Mannheim, Germany). 
Equivalent protein samples were resolved on 8–12% sodium dodecyl 
sulfate (SDS)-polyacrylamide gels and transferred to nitrocellulose 
membranes (Bio-Rad, Germany). For immunodetection, membranes 
were incubated overnight with specific antibody at the concentrations 
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indicated in manufacter’s protocol (Santa Cruz Biotechnology). The 
two antibodies were diluted in Tris-buffered saline/Tween 20-1% milk 
powder. This step was followed by incubation with the corresponding 
horseradish peroxidase conjugated antibody (antirabbit-IgG 1:6000; 
Biosource, Germany). Bands were read by enhanced 
chemiluminescence (ECL-kit, Amersham, Germany). 
Alkaline phosphatase activity. Alkaline phosphatase (ALP) 
activity was used as marker of the degree of cells differentiation. 
Attached and floating cells were washed and lysed with 0.25% sodium 
deoxycholate, essentially as described by Herz et al.[220] ALP 
activity was determined using Sigma Diagnostics ALP reagent (No. 
245). Total cellular protein content of the samples was determined in a 
microassay procedure as described by Bradford [221] using the 
Coomassie Protein Assay Reagent Kit (Pierce). ALP activity was 
calculated as units of activity per mg of protein. 
H9C2 cell viability. Cardiomyoblasts H9C2 were cultured in 
Dulbecco’s minimal essential medium (DMEM, GIBCO) 
supplemented with 0.1 g/L fetal bovine serum (FBS, GIBCO) 200 
mg/mL L-glutamine, 100 units/mL penicillin, and 10  mg/mL 
streptomycin (Sigma-Aldrich), at 37°C in 0.95 g/L air-0.05 g/L CO2. 
The H9C2 were studied between passages 4 and 10. The MTT-
colorimetric assay (Invitrogen, San Diego, CA), was used to evaluate 
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cell proliferation in presence or absence  of   inhibitors. Briefly, H9C2 
cells were plated into 96 multiwell at a density of 2000 cells/well in 
quadruplicate.  Inhibitors (11m, 11p, and Doxorubicin) were added to 
each well at a concentration of 1 M  for the indicated time points.. 
Then 10 l of MTT reagent were added to each well, the plate was 
returned to cell culture incubator for 2 hours. The absorbance in each 
well, including the blanks, was measured at 570 nm in a microplate 
plate reader.  
Statistical analysis. Data were expressed as mean ± standard 
deviation (SD). Statistical significance was assessed by Student-t test. 
P value adjustment for multiple comparisons was done by the Holm 
(sequential Bonferonni correction method). P<0.05 was considered 
statistically significant. 
STD-NMR and WaterLOGSY Spectroscopy. STD-NMR  [208] 
and WaterLOGSY  [209] experiments were performed on a Varian 
Inova 700 MHz spectrometer at 25 °C. NMR samples were prepared 
by dissolving the ligand and the poly(dGdC)·poly(dG-dC) copolymer 
(Pharmacia Biochemicals) in H2O/D2O 9:1 (final volume 600 μL; D2O 
99.996%, CIL Laboratories) containing phosphate-buffered saline 
(100 mM) at pH 7.1. A high ligand–receptor molar excess (20:1) was 
used. In particular, the concentration of 11c, 11m, and 11p was 1.0 
mM, whereas that of the DNA was 50 μM, expressed as molarity of 
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phosphate groups. Water suppression was achieved by using the 
double-pulsed field gradient spin-echo (DPFGSE) scheme.[68] The 
STD effects of the individual protons were calculated for each 
compound relative to a reference spectrum with off-resonance 
saturation at δ = -16 ppm. Typically, 512 scans were recorded for each 
DF-STD spectrum (saturation time = 2 s). The relative STD effect was 
calculated for each signal as the difference between the intensity 
(expressed as S/N ratio) of one signal in the on-resonance STD 
spectrum and that of the same signal in the off-resonance NMR 
spectrum divided by the intensity of the same signal in the off-
resonance spectrum. BMI values were obtained as ratio of the relative 
STD effects upon irradiation at 10.0 and -1.0 ppm.[210] The absence 
of STD effects in samples in which the DNA was not added ensured a 
selective macromolecule saturation. WaterLOGSY NMR experiments 
employed a 20 ms selective Gaussian 180° pulse at the water signal 
frequency and an NOE mixing time of 1.5 s.  
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Figure S1. Chemical structures of the non-coded amino acids cited throughout the 
manuscript. 
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Table S1. Analytical Data for the P5U and Urantide Analogues 
Peptide Structure 
HPLCa MS (M+H) 
k’ Found Calcd 
1 H-Ala-c[Pen-Phe-Trp-Lys-Tyr-Cys]-Val-OH 8.22 1045.80 1045.30 
2 H-Ala-c[Pen-Phe-DTrp-Orn-Tyr-Cys]-Val-OH 8.16 1031.90 1031.27 
3 H-Phe-c[Pen-Phe-Trp-Lys-Tyr-Cys]-Val-OH 8.31 1121.90 1121.40 
4 H-Phe-c[Pen-Phe-DTrp-Orn-Tyr-Cys]-Val-OH 8.26 1108.10 1107.37 
5 H-Cpa-c[Pen-Phe-Trp-Lys-Tyr-Cys]-Val-OH 8.33 1156.44 1155.85 
6 H-Cpa-c[Pen-Phe-DTrp-Orn-Tyr-Cys]-Val-OH 8.30 1142.32 1141.82 
7 H-Nal(1)-c[Pen-Phe-Trp-Lys-Tyr-Cys]-Val-OH 8.35 1171.98 1171.46 
8 H-Nal(1)-c[Pen-Phe-DTrp-Orn-Tyr-Cys]-Val-OH 8.32 1158.10 1157.43 
9 H-Nal(2)-c[Pen-Phe-Trp-Lys-Tyr-Cys]-Val-OH 8.35 1171.96 1171.46 
10 H-Nal(2)-c[Pen-Phe-DTrp-Orn-Tyr-Cys]-Val-OH 8.31 1158.15 1157.43 
11 H-(pNO2)Phe-c[Pen-Phe-Trp-Lys-Tyr-Cys]-Val-
OH 
8.31 1167.01 1166.40 
12 H-(pNO2)Phe-c[Pen-Phe-DTrp-Orn-Tyr-Cys]-Val-
OH 
8.27 1152.97 1152.38 
13 H-Tic-c[Pen-Phe-Trp-Lys-Tyr-Cys]-Val-OH 8.34 1134.03 1133.41 
14 H-Tic-c[Pen-Phe-DTrp-Orn-Tyr-Cys]-Val-OH 8.31 1120.10 1119.38 
15 H-Lys-c[Pen-Phe-Trp-Lys-Tyr-Cys]-Val-OH 8.12 1103.12 1102.39 
16 H-Lys-c[Pen-Phe-DTrp-Orn-Tyr-Cys]-Val-OH 8.09 1089.11 1088.37 
ak’ = [(peptide retention time – solvent retention time)/solvent retention time]. 
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Table S2. Amino Acid Analysis of the P5U and Urantide Analogues a 
R-c[Pen-Phe-Xaa-Yaa-Tyr-Cys]-Val-OH 
Peptide R Pen Phe Xaab Yaac Tyr Cys Val
1 0.97 N.D. 1.0 - 0.91 0.92 1.02 0.98 
2 0.98 0.98 0.97 - 0.92 0.98 1.00 0.99 
3 0.89 N.D. 0.98 - 1.00 1.00 0.98 0.97 
4 0.92 0.98 0.93 - 0.92 0.93 0.97 1.02 
5 0.96 N.D. 0.96 - 0.88 0.97 0.99 0.93 
6 0.98 0.91 0.91 - 0.89 0.91 0.94 0.92 
7 0.87 N.D. 0.96 - 0.97 0.95 0.91 0.89 
8 0.91 N.D. 0.90 - 0.89 0.91 1.00 0.93 
9 0.89 0.91 0.98 - 0.91 0.96 0.97 0.96 
10 0.91 0.89 0.97 - 0.90 0.97 0.89 0.99 
11 0.98 0.93 0.95 - 0.90 0.93 0.95 0.92 
12 N.D. 0.92 0.93 - 0.94 0.91 0.93 0.94 
13 0.93 N.D. 0.99 - 0.93 0.97 0.95 0.96 
14 0.96 0.90 1.01 - 0.99 0.98 0.96 0.93 
15 0.98 0.95 0.97 - 0.98 0.95 0.99 0.91 
16 0.99 0.94 0.97 - 0.98 0.99 1.00 0.93 
a The analyses were performed using an Applied Biosystems Model 420A amino 
acid analyzer with automatic hydrolysis (Vapor Phase at 160 ºC for 1 h 40 min 
using 6 N HCl) and a precolumn phenylthiocarbamyl-amino acid (PTC-AA) 
analysis. No correction is made for amino acid decomposition. bTrp was not well  
determined due to decomposition under these conditions. Other notations: "ND" 
(not determined) refers to the amino acid that could not be estimated due to 
unavailability of a standard sample. cYaa = Lys (1,3,5,7,9,11,13,15), Orn 
(2,4,6,8,10,12,14,16);  
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Table S3. NMR Resonance Assignmentsa of Peptide 14 in SDS-d25 
200mM Solution. 
residue NH (3JN, exc, -/T)b CH (3J)b CH Others 
Tic  4   4.57 (5.5, 9.5) 3.22, 2.93 6.97(); 7.23(); 
Pen  5 8.50 (8.8, f, 6.9) 5.14  1.32,1.13() 
Phe  6 9.05 (8.5, ms, 3.2) 4.71 (overl.) 2.98 7.08();  
D-Trp  7 8.18 (4.5, f, 6.3) 4.58 (9.0, 7.3) 3.19, 3.00 7.14(); 9.92, 7.67(); 
7.51, 7.11(); 7.20() 
Orn  8 7.47 (5.9, f, 4.7) 4.09 (3.2, 7.3) 1.44, 1.13 0.97, 0.65(); 2.71,2.67(); 
7.22() 
Tyr  9 8.07 (8.4, s, 2.7) 4.69 (5.3, 10.0) 2.99, 2.90 7.11(); 6.76() 
Cys 10 8.30 (8.7, f, 6.8) 5.38 (overl.) 2.89  
Val 11 8.14 (8.6, ms, 3.4) 4.40 2.05 0.88, 0.80() 
aObtained at 25°C, pH = 5.5, with TSP ( 0.00 ppm) as reference shift. Chemical 
shifts are accurate to ±0.02 ppm.  
b  3JN, and 3J coupling constants in Hz.  exc = NH exchange rate (f, fast; ms, 
moderately slow; s, slow;). -/T = temperature coefficients (ppb/K). 
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Table S4. NMR Resonance Assignmentsa of Peptide 16 in SDS-d25 
200mM Solution. 
residue NH (3JN, exc, -/T)b CH (3J)b CH Others 
     
Lys  4   4.05 (8.7, 7.3) 1.71, 1.61 1.40, 1.26(); 1.68(); 
2.96, 2.90(); 7.48() 
Pen  5 8.26 (8.8, f, 6.7) 5.06  1.26, 1.06() 
Phe  6 9.21 (8.5, ms, 3.2) 4.69 (9.0, 6.0) 3.05, 2.90 7.13()  
D-Trp  7 8.55 (4.5, f, 6.3) 4.62 (9.1, 7.2) 3.24, 3.07 7.16(); 9.99, 7.66(); 
7.51, 7.10(); 7.18() 
Orn  8 7.30 (5.9, f, 4.8) 4.11 (3.4, 7.1) 1.42, 1.01 0.87, 0.50(); 2.69,2.63() 
Tyr  9 8.09 (8.4, s, 2.7) 4.73 (5.5, 9.9) 3.05, 2.97 7.13(); 6.75() 
Cys 10 8.50 (8.7, f, 6.8) 5.44 (overl.) 2.87  
Val 11 8.39 (8.6, ms, 3.1) 4.46 2.27 1.01() 
aObtained at 25°C, pH = 5.5, with TSP ( 0.00 ppm) as reference shift. Chemical 
shifts are accurate to ±0.02 ppm.  
b  3JN and 3J coupling constants in Hz.  exc = NH exchange rate (f, fast; ms, 
moderately slow; s, slow;). -/T = temperature coefficients (ppb/K). 
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NOE derived Upper Limit Constraints. 
 
  Peptide 14 
 
  4 TIC  HA      5 PEN  HN      2.83                 
  5 PEN  HN      5 PEN  QG1     3.71                 
  5 PEN  HN     10 CYSS HA      5.50                 
  5 PEN  HA      6 PHE  HN      2.71                 
  5 PEN  HA     10 CYSS HA      2.65                 
  5 PEN  HA     10 CYSS QB      5.35                 
  5 PEN  HA     11 VAL  HN      3.55                 
  5 PEN  QG1    10 CYSS HA      6.53                 
  5 PEN  QG1    10 CYSS QB      6.51                 
  5 PEN  QG2     6 PHE  HN      5.85                 
  5 PEN  QG2     7 DTRP HN      6.50                 
  5 PEN  QG2    10 CYSS HA      6.40                 
  5 PEN  QG2    10 CYSS QB      7.03                 
  6 PHE  HN      9 TYR  HN      4.26                 
  6 PHE  HN     10 CYSS HA      4.11                 
  6 PHE  HA      7 DTRP HN      2.71                 
  7 DTRP HN      7 DTRP HB2     2.86                 
  7 DTRP HN      7 DTRP HB3     3.02                 
  7 DTRP HN      7 DTRP HD1     5.31                 
  7 DTRP HA      7 DTRP HB2     2.83                 
  7 DTRP HA      7 DTRP HB3     2.80                 
  7 DTRP HA      7 DTRP HD1     4.01                 
  7 DTRP HA      7 DTRP HE3     4.24                 
  7 DTRP HA      8 ORN  HN      2.59                 
  7 DTRP HA      9 TYR  HN      3.42                 
  7 DTRP HB2     7 DTRP HD1     3.14                 
  7 DTRP HB2     7 DTRP HE3     4.07                 
  7 DTRP HB2     8 ORN  HN      3.76                 
  7 DTRP HB3     7 DTRP HD1     3.70                 
  7 DTRP HB3     7 DTRP HE3     3.86                 
  7 DTRP HB3     8 ORN  HN      4.07                 
  8 ORN  HN      8 ORN  HB2     3.52                 
  8 ORN  HN      8 ORN  HB3     3.52                 
  8 ORN  HN      8 ORN  QB      3.28                 
  8 ORN  HN      8 ORN  HG2     4.35                 
  8 ORN  HN      8 ORN  HG3     4.35                 
  8 ORN  HN      8 ORN  QG      4.18                 
  8 ORN  HN      8 ORN  HD2     5.50                 
  8 ORN  HN      8 ORN  HD3     5.50                 
  8 ORN  HN      9 TYR  HN      2.86                 
  8 ORN  HA      8 ORN  HB2     3.05                 
  8 ORN  HA      8 ORN  HB3     3.05                 
  8 ORN  HA      8 ORN  QG      4.05                 
  8 ORN  HA      9 TYR  HN      3.36                 
  8 ORN  HA      9 TYR  QD      7.64                 
  8 ORN  HB2     8 ORN  HE1     5.50                 
  8 ORN  HB2     9 TYR  HN      4.51                 
  8 ORN  HB2     9 TYR  QD      7.64                 
  8 ORN  HB2     9 TYR  QE      7.63                 
  8 ORN  HB3     8 ORN  HE1     5.50                 
  8 ORN  HB3     9 TYR  HN      4.51                 
  8 ORN  HB3     9 TYR  QD      7.64                 
  8 ORN  HB3     9 TYR  QE      7.63                 
  8 ORN  QB      9 TYR  HN      3.91                 
  8 ORN  HG2     9 TYR  HN      5.50                 
  8 ORN  HG2     9 TYR  QD      7.64                 
  8 ORN  HG2     9 TYR  QE      7.63                 
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  8 ORN  HG3     9 TYR  HN      5.50                 
  8 ORN  HG3     9 TYR  QD      7.64                 
  8 ORN  HG3     9 TYR  QE      7.63                 
  8 ORN  HD2     9 TYR  QE      7.63                 
  8 ORN  HD3     9 TYR  QE      7.63                 
  9 TYR  HN      9 TYR  HB2     2.90                 
  9 TYR  HN      9 TYR  HB3     2.90                 
  9 TYR  HN      9 TYR  QE      7.63                 
  9 TYR  HA      9 TYR  HB2     3.08                 
  9 TYR  HA      9 TYR  HB3     3.08                 
  9 TYR  HA     10 CYSS HN      3.11                 
 10 CYSS HA     11 VAL  HN      2.74                 
 10 CYSS HA     11 VAL  QQG     8.09                 
 10 CYSS QB     11 VAL  HN      4.08                 
 10 CYSS QB     11 VAL  QG1     7.40                 
 10 CYSS QB     11 VAL  QG2     7.40                 
 11 VAL  HN     11 VAL  HB      3.95                 
 11 VAL  HA     11 VAL  HB      2.86                 
 
 
  Peptide 16 
 
  4 LYS  HA      4 LYS  HG2     3.70                 
  4 LYS  HA      4 LYS  HG3     3.70                 
  4 LYS  HA      4 LYS  QG      3.52                 
  4 LYS  HA      5 PEN  HN      2.80                 
  4 LYS  HB2     5 PEN  HN      3.58                 
  4 LYS  HB3     5 PEN  HN      3.58                 
  4 LYS  QB      5 PEN  HN      3.39                 
  4 LYS  HG2     4 LYS  HE2     4.29                 
  4 LYS  HG2     4 LYS  HE3     4.29                 
  4 LYS  HG2     4 LYS  QZ      6.44                 
  4 LYS  HG3     4 LYS  HE2     4.29                 
  4 LYS  HG3     4 LYS  HE3     4.29                 
  4 LYS  HG3     4 LYS  QZ      6.44                 
  4 LYS  QG      5 PEN  HN      6.38                 
  5 PEN  HN      5 PEN  QG1     3.90                 
  5 PEN  HA      6 PHE  HN      3.58                 
  5 PEN  HA     10 CYSS HA      3.02                 
  5 PEN  HA     10 CYSS QB      5.54                 
  5 PEN  HA     11 VAL  HN      3.70                 
  5 PEN  QG2     6 PHE  HN      4.73                 
  5 PEN  QG2     7 DTRP HN      5.69                 
  5 PEN  QG2     9 TYR  HN      5.16                 
  5 PEN  QG2    10 CYSS HN      6.53                 
  5 PEN  QG2    10 CYSS HA      5.16                 
  6 PHE  HN      6 PHE  HB2     3.73                 
  6 PHE  HN      6 PHE  HB3     3.73                 
  6 PHE  HN      6 PHE  QB      3.50                 
  6 PHE  HN      9 TYR  HN      5.50                 
  6 PHE  HN     10 CYSS HA      3.89                 
  6 PHE  HA      6 PHE  HB2     2.96                 
  6 PHE  HA      6 PHE  HB3     2.96                 
  6 PHE  HA      6 PHE  QB      2.76                 
  6 PHE  HA      7 DTRP HN      2.99                 
  7 DTRP HN      7 DTRP HB2     3.08                 
  7 DTRP HN      7 DTRP HB3     3.48                 
  7 DTRP HN      7 DTRP HE3     5.50                 
  7 DTRP HA      7 DTRP HB2     3.02                 
  7 DTRP HA      7 DTRP HE3     3.39                 
  7 DTRP HA      8 ORN  HN      2.90                 
  7 DTRP HA      9 TYR  HN      3.55                 
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  7 DTRP HB2     7 DTRP HD1     3.17                 
  7 DTRP HB2     8 ORN  HN      3.89                 
  7 DTRP HB3     7 DTRP HD1     3.42                 
  7 DTRP HB3     8 ORN  HN      4.32                 
  7 DTRP HE3     8 ORN  HN      4.57                 
  8 ORN  HN      8 ORN  HB2     3.55                 
  8 ORN  HN      8 ORN  HB3     3.55                 
  8 ORN  HN      8 ORN  QB      3.30                 
  8 ORN  HN      8 ORN  HG2     5.04                 
  8 ORN  HN      8 ORN  HG3     5.04                 
  8 ORN  HN      8 ORN  QG      4.73                 
  8 ORN  HN      9 TYR  HN      3.21                 
  8 ORN  HA      8 ORN  QG      3.97                 
  8 ORN  HA      9 TYR  HN      3.58                 
  8 ORN  HB2     9 TYR  QE      7.63                 
  8 ORN  HB3     9 TYR  QE      7.63                 
  8 ORN  QB      9 TYR  QE      7.30                 
  8 ORN  HG2     9 TYR  HN      5.50                 
  8 ORN  HG2     9 TYR  QE      7.63                 
  8 ORN  HG3     9 TYR  HN      5.50                 
  8 ORN  HG3     9 TYR  QE      7.63                 
  8 ORN  QG      9 TYR  QD      8.52                 
  8 ORN  HD2     9 TYR  QE      7.63                 
  8 ORN  HD3     9 TYR  QE      7.63                 
  9 TYR  HN      9 TYR  HB2     3.08                 
  9 TYR  HN      9 TYR  HB3     3.08                 
  9 TYR  HN      9 TYR  QE      7.63                 
  9 TYR  HN     10 CYSS HN      5.28                 
  9 TYR  HA     10 CYSS HN      3.08                 
 10 CYSS HA     11 VAL  HN      3.08                 
 10 CYSS QB     11 VAL  HN      4.30                 
 10 CYSS QB     11 VAL  HA      5.20                 
 11 VAL  HA     11 VAL  HB      2.86                 
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Figure S2. Results of MD simulations of h-UTR complexed with Urantide. 
Graphic shows plot of the monitored distance, in the complex, between the 
protonated N of Orn8 in Urantide and the O of Asp130 in h-UTR. 
 
 
 
 
Figure S3. Distance between the OH oxygen of Tyr9 in Urantide and the side 
chain CO oxygen of Asn297 in h-UTR. 
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Figure S4. Distance between the OH oxygen of Tyr9 in Urantide and the OH 
hydrogen of Thr301 in h-UTR. 
 
 
 
 
Figure S5. Distance between the the O of Asp4 in Urantide and the guanidinium 
group N of Arg206 in h-UTR. 
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Figure S6. Distance between the protonated backbone NH3 nitrogen of Asp4 in 
Urantide and the backbone CO oxygen of Ala187 in h-UTR. 
 
 
 
 
Figure S7. Distance between the protonated backbone NH3 nitrogen of Asp4 in 
Urantide and the backbone CO oxygen of Cys199 in h-UTR. 
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Figure S8. Distance between the protonated backbone NH3 nitrogen of Asp4 in 
Urantide and the backbone CO oxygen of Met188 in h-UTR. 
 
 
 
 
Figure S9. Distance between the negatively charged carboxyl  group of Val11 in 
Urantide and the backbone NH hydrogen of Cys123 in h-UTR. 
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Figure S10. Distance between the negatively charged carboxyl  group of Val11 in 
Urantide and the backbone NH hydrogen of Cys199 in h-UTR. 
 
 
 
 
Figure S11. Distance between the negatively charged carboxyl  group of Val11 in 
Urantide and the backbone NH hydrogen of Arg189 in h-UTR. 
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Figure S12. Distance between the protonated N of Lys8 in P5U and the O of 
Asp130 in h-UTR. 
 
 
 
 
Figure S13. Distance between the the O of Asp4 in P5U and the side chain NH2 
hydrogen of Gln285 in h-UTR. 
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Figure S14. (a) Stereoview of Urantide/h-UTRa (a) and P5U/ h-UTRi (b) model 
complex. Urantide and P5U heavy atoms are colour coded (carbon, green; 
nitrogen, blue; oxygen, red; sulfur, yellow). Receptor backbones are represented 
in azure. 
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Figure S15. Pairwise alignment of h-UTR and r-UTR. The conserved key 
residues used to align the sequences are shown in bold. In all sequence alignment 
figures, an asterisk (*) indicates an identical amino acid; punctuations indicate a 
“conserved” amino acid, which meets the criteria for either highly conservative 
substitutions (:) or semiconservative substitutions (.), as defined by CLUSTALW.  
 
 
Figure S16. Stereoview of the TM domains of the h-UTRi model (azure) 
superimposed to 2AR crystal structure (gold, PDB code 2RH1). Backbone heavy 
atoms of TM-II÷TM-VII were used for the superimposition. Bound urantide is 
shown as green surface.  
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Figure S17. Chemical shift deviations from the random coil shift values 
(reference [110] of the manuscript) for H resonances at 25 °C. 
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Figure S18. Results of MD simulations of h-MC4Ra complexed with MTII. 
Graphic shows plot of the monitored distances, in the complex, between the 
protonated guanidinium N of Arg8 in MTII and the O of Glu100 (a), O of 
Asp122 (b), Asp126 (c), and between N of His6 and the O of Glu100 (d). 
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. 
Figure S19. Results of MD simulations of h-MC4Ri complexed with SHU9119. 
Graphic shows plot of the monitored distances, in the complex, between the 
protonated guanidinium N of Arg8 in SHU9119 and the O of Glu100 (a), O of 
Asp122 (b), Asp126 (c), and between N of His6 and the O of Glu100 (d). 
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Figure S20. Stereoview of h-MC4R models in the “active” state proposed by 
Chapman et al. (violet ribbon; reference [129] of the manuscript) and that 
proposed by Mosberg et al. (grey ribbon; reference  [114] of the manuscript). The 
h-MC4R models were superimposed using the backbone heavy atoms of TM 
residues.  
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Table S5. Analytical data of synthesized peptides MTII and 
SHU9119. 
 
 
 
 
 
 
 
 
 
aHPLC column, Vydac 218TP1010, 1.0 x 25 cm, using a gradient of CH3CN in 
0.1% aqueous TFA (from 10 to 90% in 30 min) at a flow rate of 1.0 mL/min..  
 bk’ = [(peptide retention time – solvent retention time)/solvent retention time]. 
 
  
Code M.W. MS HPLCa,b 
MT-II 1024.22 1024.87 4.15 
SHU9119 1074.28 1075.12 4.31 
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Table S6. NMR Resonance Assignmentsa of Peptide MTII in H2O 
Solution at 25 °C. 
residue NH (3JN, exc, -/T)b CH CH Others 
     
Nleu4 8.22 (6.6, f, 9.1) 4.20 1.65 1.26(); 0.85() 
Asp5 8.52 (7.5, f, 8.3) 4.63 2.89, 2.68  
His6 8.46 (7.0, f, 6.5) 4.40 3.16, 3.01 7.03(); 8.33() 
DPhe7 8.39 (7.1, f, 8.3) 4.57 3.15, 2.88 7.22(); 7.35() 
Arg8 7.89 (7.2, f, 6.3) 4.27 1.61, 1.57 1.32(); 3.08(); 7.10() 
Trp9 8.44 (6.7, f, 8.7) 4.65 3.31 7.27(); 10.15, 7.69(); 7.50, 7.33(); 
7.18() 
Lys10 
 
8.06 (8.1, f, 7.3) 4.22 1.75, 1.60 1.31, 1.23(); 1.51, 1.41(); 3.22, 
3.17(); 7.91() 
a Obtained at pH = 5, with TSP ( 0.00 ppm) as reference shift. Chemical shifts 
are accurate to ±0.02 ppm.  
b  3JN coupling constants in Hz.  exc = NH exchange rate (f, fast; ms, moderately 
slow; s, slow;). -/T = temperature coefficients (ppb/K) calculated in the range 
25-40 °C. Further signals: CH3CO, 2.01; CONH2, 6.65, 6.84. 
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Table S7. NMR Resonance Assignmentsa of Peptide SHU9119 in 
H2O Solution at 25 °C. 
 
residue NH (3JN, exc, -/T)b CH CH Others 
     
Nleu4 8.18 (5.7, f, 8.3) 4.15 1.60 1.22(); 0.83() 
Asp5 8.46 (7.3, f, 8.1) 4.61 2.82, 2.63  
His6 8.41 (7.2, f, 6.0) 4.45 3.14, 2.96 6.95(); 8.04() 
DNal7 8.53 (7.0, f, 8.3) 4.70 3.29, 3.06 7.65, 7.38(); 7.87() 
Arg8 7.93 (7.1, f, 6.8) 4.18 1.48, 1.39 1.05, 1.01(); 2.83(); 6.90() 
Trp9 8.39 (6.1, f, 9.1) 4.64 3.31, 3.27 7.26(); 10.13, 7.26(); 7.49, 7.33(); 7.19()
Lys10 7.99 (8.8, f, 6.3) 4.21 1.74, 1.59 1.49(); 1.29, 1.19(); 3.18(); 7.91() 
a Obtained at pH = 5, with TSP ( 0.00 ppm) as reference shift. Chemical shifts 
are accurate to ±0.02 ppm.  
b  3JN coupling constants in Hz.  exc = NH exchange rate (f, fast; ms, moderately 
slow; s, slow;). -/T = temperature coefficients (ppb/K) calculated in the range 
25-40 °C. Further signals: CH3CO, 1.96; CONH2, 6.65, 6.84.  
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Table S8. NMR Resonance Assignmentsa of Peptide MTII in H2O 
Solution at 5 °C. 
residue NH (3JN, exc, -/T)b CH CH Others 
     
Nleu4 8.41 (6.0, f, 9.0) 4.18 1.64 1.23(); 0.83() 
Asp5 8.70 (7.5, f, 8.4) 4.63 2.90, 2.68  
His6 8.57 (6.4, f, 6.2) 4.38 3.16, 3.04 7.02(); 8.32() 
DPhe7 8.58 (6.8, f, 6.3) 4.13 3.16, 2.87 7.21(); 7.34() 
Arg8 8.00 (7.3, f, 6.2) 4.28 1.62, 1.56 1.29(); 3.07(); 7.17() 
Trp9 8.63 (6.4, f, 8.8) 4.65 3.30 7.27(); 10.24, 7.67(); 7.49, 7.33 (); 
7.17() 
Lys10 
 
8.17 (8.1, f, 7.4) 4.19 1.72, 1.58 1.31, 1.21(); 1.51, 1.39(); 3.23, 
3.15(); 8.10() 
a Obtained at pH = 5, with TSP ( 0.00 ppm) as reference shift. Chemical shifts 
are accurate to ±0.02 ppm.  
b  3JN coupling constants in Hz.  exc = NH exchange rate (f, fast; ms, moderately 
slow; s, slow;). -/T = temperature coefficients (ppb/K) calculated in the range 
5-15 °C. Further signals: CH3CO, 1.99; CONH2, 6.52, 6.94.  
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Table S9. NMR Resonance Assignmentsa of Peptide SHU9119 in 
H2O Solution at 5 °C. 
residue NH (3JN, exc, -/T)b CH CH Others 
     
Nleu4 8.34 (5.7, f, 8.3) 4.14 1.59 1.23(); 0.82(); 
Asp5 8.61 (7.2, f, 8.1) 4.60 2.83, 2.63  
His6 8.53 (6.5, f, 6.0) 4.44 3.14, 2.95 6.93(); 8.04() 
DNal7 8.73 (6.7, f, 6.5) 4.70 3.29, 3.04 7.66, 7.40(); 7.85() 
Arg8 8.10 (7.1, f, 6.7) 4.16 1.48, 1.39 1.05, 0.97(); 2.82(); 6.95() 
Trp9 8.55 (6.2, f, 9.1) 4.63 3.29, 3.27 7.25(); 10.21(); 7.47, 7.33 (); 7.16() 
Lys10 8.09 (8.2, f, 6.3) 4.19 1.74, 1.59 1.49(); 1.29, 1.19(); 3.15(); 8.09() 
a Obtained at pH = 5, with TSP ( 0.00 ppm) as reference shift. Chemical shifts 
are accurate to ±0.02 ppm.  
b  3JN coupling constants in Hz.  exc = NH exchange rate (f, fast; ms, moderately 
slow; s, slow;). -/T = temperature coefficients (ppb/K) calculated in the range 
5-15 °C. Further signals: CH3CO, 1.96; CONH2, 6.73, 6.96.  
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Table S10. NMR Resonance Assignmentsa of Peptide MTII in 
H2O/DMSO Solution at -10 °C. 
residue NH (3JN, exc, -/T)b CH CH Others 
     
Nleu4 8.43 (6.4, f, 9.0) 4.18 1.60 1.21(); 0.83() 
Asp5 8.71 (6.8, f, 8.2) 4.60 2.90, 2.66  
His6 8.59 (6.4, f, 6.2) 4.33 3.17, 3.01 7.01(); 8.38() 
DPhe7 8.56 (7.0, f, 6.3) 4.52 3.16, 2.86 7.22(); 7.33() 
Arg8 7.99 (7.0, f, 6.6) 4.30 1.64, 1.58 1.33(); 3.08(); 7.25() 
Trp9 8.64 (6.0, f, 8.7) 4.63 3.30, 3.26 7.27(); 10.35, 7.68(); 7.47, 7.16(); 7.23()
Lys10 8.25 (8.1, f, 7.3) 4.18 1.74, 1.58 1.32, 1.22(); 1.49, 1.37(); 3.19(); 8.11() 
a Obtained at -10 °C, with TSP ( 0.00 ppm) as reference shift. Chemical shifts are 
accurate to ±0.02 ppm.  
b  3JN coupling constants in Hz.  exc = NH exchange rate (f, fast; ms, moderately 
slow; s, slow;). -/T = temperature coefficients (ppb/K) calculated in the range 
-10 to 0 °C. Further signals: CH3CO, 1.97; CONH2, 6.59, 7.01.  
 
. 
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Table S11. NMR Resonance Assignmentsa of Peptide SHU9119 in 
H2O/DMSO Solution. 
residue NH (3JN, exc, -/T)b CH CH Others 
     
Nleu4 8.38 (5.8, f, 8.4) 4.14 1.56 1.18(); 0.79(); 
Asp5 8.65 (6.7, f, 8.1) 4.58 2.85, 2.62  
His6 8.57 (6.4, f, 6.0) 4.36 3.15, 2.96 6.93(); 8.07() 
DNal7 8.70 (6.7, f, 6.5) 4.67 3.30, 3.04 7.66, 7.39(); 7.86() 
Arg8 8.07 (7.0, f, 6.7) 4.21 1.53, 1.48 1.11, 1.08(); 2.90(); 7.09() 
Trp9 8.60 (6.1, f, 9.1) 4.63 3.29, 3.24 7.23(); 10.33, 7.26(); 7.46, 7.15(); 7.23()
Lys10 8.17 (8.3, f, 6.3) 4.19 1.73, 1.58 1.24(); 1.48, 1.37(); 3.17(); 8.10() 
a Obtained at -10 °C,with TSP ( 0.00 ppm) as reference shift. Chemical shifts are 
accurate to ±0.02 ppm.  
b  3JN coupling constants in Hz.  exc = NH exchange rate (f, fast; ms, moderately 
slow; s, slow;). -/T = temperature coefficients (ppb/K) calculated in the range 
-10 to 0 °C. Further signals: CH3CO, 1.94; CONH2, 6.66, 7.02.  
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Table S12. NMR Resonance Assignmentsa of Peptide MTII in DPC 
200mM Solution. 
residue NH (3JN, exc, -/T)b CH(J(l),J(h)) CH Others 
     
Nleu4 8.23 (5.8, f, 7.6) 4.22 (8.6, 7.3) 1.69, 1.63 1.23(); 1.30(); 0.82(); 
Asp5 8.70 (5.5, f, 5.0) 4.40 (6.1, 8.5) 3.13, 2.47   
His6 8.84 (6.0, f, 4.7) 4.14 (6.3, 7.2) 3.29, 3.15 7.12(); 8.51() 
DPhe7 8.21 (7.0, ms, 3.2) 4.46 (9.5, 5.2) 3.16, 2.92  7.19(); 7.22(); 7.16() 
Arg8 7.49 (8.2, s, 1.4) 4.54 (ov.) 1.73, 1.70 1.52, 1.47(); 3.15(); 
7.23() 
Trp9 8.72 (7.0, f, 8.9) 4.75 (9.0, 5.8) 3.33, 3.14 7.21(); 10.63, 7.61(); 7.46, 
6.99(); 7.07() 
Lys10 
 
8.19 (8.1, f, 5.3) 4.16 (5.2, 9.1) 1.73, 1.53 1.35, 1.28(); 1.42(); 3.20, 
3.06(); 7.95() 
a Obtained at 25°C, pH = 5, with TSP ( 0.00 ppm) as reference shift. Chemical 
shifts are accurate to ±0.02 ppm.  
b  3JN and 3J coupling constants in Hz.  exc = NH exchange rate (f, fast; ms, 
moderately slow; s, slow;). -/T = temperature coefficients (ppb/K) calculated 
in the range 25 – 40 °C. The subscripts (l) and (h) denote the coupling constant of 
the low- and high-field H signal, respectively. Further signals: CH3CO, 1.93; 
CONH2, 6.37, 7.08.  
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Table S13. NMR Resonance Assignmentsa of Peptide SHU9119 in 
DPC 200mM Solution  
residue NH (3JN, exc, -/T)b CH(J(l),J(h)) CH Others 
     
Nleu4 8.18 (5.6, f, 7.8) 4.26 (8.6, 7.4) 1.69, 1.63 1.26(); 1.18(); 0.78(); 
Asp5 8.73 (5.4, f, 5.7) 4.42 (6.0, 8.5) 3.13, 2.49  
His6 8.87 (6.1, f, 4.5) 4.16 (6.5, 7.3) 3.30, 3.16 7.12(); 8.39() 
DNal7 8.38 (6.9, ms, 3.2) 4.57 (8.5, 7.2) 3.31, 3.11 7.65, 7.35(); 7.75(); 7.80(); 
7.80, 7.79(); 7.43(θ) 
Arg8 7.53 (8.2, s, 1.5) 4.55 (6.8, 8.0) 1.76, 1.69 1.52, 1.47(); 3.12(); 7.23() 
Trp9 8.74 (7.1, f, 8.5) 4.77 (9.0, 5.8) 3.35, 3.15 7.23(); 10.65, 7.63(); 7.47, 
7.01(); 7.08() 
Lys10 
 
8.22 (8.1, f, 5.8) 4.18 (5.2, 9.0) 1.74, 1.55 1.31(); 1.44, 1.37(); 3.22, 
3.07(); 7.97() 
a Obtained at 25°C, pH = 5, with TSP ( 0.00 ppm) as reference shift. Chemical 
shifts are accurate to ±0.02 ppm.  
b  3JN and 3J coupling constants in Hz.  exc = NH exchange rate (f, fast; ms, 
moderately slow; s, slow;). -/T = temperature coefficients (ppb/K) calculated 
in the range 25 - 40 °C. The subscripts (l) and (h) denote the coupling constant of 
the low- and high-field H signal, respectively. Further signals: CH3CO, 1.90; 
CONH2, 6.40, 7.10.  
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Table S14. NOE Derived Upper Limit Constraints of MTII in DPC 
solution 
  3 ACE  QH      5 ASP  HN      6.19                 
  4 NLE  HN      4 NLE  HA      2.93                 
  4 NLE  HN      4 NLE  HB2     3.92                 
  4 NLE  HN      4 NLE  HB3     3.92                 
  4 NLE  HN      4 NLE  QB      2.84                 
  4 NLE  HN      4 NLE  QG      5.27                 
  4 NLE  HN      4 NLE  QD      6.38                 
  4 NLE  HN      5 ASP  HN      2.99                 
  4 NLE  HA      4 NLE  HB2     2.96                 
  4 NLE  HA      4 NLE  HB3     2.96                 
  4 NLE  HA      4 NLE  QD      5.02                 
  4 NLE  HA      4 NLE  QE      6.53                 
  4 NLE  HA      5 ASP  HN      3.50                 
  4 NLE  HA      6 HIS  HN      4.76                 
  4 NLE  HB2     4 NLE  QE      6.53                 
  4 NLE  HB2     5 ASP  HN      3.48                 
  4 NLE  HB2     6 HIS  HN      4.72                 
  4 NLE  HB3     4 NLE  QE      6.53                 
  4 NLE  HB3     5 ASP  HN      3.48                 
  4 NLE  HB3     6 HIS  HN      4.72                 
  4 NLE  QB      4 NLE  QE      6.41                 
  4 NLE  QB      5 ASP  HN      3.26                 
  4 NLE  QB      6 HIS  HN      4.50                 
  4 NLE  QG      5 ASP  HN      6.32                 
  4 NLE  QG      6 HIS  HN      6.38                 
  4 NLE  QG      7 DPHE QD      8.50                 
  4 NLE  QG      9 TRP  HE3     6.38                 
  4 NLE  QG      9 TRP  HZ3     6.38                 
  4 NLE  QD      5 ASP  HN      6.38                 
  4 NLE  QD      9 TRP  HE3     6.38                 
  4 NLE  QE      7 DPHE QD      8.65                 
  4 NLE  QE      9 TRP  HE3     6.53                 
  5 ASP  HN      5 ASP  HA      2.55                 
  5 ASP  HN      6 HIS  HN      3.17                 
  5 ASP  HN     10 LYS  HZ1     5.50                 
  5 ASP  HA      5 ASP  HB2     2.99                 
  5 ASP  HA      5 ASP  HB3     2.99                 
  5 ASP  HA      6 HIS  HN      3.60                 
  5 ASP  HA      7 DPHE HN      5.00                 
  5 ASP  HA     10 LYS  HZ1     5.13                 
  5 ASP  HB2    10 LYS  HE2     6.85                 
  5 ASP  HB2    10 LYS  HE3     6.85                 
  5 ASP  HB2    10 LYS  HZ1     3.11                 
  5 ASP  HB3    10 LYS  HE2     6.85                 
  5 ASP  HB3    10 LYS  HE3     6.85                 
  5 ASP  HB3    10 LYS  HZ1     3.11                 
  5 ASP  QB      8 ARG  HN      5.50                 
  5 ASP  QB     10 LYS  QB      7.25                 
  5 ASP  QB     10 LYS  QE      5.90                 
  5 ASP  QB     10 LYS  HZ1     2.88                 
  6 HIS  HN      6 HIS  HA      2.68                 
  6 HIS  HN      6 HIS  HB2     3.42                 
  6 HIS  HN      6 HIS  HB3     3.42                 
  6 HIS  HN      6 HIS  HD2     5.25                 
  6 HIS  HN      7 DPHE HN      3.21                 
  6 HIS  HN      8 ARG  HN      4.63                 
  6 HIS  HA      6 HIS  HB2     2.77                 
  6 HIS  HA      6 HIS  HB3     2.77                 
  6 HIS  HA      6 HIS  HD2     4.60                 
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  6 HIS  HA      7 DPHE HN      2.86                 
  6 HIS  HA      7 DPHE QD      7.62                 
  6 HIS  HA      8 ARG  HN      4.88                 
  6 HIS  QB      7 DPHE HN      4.86                 
  7 DPHE HN      7 DPHE HB2     2.83                 
  7 DPHE HN      7 DPHE HB3     2.83                 
  7 DPHE HN      7 DPHE QB      2.63                 
  7 DPHE HN      8 ARG  HN      3.50                 
  7 DPHE HA      8 ARG  HN      3.14                 
  8 ARG  HN      9 TRP  HN      4.58                 
  8 ARG  HA      8 ARG  QB      2.76                 
  8 ARG  HA      8 ARG  HG2     4.04                 
  8 ARG  HA      8 ARG  HG3     4.04                 
  8 ARG  HA      9 TRP  HN      2.55                 
  8 ARG  HB2     9 TRP  HN      3.24                 
  8 ARG  HB3     9 TRP  HN      3.24                 
  8 ARG  HG2     9 TRP  HN      5.25                 
  8 ARG  HG3     9 TRP  HN      5.25                 
  8 ARG  QG      9 TRP  HN      5.10                 
  9 TRP  HN      9 TRP  HB2     2.90                 
  9 TRP  HN      9 TRP  HB3     2.90                 
  9 TRP  HN      9 TRP  QB      2.68                 
  9 TRP  HN      9 TRP  HD1     5.20                 
  9 TRP  HN     10 LYS  HN      4.61                 
  9 TRP  HA      9 TRP  HD1     5.07                 
  9 TRP  HA      9 TRP  HE3     4.67                 
  9 TRP  HA     10 LYS  HN      2.93                 
  9 TRP  HB2     9 TRP  HE3     3.64                 
  9 TRP  HB2    10 LYS  HN      3.83                 
  9 TRP  HB3     9 TRP  HE3     3.64                 
  9 TRP  HB3    10 LYS  HN      3.83                 
  9 TRP  QB      9 TRP  HD1     3.49                 
  9 TRP  QB      9 TRP  HE3     3.42                 
  9 TRP  QB     10 LYS  HN      3.63                 
  9 TRP  HD1    10 LYS  HN      4.72                 
  9 TRP  HD1    10 LYS  HA      5.50                 
  9 TRP  HD1    11 CNH2 HN1     5.16                 
  9 TRP  HE1    11 CNH2 HN1     5.50                 
 10 LYS  HN     10 LYS  HA      2.90                 
 10 LYS  HN     10 LYS  HB2     3.08                 
 10 LYS  HN     10 LYS  HB3     3.08                 
 10 LYS  HN     11 CNH2 HN1     4.35                 
 10 LYS  HA     10 LYS  HB2     2.83                 
 10 LYS  HA     10 LYS  HB3     2.83                 
 10 LYS  HA     10 LYS  QB      2.63                 
 10 LYS  HA     10 LYS  HG2     3.30                 
 10 LYS  HA     10 LYS  HG3     3.30                 
 10 LYS  HA     10 LYS  QG      2.95                 
 10 LYS  HB2    11 CNH2 HN1     5.50                 
 10 LYS  HB3    11 CNH2 HN1     5.50                 
 10 LYS  HG2    10 LYS  HE2     4.04                 
 10 LYS  HG2    10 LYS  HE3     4.04                 
 10 LYS  HG2    10 LYS  HZ1     3.76                 
 10 LYS  HG3    10 LYS  HE2     4.04                 
 10 LYS  HG3    10 LYS  HE3     4.04                 
 10 LYS  HG3    10 LYS  HZ1     3.76                 
 10 LYS  QG     10 LYS  QE      3.23                 
 10 LYS  QG     10 LYS  HZ1     3.41                 
 
ACE QH is the methyl group of the N-terminal acetyl funtion. CNH2 
HN1 is one of the amide protons of the C-terminal carboxamide 
function.  
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Table S15. NOE Derived Upper Limit Constraints of SHU9119 in 
DPC solution 
  3 ACE  QH      5 ASP  HN      6.09                 
  4 NLE  HN      4 NLE  HA      2.86                 
  4 NLE  HN      4 NLE  HB2     3.90                 
  4 NLE  HN      4 NLE  HB3     3.90                 
  4 NLE  HN      4 NLE  QB      2.80                 
  4 NLE  HN      4 NLE  QG      5.39                 
  4 NLE  HN      4 NLE  QD      5.92                 
  4 NLE  HN      5 ASP  HN      2.97                 
  4 NLE  HA      4 NLE  HB2     2.96                 
  4 NLE  HA      4 NLE  HB3     2.96                 
  4 NLE  HA      4 NLE  QD      4.62                 
  4 NLE  HA      5 ASP  HN      3.52                 
  4 NLE  HA      6 HIS  HN      4.88                 
  4 NLE  HB2     4 NLE  QE      6.25                 
  4 NLE  HB2     5 ASP  HN      3.52                 
  4 NLE  HB3     4 NLE  QE      6.25                 
  4 NLE  HB3     5 ASP  HN      3.52                 
  4 NLE  QB      4 NLE  QE      6.03                 
  4 NLE  QB      5 ASP  HN      3.22                 
  4 NLE  QB      6 HIS  HN      5.82 
  4 NLE  QB      7 DNAL HN      5.67                 
  4 NLE  QB      7 DNAL QB      5.50                 
  4 NLE  QG      5 ASP  HN      6.38                 
  4 NLE  QG      9 TRP  HE3     6.38                 
  4 NLE  QD      5 ASP  HN      6.38                 
  4 NLE  QD      9 TRP  HE3     6.38                 
  4 NLE  QE      5 ASP  HN      6.53                 
  4 NLE  QE      9 TRP  HE3     6.53                 
  5 ASP  HN      5 ASP  HA      2.55                 
  5 ASP  HN      6 HIS  HN      3.08                 
  5 ASP  HN      7 DNAL HN      4.30                 
  5 ASP  HN     10 LYS  HZ1     5.50                 
  5 ASP  HA      5 ASP  HB2     2.90                 
  5 ASP  HA      5 ASP  HB3     2.90                 
  5 ASP  HA      5 ASP  QB      2.68               
  5 ASP  HA      6 HIS  HN      3.64                 
  5 ASP  HA      7 DNAL HN      4.98                 
  5 ASP  HA     10 LYS  HZ1     5.07                 
  5 ASP  HB2    10 LYS  HZ1     3.05                 
  5 ASP  HB3    10 LYS  HZ1     3.05                 
  5 ASP  QB      8 ARG  HN      5.50                 
  5 ASP  QB     10 LYS  HZ1     2.85                 
  6 HIS  HN      6 HIS  HA      2.71                 
  6 HIS  HN      6 HIS  HB2     3.48                 
  6 HIS  HN      6 HIS  HB3     3.48                 
  6 HIS  HN      6 HIS  QB      3.20                
  6 HIS  HN      7 DNAL HN      3.33                 
  6 HIS  HN      8 ARG  HN      4.66                 
  6 HIS  HA      6 HIS  HB2     2.72                 
  6 HIS  HA      6 HIS  HB3     2.72                 
  6 HIS  HA      6 HIS  HD2     4.51                 
  6 HIS  HA      7 DNAL HN      3.02                 
  6 HIS  HA      8 ARG  HN      4.83                 
  6 HIS  QB      7 DNAL HN      4.80                 
  7 DNAL HN      7 DNAL HB2     2.90                 
  7 DNAL HN      7 DNAL HB3     2.90                 
  7 DNAL HN      7 DNAL QB      2.66                 
  7 DNAL HN      8 ARG  HN      3.52                 
  7 DNAL HA      8 ARG  HN      3.24                 
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  8 ARG  HN      9 TRP  HN      4.52                 
  8 ARG  HA      8 ARG  QB      2.78                 
  8 ARG  HA      9 TRP  HN      2.59                 
  8 ARG  HB2     9 TRP  HN      3.24                 
  8 ARG  HB3     9 TRP  HN      3.24                 
  9 TRP  HN      9 TRP  HB2     2.93                 
  9 TRP  HN      9 TRP  HB3     2.93                 
  9 TRP  HN      9 TRP  QB      2.69                 
  9 TRP  HN      9 TRP  HD1     5.22                 
  9 TRP  HN     10 LYS  HN      4.64                 
  9 TRP  HA      9 TRP  HD1     5.04                 
  9 TRP  HA      9 TRP  HE3     4.74                 
  9 TRP  HA     10 LYS  HN      2.68                 
  9 TRP  HB2     9 TRP  HE3     3.79                 
  9 TRP  HB2    10 LYS  HN      3.84                 
  9 TRP  HB3     9 TRP  HE3     3.79                 
  9 TRP  HB3    10 LYS  HN      3.84                 
  9 TRP  QB      9 TRP  HD1     3.49                 
  9 TRP  QB      9 TRP  HE3     3.53                 
  9 TRP  QB     10 LYS  HN      3.63                 
  9 TRP  HD1    10 LYS  HN      5.04                 
  9 TRP  HD1    10 LYS  HA      5.50                 
  9 TRP  HD1    11 CNH2 HN1     5.18                 
  9 TRP  HE1    11 CNH2 HN1     5.46                 
 10 LYS  HN     10 LYS  HA      2.96                 
 10 LYS  HN     10 LYS  HB2     3.14                 
 10 LYS  HN     10 LYS  HB3     3.14                 
 10 LYS  HN     11 CNH2 HN1     4.36                 
 10 LYS  HA     10 LYS  HB2     2.86                 
 10 LYS  HA     10 LYS  HB3     2.86                 
 10 LYS  HA     10 LYS  QB      2.64                 
 10 LYS  HB2    11 CNH2 HN1     5.50                 
 10 LYS  HB3    11 CNH2 HN1     5.50                 
 10 LYS  HG2    10 LYS  HE2     3.98                 
 10 LYS  HG2    10 LYS  HE3     3.98                 
 10 LYS  HG2    10 LYS  HZ1     3.73                 
 10 LYS  HG3    10 LYS  HE2     4.08                 
 10 LYS  HG3    10 LYS  HE3     4.08                 
 10 LYS  HG3    10 LYS  HZ1     3.76                 
 10 LYS  QG     10 LYS  HZ1     4.64                 
 
ACE QH is the methyl group of the N-terminal acetyl funtion. CNH2 
HN1 is one of the amide protons of the C-terminal carboxamide 
function. 
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Table S16. Dihedral angles of the NMR structures of MTII and 
SHU9119  
 
   MTII     SHU9119 
 4 NLE  OMEGA  -178.8 +/-   6.4        4 NLE  OMEGA   169.1 +/-    2.4  
 4 NLE  PHI     -90.2 +/-  22.8        4 NLE  PHI     -78.6 +/-   24.4  
 4 NLE  CHI1   -125.6 +/-  44.7        4 NLE  CHI1   -134.5 +/-   32.7  
 4 NLE  CHI2     63.0 +/-  52.3        4 NLE  CHI2    119.8 +/-   54.9  
 4 NLE  CHI3     54.1 +/-  68.6        4 NLE  CHI3     98.8 +/-  111.5 
 4 NLE  PSI     -72.4 +/-  29.2        4 NLE  PSI     -57.9 +/-   27.6 
 5 ASP  OMEGA  -175.6 +/-   5.5        5 ASP  OMEGA   176.7 +/-    4.6  
 5 ASP  PHI    -118.0 +/-  25.6        5 ASP  PHI    -135.4 +/-   24.5  
 5 ASP  CHI1   -167.9 +/-  23.9        5 ASP  CHI1   -170.6 +/-   15.3  
 5 ASP  CHI2     -0.1 +/-  24.3        5 ASP  CHI2     10.1 +/-   29.5  
 5 ASP  PSI     -51.6 +/-  10.3        5 ASP  PSI     -63.8 +/-    7.9  
 6 HIS  OMEGA   173.0 +/-   5.6        6 HIS  OMEGA  -178.1 +/-    2.9  
 6 HIS  PHI    -164.6 +/-   4.0        6 HIS  PHI    -143.8 +/-    7.9  
 6 HIS  CHI1   -128.3 +/-  48.3        6 HIS  CHI1    -67.6 +/-   83.8  
 6 HIS  CHI2    -77.7 +/-  64.1        6 HIS  CHI2    -85.0 +/-   78.3  
 6 HIS  PSI      42.1 +/-  13.1        6 HIS  PSI      53.4 +/-   14.7  
 7 DPHE OMEGA  -174.8 +/-   6.8        7 DNAL OMEGA  -173.7 +/-    2.5  
 7 DPHE PHI      87.7 +/-  24.4        7 DNAL PHI      64.0 +/-   18.3  
 7 DPHE CHI1    157.3 +/-   4.4        7 DNAL CHI1    112.0 +/-   48.0  
 7 DPHE CHI2   -118.5 +/-  84.2        7 DNAL CHI2    101.6 +/-   36.4  
 7 DPHE PSI     -55.4 +/-  23.0        7 DNAL PSI       5.0 +/-   21.1  
 8 ARG  OMEGA  -179.2 +/-   6.5        8 ARG  OMEGA  -178.9 +/-    2.0  
 8 ARG  PHI     -79.4 +/-   6.0        8 ARG  PHI    -132.9 +/-   18.1  
 8 ARG  CHI1    -74.3 +/-  12.6        8 ARG  CHI1    -71.6 +/-   13.1  
 8 ARG  CHI2   -123.0 +/-  38.8        8 ARG  CHI2   -166.3 +/-   33.6  
 8 ARG  CHI3   -112.5 +/- 113.2        8 ARG  CHI3    174.0 +/-   56.6  
 8 ARG  CHI4   -168.3 +/-  45.0        8 ARG  CHI4    172.5 +/-   49.7  
 8 ARG  PSI     159.6 +/-   7.1        8 ARG  PSI     157.7 +/-    4.3  
 9 TRP  OMEGA  -175.4 +/-   7.7        9 TRP  OMEGA   179.9 +/-    2.7  
 9 TRP  PHI     -90.6 +/-  18.4        9 TRP  PHI     -68.2 +/-   25.0  
 9 TRP  CHI1    179.4 +/-   4.6        9 TRP  CHI1   -174.7 +/-    3.1  
 9 TRP  CHI2    -99.9 +/-  23.7        9 TRP  CHI2   -104.7 +/-   11.7  
 9 TRP  PSI     155.0 +/-   3.9        9 TRP  PSI     149.1 +/-    3.6  
10 LYS  OMEGA  -172.8 +/-   4.1       10 LYS  OMEGA  -168.8 +/-    1.3  
10 LYS  PHI     -92.1 +/-  11.5       10 LYS  PHI     -92.8 +/-   14.0  
10 LYS  CHI1    -73.6 +/-   5.5       10 LYS  CHI1    -84.1 +/-   10.0  
10 LYS  CHI2    173.0 +/-  43.8       10 LYS  CHI2    166.0 +/-   27.5  
10 LYS  CHI3    172.6 +/-   4.2       10 LYS  CHI3   -175.0 +/-    6.9  
10 LYS  CHI4     44.8 +/-  44.3       10 LYS  CHI4     59.7 +/-   68.3  
10 LYS  PSI      88.3 +/-  26.1       10 LYS  PSI      97.2 +/-    8.8 
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  I)  Y= L-Phe      Z= L-Tyr(Bzl)
 II)  Y= L-1-Nal   Z= L-Thr
 III) Y= L-Phe      Z= L-Tyr  
 IV) Y= L-1-Nal   Z= L-Tyr(Bzl)
a
 
Scheme 1. Synthesis of linear peptides on H–l-Thr(t-Bu)–ol–2-chlorotrityl resin.  
a) (i) Fmoc- L- Hag, HATU/NMM, 40 min r.t.; (ii) 20% piperidine in DMF (2 x 15 
min); (iii) coupling with the amino acids. 
 
The resin aliquots containing the linear peptides were swollen for 2 h in 
anhydrous DCM. After two hours, the vessels were heated to 45 °C and a DCM 
solution of catalyst 9 (0.5 mole equiv. calculated on the basis of 0.5 mmol/g of 
peptide) was added. The suspension was then stirred for 48 h at 45 °C. The resin 
aliquots were washed with DCM, DMF, and MeOH, then swelled for 45 min at 
room temperature in DMF. Fmoc–Hag was deprotected (2.5 mL of 20% 
piperidine in DMF for 5 min, 4 time repeated) and coupled with Fmoc–D-Phe 
affording the on-resin peptides 4-8 which were deprotected and cleaved as 
previously described (Scheme 2). 
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V)  Y= L-Phe      Z= L-Tyr(Bzl)
VI)  Y= L-1-Nal   Z= L-Thr
VII)   Y= L-Phe      Z= L-Tyr
VIII)   Y= L-1-Nal   Z= L-Tyr(Bzl)
4)  Y= L-Phe      Z= L-Tyr(Bzl)
5)  Y= L-1-Nal   Z= L-Thr
6)  Y= L-Phe      Z= L-Tyr
7)  Y= L-Phe      Z= L-Tyr
8)  Y= L-1-Nal    Z= L-Tyr(Bzl)
I-IV
Z-isomer
Z-isomer
E-isomer
Z-isomer
H
A
Z-isomer
  
Scheme 2. Synthesis of ciclic octapeptides. b) (i) Catalyst, 45 °C, 48 h; (ii) 20% 
piperidine in DMF, Fmoc-D-Phe/HATU/NMM 40 min, r.t.  
c) i) 20% piperidine in DMF; ii) Cleavage of 5-7 by TFA/DCM/EDT/Phenol 
(94:2:2:2); 4 and 8 by TFA/DCM/EDT/Phenol (70:26:2:2). 
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Table S17. RP-HPLC data of the purified analogues. 
Compound HPLC method a Retention times (min.)b 
4 45%-55% B in 20 min. 9.64 
5 20%-60% B in 20 min. 13.26 
6 32% B in 20 min. 13.03 
7 30%-40% B in 20 min. 15.08 
8 50%-60% B in 10 min. 7.02 
a A: H2O 0.1% TFA;B: CH3CN 0.1% TFA. b Rt of the pure compounds. 
 
Table S18. Mass Spectral data of the purified analogues. 
Compound [M]+ calcd. [M+H]+ found [M+2H]2+ [M+Na]+ 
4 1132.57 1133.53 567.6 1156.66 
5 1030.53 1032.0 514.46 1054.98 
6 1042.53 1043.55 (20%) 523,53 (100%) 1066.67 
7 1042.53 1043.63 (20%) 522,35 (100%) 1066.67 
8 1182.59 1184,04 (10%) 592,51  (100 %) 1206.94 
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Figure S21. RP-HPLC trace of pure (4) 
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Figure S22. RP-HPLC trace of pure (5) 
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Figure S23. RP-HPLC trace of pure (6)-E isomer 
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Figure S24. RP-HPLC trace of pure (7) Z-isomer 
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Figure S25. RP-HPLC trace of pure (8) 
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Table S19. NMR Resonance Assignmentsa of Peptide 3 in SDS-d25 
200mM Solution. 
residue NH (3JN, -/T)b CH CH Others 
     
D-Phe2  4.23 3.23, 3.10 7.26 (); 7.31(); 
dhDsa-Nc 8.02 (6.8, 6.7) 3.81 2.22 5.16() 
Phe7 7.00 (8.2, 6.2) 4.74 2.98 7.03(); 7.16() 
D-Trp8 8.09 (5.5, 6.5) 4.38 3.21, 3.09 
7.21();10.05, 
7.68();7.49, 7.14(); 
7.14() 
Lys9 7.36 (5.9, 3.7) 4.09 1.44, 1.25 0.52, 0.43(); 1.39(); 
2.76() 
Tyr(Bzl)10 7.67 (5.4, 2.6) 4.25 3.13, 2.87 7.09(); 6.89();d 
dhDsa-Cc 7.15 (6.7, 3.0) 4.39 2.52, 2.23 5.27() 
Thr(ol)15 7.28 (6.9, 3.4) 3.80 3.95 1.15(); 3.68, 3.61 ( 
aObtained at 35 °C, pH = 5.5, with TSP ( 0.00 ppm) as reference shift. Chemical 
shifts are accurate to ±0.02 ppm. b 3JN coupling constants in Hz.  -/T = 
temperature coefficients (ppb/K). c dh-DSA-N: N-terminal portion of 
dehydrodiaminosuberic acid. dh-DSA-C: C-terminal portion of 
dehydrodiaminosuberic acid. d Other signals: CH2: 5.09, 5.04, Arom: 7.44, 7.40, 
7.30. 
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Table S20. NMR Resonance Assignmentsa of Peptide 4 in SDS-d25 
200mM Solution. 
residue NH (3JN, -/T)b CH CH Others 
     
D-Phe2   4.21 3.08; 3.29 7.25(); 7.32() 
dhDsa-Nc 8.12 (8.2, 6.9) 3.79 2.32, 2.13 5.11() 
Phe7 6.94 (8.5, 5.3) 4.73 2.95, 2.90 6.84(); 7.02() 
D-Trp8 8.24 (4.7, 6.3) 4.61 3.34, 3.04 7.28(); 10.03, 7.89(); 
7.50, 7.16(); 7.15() 
Lys9 7.51 (5.9, 4.7) 4.07 1.51, 1.37 0.68, 0.63(); 1.45 (); 
2.82(); 7.37() 
Tyr(Bzl)10 7.92 (6.5, 2.7) 4.41 3.09, 2.96 7.14(); 6.89();d 
dhDsa-Cc 7.61 (7.1, 5.8) 4.27 2.44, 2.12 5.20() 
Thr(ol)15 7.40 (7.6, 5.4) 3.84 3.95 1.14(); 3.71, 3.63 ( 
aObtained at 35 °C, pH = 5.5, with TSP ( 0.00 ppm) as reference shift. Chemical 
shifts are accurate to ±0.02 ppm. b 3JN coupling constants in Hz.  -/T = 
temperature coefficients (ppb/K). c dh-DSA-N: N-terminal portion of 
dehydrodiaminosuberic acid. dh-DSA-C: C-terminal portion of 
dehydrodiaminosuberic acid. d Other signals: CH2: 5.03; Arom: 7.43, 7.39, 7.32. 
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Table S21. NMR Resonance Assignmentsa of Peptide 5 in SDS-d25 
200mM Solution. 
residue NH (3JN, -/T)b CH CH Others 
     
D-Phe2   4.24 3.24, 3.14 7.31() 
dhDsa- 7.96 (8.1, 7.9) 4.23 2.45, 2.29 5.29() 
1-Nal7 8.13 (7.5, 6.3) 4.73 3.54, 3.42 7.69(); 8.18, 7.42(); 
7.45()
D-Trp8 7.31 (4.8, 6.3) 4.04 2.59, 2.28 6.88();9.86, 7.07();7.43, 
6.98(); 7.11() 
Lys9 7.90 (6.2, 4.6) 3.88 1.50, 1.25 0.58, 0.32(); 1.33(); 2.69, 
2.65(); 7.24() 
Thr10 8.04 (6.1, 2.7) 4.04 4.22 1.25(γ) 
dhDsa- 7.76 (7.5, 6.0) 4.36 2.41, 2.22 5.39() 
Thr(ol)15 7.26 (8.0, 6.4) 3.77 3.83 1.05(); 3.63, 3.53 ( 
aObtained at 35 °C, pH = 5.5, with TSP ( 0.00 ppm) as reference shift. Chemical 
shifts are accurate to ±0.02 ppm. b 3JN coupling constants in Hz.  -/T = 
temperature coefficients (ppb/K). c dh-DSA-N: N-terminal portion of 
dehydrodiaminosuberic acid. dh-DSA-C: C-terminal portion of 
dehydrodiaminosuberic acid. 
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Table S22. NMR Resonance Assignmentsa of Peptide 6 in SDS-d25 
200mM Solution. 
residue NH (3JN, -/T)b CH CH Others 
     
D-Phe2   4.21 3.24, 3.07 7.26(); 7.31() 
dhDsa- 7.87 (6.7, 7.7) 3.96 2.18 5.21() 
Phe7 7.27 (8.3, 6.7) 4.67 2.92 6.98(); 7.16() 
D-Trp8 7.81 (5.3, 6.6) 4.43 3.07, 2.97 7.11(); 10.01, 7.58(); 
7.44, 7.08(); 7.15() 
Lys9 7.66 (6.0, 3.8) 3.95 1.31, 1.24 0.54, 0.36(); 1.34(); 
2.71(); 7.31() 
Tyr10 7.98 (5.3, 2.8) 4.22 3.04, 2.86 6.77(); 7.03(γ) 
dhDsa- 7.27 (6.8, 3.1) 4.31 2.49, 2.30 5.33() 
Thr(ol)15 7.31 (6.9, 3.8) 3.78 3.94 1.14(); 3.66, 3.59 ( 
aObtained at 35 °C, pH = 5.5, with TSP ( 0.00 ppm) as reference shift. Chemical 
shifts are accurate to ±0.02 ppm. b 3JN coupling constants in Hz.  -/T = 
temperature coefficients (ppb/K). c dh-DSA-N: N-terminal portion of 
dehydrodiaminosuberic acid. dh-DSA-C: C-terminal portion of 
dehydrodiaminosuberic acid. 
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Table S23. NMR Resonance Assignmentsa of Peptide 7 in SDS-d25 
200mM Solution. 
residue NH (3JN, -/T)b CH CH Others 
     
D-Phe2   4.23 3.29, 3.10 7.28(); 7.34() 
dhDsa- 8.12 (8.2, 6.9) 3.80 2.42, 2.11 5.29() 
Phe7 6.97 (8.1, 6.6) 4.73 2.89, 2.76 6.67(); 6.95(); 7.03() 
D-Trp8 8.16 (4.8, 6.8) 4.74 3.34, 3.00 7.29(); 9.99, 7.89(); 7.45, 
7.18(); 7.21() 
Lys9 7.83 (6.9, 4.3) 3.94 1.41 0.74, 0.61(); 1.46(); 2.81(); 7.33() 
Tyr10 8.36 (6.4, 2.6) 4.41 3.14, 2.88  7.12(); 6.79() 
dhDsa- 7.53 (7.2, 5.9) 4.28 2.49, 1.93  5.43() 
Thr(ol)15 7.44 (7.5, 5.5) 3.83 3.96 1.15(); 3.70, 3.61 ( 
aObtained at 35 °C, pH = 5.5, with TSP ( 0.00 ppm) as reference shift. Chemical 
shifts are accurate to ±0.02 ppm. b 3JN coupling constants in Hz.  -/T = 
temperature coefficients (ppb/K). c dh-DSA-N: N-terminal portion of 
dehydrodiaminosuberic acid. dh-DSA-C: C-terminal portion of 
dehydrodiaminosuberic acid. 
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Table S24. NMR Resonance Assignmentsa of Peptide 8 in SDS-d25 
200mM Solution. 
residue NH (3JN, -/T)b CH CH Others 
     
D-Phe2   4.26 3.30, 3.17 7.31(); 7.37() 
dhDsa-Nc 8.12 (8.1, 6.8) 4.20 2.34 5.19() 
1-Nal7 7.60 (8.4, 5.4) 4.93 3.64, 3.53 7.67(); 8.22, 7.31(); 7.80()
D-Trp8 8.22 (4.8, 6.3) 4.10 3.03, 2.72 7.12(); 10.00, 7.46(); 7.51, 
7.15(); 7.14() 
Lys9 6.64 (6.9, 4.6) 4.00 1.29, 0.93 0.22, 0.08(); 1.27(); 2.69() 
Tyr(Bzl)10 7.83 (6.5, 2.6) 4.43 3.06, 2.91 7.09(); 6.87();d 
dhDsa-Cc 7.95 (7.1, 5.7) 4.44 2.45, 2.35 5.37() 
Thr(ol)15 7.51 (7.6, 5.9) 3.85 3.97 1.15(); 3.71, 3.62 ( 
aObtained at 35 °C, pH = 5.5, with TSP ( 0.00 ppm) as reference shift. Chemical 
shifts are accurate to ±0.02 ppm. b 3JN coupling constants in Hz.  -/T = 
temperature coefficients (ppb/K). c dh-DSA-N: N-terminal portion of 
dehydrodiaminosuberic acid. dh-DSA-C: C-terminal portion of 
dehydrodiaminosuberic acid. d Other signals: CH2: 5.05, 5.02, Arom: 7.47, 7.42, 
7.35. 
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Table S25. NOE Derived Upper Limit Constraints of Compound 3 
Atom1  Atom2  Upper Limit Violation 
2 DPHE HA 3 DHS HN 2.52    
2 DPHE HB2 3 DHS HN 5.31    
2 DPHE HB3 3 DHS HN 5.31    
2 DPHE QB 3 DHS HN 4.49    
3 DHS HN 3 DHS QB 3.84    
3 DHS HA 14 DHS HG 4.60    
3 DHS HA 7 PHE HN 2.40    
3 DHS HG 14 DHS HA 3.58    
3 DHS HG 14 DHS QB 3.21    
7 PHE HN 10 TBZ HB2 2.99    
7 PHE HA 8 DTRP HN 2.83    
7 PHE QB 8 DTRP HN 3.93    
7 PHE QD 8 DTRP HN 6.69    
8 DTRP HN 8 DTRP HB2 2.86    
8 DTRP HN 8 DTRP HB3 2.86    
8 DTRP HN 8 DTRP QB 2.64    
8 DTRP HN 8 DTRP HD1 5.50    
8 DTRP HA 8 DTRP HD1 4.97    
8 DTRP HA 8 DTRP HE3 2.70    
8 DTRP HA 9 LYS HN 2.40    
8 DTRP HB2 8 DTRP HD1 3.70    
8 DTRP HB2 8 DTRP HE3 4.19    
8 DTRP HB2 9 LYS HN 4.60    
8 DTRP HB3 8 DTRP HD1 3.70    
8 DTRP HB3 8 DTRP HE3 4.19    
8 DTRP HB3 9 LYS HN 4.60    
8 DTRP QB 8 DTRP HD1 3.13    
8 DTRP QB 8 DTRP HE3 3.70    
8 DTRP QB 9 LYS HN 4.18    
8 DTRP HD1 9 LYS QG 6.38    
8 DTRP HE1 9 LYS QG 6.38    
8 DTRP HE1 9 LYS QD 6.38    
8 DTRP HE1 9 LYS QE 6.38    
8 DTRP HE1 15 THO HA 5.50    
8 DTRP HZ2 9 LYS QE 6.38    
9 LYS HN 9 LYS HA 2.91    
9 LYS HN 9 LYS HB2 2.60    
9 LYS HN 9 LYS HB3 3.74    
9 LYS HN 9 LYS HG2 3.45    
9 LYS HN 9 LYS HG3 3.45    
9 LYS HN 9 LYS QG 3.21    
9 LYS HN 10 TBZ HN 3.03    
9 LYS HA 9 LYS HG2 3.76    
9 LYS HA 9 LYS HG3 3.76    
9 LYS HA 9 LYS QG 3.35    
9 LYS HA 9 LYS QD 6.38    
Chapter 3 
- 222 -	
 
9 LYS HA 10 TBZ HN 3.56    
9 LYS HA 15 THO HN 4.80    
9 LYS HA 15 THO QG2 6.53    
9 LYS HB2 10 TBZ HN 3.54    
9 LYS HB2 10 TBZ QD 7.64    
9 LYS HB3 10 TBZ HN 3.69    
9 LYS HB3 10 TBZ QD 7.64    
9 LYS HG2 10 TBZ HN 5.50    
9 LYS HG3 10 TBZ HN 5.50    
9 LYS QG 10 TBZ QE 8.51    
10 TBZ HN 10 TBZ HB2 2.63    
10 TBZ HN 10 TBZ HB3 3.60    
10 TBZ HN 10 TBZ QE 6.83    
10 TBZ HN 14 DHS HN 2.60    
10 TBZ HN 15 THO HN 4.83    
10 TBZ HA 14 DHS HN 3.35  0.10  
14 DHS HN 14 DHS HA 2.91    
14 DHS HN 14 DHS HB2 3.02    
14 DHS HN 14 DHS HB3 3.90    
14 DHS HN 14 DHS HG 5.07    
14 DHS HA 14 DHS HG 4.04    
14 DHS HA 15 THO HN 3.50    
14 DHS HB2 15 THO HN 3.72    
14 DHS HB3 15 THO HN 4.49    
15 THO HN 15 THO HA 2.85    
15 THO HN 15 THO HB 3.05    
15 THO HA 15 THO HB 2.40    
3 DHS: N-terminal portion of dehydrodiaminosuberic acid. 14 DHS: C-terminal 
portion of dehydrodiaminosuberic acid. 
TBZ: Tyr(Bzl). THO: Threoninol. b Violations (Å) observed for the mean 
structure of the ensemble. 
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Table S26. NOE derived Upper Limit Constraints. Compound 4 
Atom1a Atom2 Upper Limit V i o l a t i o n
b  
Helix Extend Ensemble
2 DPHE HA 3 DHS HN 2.59    
2 DPHE QD 3 DHS HA 7.62    
3 DHS HN 3 DHS HB2 3.24    
3 DHS HN 3 DHS HB3 3.24    
3 DHS HN 3 DHS QB 3.02    
3 DHS HA 3 DHS HB2 2.74    
3 DHS HA 3 DHS HB3 2.74    
3 DHS HA 3 DHS QB 2.48    
3 DHS HA 3 DHS HG 3.75  0.40  
3 DHS HA 14 DHS HG 5.10    
3 DHS HA 7 PHE HN 2.40    
3 DHS HA 7 PHE QD 7.62    
3 DHS HA 14 DHS HA 3.30 1.20  0.28 
3 DHS QB 3 DHS HG 2.75    
3 DHS HG 14 DHS HA 4.72    
7 PHE HN 7 PHE HB2 3.73    
7 PHE HN 7 PHE HB3 3.73    
7 PHE HN 7 PHE QB 3.35    
7 PHE HN 14 DHS HA 4.01 1.38  0.39 
7 PHE HA 8 DTRP HN 2.49    
7 PHE QB 8 DTRP HN 3.93    
7 PHE QD 8 DTRP HN 7.28    
8 DTRP HN 8 DTRP HB2 2.68    
8 DTRP HN 8 DTRP HB3 2.68    
8 DTRP HN 8 DTRP QB 2.42    
8 DTRP HN 8 DTRP HD1 5.28    
8 DTRP HA 8 DTRP HE3 2.83    
8 DTRP HA 9 LYS HN 2.40    
8 DTRP HA 10 TBZ HN 3.83    
8 DTRP HB2 8 DTRP HD1 3.70    
8 DTRP HB2 8 DTRP HE3 4.22    
8 DTRP HB2 9 LYS HN 4.40    
8 DTRP HB3 8 DTRP HD1 3.70    
8 DTRP HB3 8 DTRP HE3 4.22    
8 DTRP HB3 9 LYS HN 4.40    
8 DTRP QB 8 DTRP HD1 3.16    
8 DTRP QB 9 LYS HN 4.20    
8 DTRP QB 8 DTRP HE3 3.60    
8 DTRP HD1 9 LYS QG 6.38    
8 DTRP HE3 9 LYS HN 4.01    
9 LYS HN 9 LYS HB2 2.50    
9 LYS HN 9 LYS HB3 3.70    
9 LYS HN 9 LYS QG 3.49    
9 LYS HN 10 TBZ HN 3.00    
9 LYS HA 9 LYS HG2 3.83    
9 LYS HA 9 LYS HG3 3.83    
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9 LYS HA 9 LYS QG 3.32    
9 LYS HA 10 TBZ HN 3.46    
9 LYS HA 15 THO HN 5.44  2.80 0.46 
9 LYS HA 15 THO QG2 6.53  2.10 0.33 
9 LYS HB2 10 TBZ HN 3.60 0.74   
9 LYS HB3 10 TBZ HN 4.10 0.20   
9 LYS QG 10 TBZ HN 6.38    
9 LYS QG 10 TBZ QD 7.52  1.02  
10 TBZ HN 10 TBZ HB2 2.83    
10 TBZ HN 10 TBZ HB3 3.14    
10 TBZ HN 14 DHS HN 2.95  0.36  
10 TBZ HA 14 DHS HN 2.62 0.82  0.27 
10 TBZ HA 15 THO HN 5.31    
10 TBZ HB2 14 DHS HN 4.01  0.40  
10 TBZ HB3 14 DHS HN 3.86  0.58  
10 TBZ QD 14 DHS HN 6.68    
10 TBZ QD 14 DHS HA 6.05 0.74   
10 TBZ QD 15 THO QG2 7.27 0.52   
14 DHS HN 14 DHS HB2 2.52    
14 DHS HN 14 DHS HB3 3.29 0.43   
14 DHS HN 14 DHS HG 5.01    
14 DHS HN 15 THO HN 3.16  1.16 0.12 
14 DHS HA 14 DHS HG 3.76    
14 DHS HA 15 THO HN 2.65 0.59   
14 DHS HB2 15 THO HN 3.83  0.77  
14 DHS HB3 15 THO HN 4.41    
15 THO HN 15 THO HB 3.70    
15 THO HN 15 THO QG2 4.61    
15 THO HA 15 THO HB 2.54    
a 3 DHS: N-terminal portion of dehydrodiaminosuberic acid. 14 DHS: C-terminal 
portion of dehydrodiaminosuberic acid. TBZ: Tyr(Bzl). THO: Threoninol.   
b Violations (Å) observed for the mean structure of the family I (helix), family II 
(extended) and an ensemble of 20 structures of both families (ensemble). 
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Table S27. NOE Derived Upper Limit Constraints of Compound 5 
Atom1a Atom2 Upper Limit V i o l a t i o n  Helix Extend Ensemble
2 DPHE HA 3 DHS HN 2.40    
2 DPHE HB2 3 DHS HN 3.86    
2 DPHE HB3 3 DHS HN 3.86    
2 DPHE QB 3 DHS HN 3.62    
2 DPHE QD 3 DHS HN 7.62    
3 DHS HN 3 DHS HB2 3.24    
3 DHS HN 3 DHS HB3 3.24    
3 DHS HN 3 DHS QB 3.24    
3 DHS HN 3 DHS HG 4.35    
3 DHS HN 7 NAL HN 3.79    
3 DHS HA 3 DHS HG 3.48  0.66  
3 DHS HA 14 DHS HG 4.38    
3 DHS HA 7 NAL HN 2.43    
3 DHS HA 14 DHS HA 3.25 1.25  0.32 
3 DHS QB 14 DHS HN 5.77    
3 DHS HG 7 NAL HN 5.50    
3 DHS HG 14 DHS HA 4.88    
3 DHS HG 14 DHS QB 4.31    
7 NAL HN 7 NAL HB2 2.71    
7 NAL HN 7 NAL HB3 2.74    
7 NAL HN 7 NAL HD1 5.50    
7 NAL HN 8 DTRP HN 4.48    
7 NAL HN 14 DHS HA 3.82 1.57  0.46 
7 NAL HN 14 DHS QB 5.00    
7 NAL HA 8 DTRP HN 2.40    
7 NAL HB2 7 NAL HD1 2.74    
7 NAL HB2 7 NAL HD3 2.49    
7 NAL HB2 8 DTRP HN 4.11    
7 NAL HB3 7 NAL HD1 2.86    
7 NAL HB3 7 NAL HD3 2.52    
7 NAL HB3 8 DTRP HN 3.92    
7 NAL HZ 8 DTRP HE3 5.50    
7 NAL HE3 8 DTRP HE3 5.50    
7 NAL HD3 8 DTRP HN 4.82    
8 DTRP HN 8 DTRP HB2 2.83    
8 DTRP HN 8 DTRP HB3 2.83    
8 DTRP HN 8 DTRP QB 2.53    
8 DTRP HN 8 DTRP HD1 5.50    
8 DTRP HA 8 DTRP HD1 4.82    
8 DTRP HA 8 DTRP HE3 3.02    
8 DTRP HA 9 LYS HN 2.43    
8 DTRP HB2 9 LYS HN 4.32    
8 DTRP HB3 9 LYS HN 4.32    
8 DTRP QB 8 DTRP HE3 4.38    
8 DTRP QB 9 LYS HN 3.80    
8 DTRP HD1 9 LYS HN 5.50    
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8 DTRP HE3 9 LYS HN 5.16    
8 DTRP HE3 9 LYS HA 5.37    
8 DTRP HE1 9 LYS QG 6.38    
8 DTRP HE1 9 LYS QD 6.38    
8 DTRP HZ2 9 LYS QD 6.38    
9 LYS HN 9 LYS HB2 2.60    
9 LYS HN 9 LYS HB3 3.71    
9 LYS HN 9 LYS HG2 4.14    
9 LYS HN 9 LYS HG3 4.14    
9 LYS HN 9 LYS QG 3.71    
9 LYS HN 10 THR HN 2.77    
9 LYS HA 9 LYS QG 3.91    
9 LYS HA 9 LYS QD 6.38    
9 LYS HA 10 THR HN 3.33    
9 LYS HA 14 DHS HN 5.50    
9 LYS HA 15 THO HN 5.35  2.90 0.41 
9 LYS QB 10 THR HN 5.51    
10 THR HN 10 THR HA 2.90    
10 THR HN 10 THR HB 3.21    
10 THR HN 14 DHS HN 2.89  0.42  
10 THR HA 10 THR HB 2.83    
10 THR HA 14 DHS HN 2.57 0.88  0.31 
10 THR HA 15 THO HN 5.34    
10 THR HB 14 DHS HN 3.61    
10 THR QG2 14 DHS HN 6.53    
14 DHS HN 14 DHS HB2 2.86    
14 DHS HN 14 DHS HB3 3.39 0.33   
14 DHS HN 14 DHS HG 4.85    
14 DHS HN 15 THO HN 3.22  1.20 0.14 
14 DHS HA 14 DHS HG 3.86    
14 DHS HA 15 THO HN 2.55 0.68   
14 DHS HB2 15 THO HN 3.80  0.80  
14 DHS HB3 15 THO HN 4.39    
15 THO HN 15 THO HB 3.58    
15 THO HA 15 THO HB 2.40    
a 3 DHS: N-terminal portion of dehydrodiaminosuberic acid. 14 DHS: C-terminal 
portion of dehydrodiaminosuberic acid. NAL: 1-naphtylalanine. THO: 
Threoninol.  b Violations (Å) observed for the mean structure of the family I 
(helix), family II (extended) and an ensemble of 20 structures of both families 
(ensemble). 
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Table S28. NOE Derived Upper Limit Constraints of Compound 8 
Atom1a Atom2 Upper Limit V i o l a t i o n  Helix Extend Ensemble
2 DPHE HA 3 DHS HN 2.52    
3 DHS HA 3 DHS HG 3.64  0.53  
3 DHS HA 7 NAL HN 2.71    
3 DHS HA 14 DHS HA 3.31 1.19  0.30 
3 DHS HG 7 NAL HN 5.50    
3 DHS HG 14 DHS HB2 4.42    
7 NAL HN 7 NAL HB2 3.39    
7 NAL HN 7 NAL HB3 3.45    
7 NAL HN 14 DHS HA 3.87 1.52  0.19 
7 NAL HA 7 NAL HD1 3.95    
7 NAL HA 8 DTRP HN 2.46    
7 NAL HB2 7 NAL HD1 3.08    
7 NAL HB3 7 NAL HD1 3.05    
8 DTRP HN 8 DTRP HB2 2.83    
8 DTRP HN 8 DTRP HB3 2.83    
8 DTRP HN 8 DTRP QB 2.53    
8 DTRP HN 8 DTRP HD1 5.06    
8 DTRP HA 8 DTRP HD1 4.98    
8 DTRP HA 8 DTRP HE3 2.71    
8 DTRP HA 9 LYS HN 2.59    
8 DTRP HA 10 TBZ HN 3.76    
8 DTRP HA 10 TBZ QD 7.64    
8 DTRP HA 10 TBZ QE 7.63    
8 DTRP HB2 8 DTRP HD1 3.45    
8 DTRP HB2 8 DTRP HE3 4.04    
8 DTRP HB2 9 LYS HN 4.11    
8 DTRP HB3 8 DTRP HD1 3.45    
8 DTRP HB3 8 DTRP HE3 4.04    
8 DTRP HB3 9 LYS HN 4.11    
8 DTRP QB 8 DTRP HD1 3.26    
8 DTRP QB 9 LYS HN 3.93    
8 DTRP HD1 9 LYS HG2 5.22    
8 DTRP HD1 9 LYS HG3 5.22    
8 DTRP HD1 9 LYS QG 4.92    
8 DTRP HE3 9 LYS HN 4.11    
8 DTRP HE3 9 LYS QG 6.38    
8 DTRP HE3 10 TBZ QE 7.51 0.38   
8 DTRP HE1 9 LYS QD 6.38    
8 DTRP HE1 9 LYS QE 6.38    
8 DTRP HZ2 9 LYS QE 6.38    
9 LYS HN 9 LYS HB2 2.61    
9 LYS HN 9 LYS HB3 3.69    
9 LYS HN 9 LYS HG2 4.11    
9 LYS HN 9 LYS HG3 4.11    
9 LYS HN 9 LYS QG 3.84    
9 LYS HN 10 TBZ HN 2.93    
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9 LYS HN 10 TBZ QD 7.64    
9 LYS HA 9 LYS QG 3.88    
9 LYS HA 9 LYS QD 5.45    
9 LYS HA 10 TBZ HN 3.45    
9 LYS HA 14 DHS HN 5.00    
9 LYS HA 15 THO HN 5.50  2.76 0.48 
9 LYS HA 15 THO QG2 6.51  2.10 0.35 
9 LYS HB2 10 TBZ HN 3.66 0.68   
9 LYS HB3 10 TBZ HN 4.16 0.20   
9 LYS QB 10 TBZ QD 8.52    
9 LYS QG 10 TBZ HN 5.50    
9 LYS QG 10 TBZ QE 7.63    
10 TBZ HN 10 TBZ HB2 2.90    
10 TBZ HN 10 TBZ HB3 3.57    
10 TBZ HN 10 TBZ QE 7.63    
10 TBZ HN 14 DHS HN 2.98  0.34  
10 TBZ HA 10 TBZ HB2 2.93    
10 TBZ HA 10 TBZ HB3 2.74    
10 TBZ HA 14 DHS HN 2.64 0.82  0.23 
10 TBZ HB2 14 DHS HN 3.95  0.46  
10 TBZ HB3 14 DHS HN 3.82  0.63  
14 DHS HN 14 DHS HB2 2.96    
14 DHS HN 14 DHS HB3 3.39 0.33   
14 DHS HN 14 DHS HG 4.51    
14 DHS HN 15 THO HN 3.21  1.21 0.13 
14 DHS HA 14 DHS HB2 2.93    
14 DHS HA 14 DHS HB3 2.83    
14 DHS HA 14 DHS HG 3.81    
14 DHS HA 15 THO HN 2.66 0.58   
14 DHS HB2 15 THO HN 3.86  0.75  
14 DHS HB3 15 THO HN 4.43    
15 THO HN 15 THO HB 3.58    
15 THO HN 15 THO QG2 4.88    
15 THO HA 15 THO HB 2.40    
a 3 DHS: N-terminal portion of dehydrodiaminosuberic acid. 14 DHS: C-terminal 
portion of dehydrodiaminosuberic acid. NAL: 1-naphtylalanine. TBZ: Tyr(Bzl). 
THO: Threoninol.  b Violations (Å) observed for the mean structure of the family 
I (helix), family II (extended) and an ensemble of 20 structures of both families 
(ensemble). 
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Table S29. Microanalysis data for the all final products 
  Found (%) Calculated (%) 
Comp. Formula C H N S C H N S 
11a C16H11F3N2O5S 48.00 2.77 7.00 8.01 48.15 2.89 7.05 8.08 
11b C17H13F3N2O5S 49.28 3.16 6.76 7.74 49.39 3.03 6.66 7.63 
11c C23H17F3N2O5S 56.32 3.49 5.71 6.54 56.24 3.59 5.74 6.63 
11d C22H21F6N3O7S 45.13 3.62 7.18 5.48 45.01 3.70 7.21 5.51 
11e C19H15F3N2O5S 51.82 3.43 6.36 7.28 51.68 3.47 6.27 7.41 
11f C17H13F3N2O5S 49.28 3.16 6.76 7.74 49.13 3.12 6.84 7.87 
11g C14H9NO4S 58.53 3.16 4.88 11.16 58.42 3.25 4.97 10.98
11h C18H19ClN2O3S 57.06 5.05 7.39 8.46 56.96 5.14 7.30 8.59 
11i C18H17ClN2O4S 55.03 4.36 7.13 8.16 55.00 4.40 7.16 8.24 
11j C14H9NO3S2 55.43 2.99 4.62 21.14 55.35 2.95 4.69 21.26
11k C18H21Cl2N3O3S 50.24 4.92 9.76 7.45 50.12 5.01 9.69 7.58 
11l C15H11NO4S 59.79 3.68 4.65 10.64 59.68 3.63 4.72 10.71
11m C19H21ClN2O3S 58.08 5.39 7.13 8.16 57.98 5.44 7.02 8.29 
11n C19H19ClN2O4S 56.09 4.71 6.88 7.88 56.00 4.76 6.78 8.01 
11o C15H11NO3S2 56.76 3.49 4.41 20.21 56.64 3.55 4.30 20.34
11p C19H23Cl2N3O3S 51.35 5.22 9.46 7.22 51.42 5.24 9.39 7.36 
11q C16H14N2O3S 61.13 4.49 8.91 10.20 61.18 4.53 8.82 10.31
11r C17H18ClN3O3S 53.75 4.78 11.06 8.44 53.83 4.68 11.11 8.38 
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Figure S26. Expression of cyclin A in control cells and upon treatment with 11p, 
11m, and 11c (1 µM) for 48h 
 
 
 
Figure S27. Effects of doxorubicin on the topo II-mediated DNA cleavage 
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